false FY 0001857044 No No Yes Yes

 2023-06-30

 2024-03-12

 us-gaap: StockOptionMember

 us-gaap: StockOptionMember

 us-gaap: WarrantMember

 us-gaap: WarrantMember

 us-gaap: PropertyPlantAndEquipmentMember
 INDP:ComputersAndOtherOfficeEquipmentMember

 us-gaap: PropertyPlantAndEquipmentMember
 INDP:FurnitureMember

 us-gaap: FairValueInputsLevel1Member

 us-gaap: FairValueInputsLevel2Member

 us-gaap: FairValueInputsLevel3Member

 INDP:EmployeesOfficersConsultantsDirectorsMember

 us-gaap: SubsequentEventMember

 2024-01-01

 us-gaap: ResearchAndDevelopmentExpenseMember

 us-gaap: ResearchAndDevelopmentExpenseMember

 us-gaap: GeneralAndAdministrativeExpenseMember

 us-gaap: GeneralAndAdministrativeExpenseMember

 INDP:ExercisePriceRangeOneMember

 INDP:ExercisePriceRangeTwoMember

 INDP:ExercisePriceRangeThreeMember

 INDP:ExercisePriceRangeOneMember

 INDP:ExercisePriceRangeTwoMember

 INDP:ExercisePriceRangeThreeMember

 us-gaap: WarrantMember

 us-gaap: WarrantMember

 INDP:AtTheMarketOfferingAgreementMember
 INDP:HCWainwrightAndCoLLCMember

 2022-09-01

 INDP:AtTheMarketOfferingAgreementMember
 INDP:HCWainwrightAndCoLLCMember

 2022-09-01
 2022-09-01

 INDP:AtTheMarketOfferingAgreementMember
 INDP:HCWainwrightAndCoLLCMember
 us-gaap: SubsequentEventMember

 2024-03-01
 2024-03-31

 INDP:LincolnParkCapitalFundLLCMember
 INDP:PurchaseAgreementsMember

 2022-12-22
 2022-12-22

 INDP:LincolnParkCapitalFundLLCMember
 INDP:PurchaseAgreementsMember

 2022-12-23
 2022-12-23

 INDP:LincolnParkCapitalFundLLCMember
 INDP:PurchaseAgreementsMember
 srt: MaximumMember

 2022-12-23
 2022-12-23

 INDP:LohmannTherapieSystemAGMember

 2022-07-13
 2022-07-13

 INDP:LohmannTherapieSystemAGMember

 INDP:LohmannTherapieSystemAGMember

 2023-02-06
 2023-02-07

 stpr: CA
 INDP:TwoYearLeaseAgreementMember

 2021-10-01

 stpr: CA
 INDP:TwoYearLeaseAgreementMember

 2021-10-01
 2021-10-01

 2023-04-19
 2023-04-19

 2023-04-19

 INDP:FederalMember

 INDP:StateMember

 INDP:ExpireInTwoThousandThirtySixMember
 INDP:FederalMember

 INDP:IndefinitePeriodMember
 INDP:FederalMember

 INDP:ExpireInTwoThousandThirtyFiveMember
 INDP:StateMember

 country: IL

 us-gaap: SubsequentEventMember

 2024-01-01
 2024-03-13

 utr:sqft

 UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 Washington,
D.C. 20549

 FORM

 (Mark
One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the fiscal year ended December 31, 2023

 OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the transition period from to

 Commission
File Number 001-40652

 (Exact
name of Registrant as specified in its Charter)

 Delaware

 86-3158720

 (State
 or other jurisdiction

 of
 incorporation or organization)

 (I.R.S.
 Employer

 Identification
 No.)

 Columbus Circle

 15th
 Floor

 New
 York, NY

 10019

 (Address
 of principal executive offices)

 (Zip
 Code)

 Registrant's
telephone number, including area code: + (646) 427-2727

 Securities
registered pursuant to Section 12(b) of the Act:

 Common
 stock, par value $0.01

 INDP

 Nasdaq
 Capital Market

 (Title
 of each class)

 Trading
 Symbol(s)

 (Name
 of each exchange on which registered)

 Securities
registered pursuant to Section 12(g) of the Act:

 None

by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES NO

by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES NO

by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. YES NO

by check mark whether the Registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant
was required to submit such files). YES NO

by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller
reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large
 accelerated filer

 Accelerated
 filer

 Non-accelerated
 filer

 Smaller
 reporting company

 Emerging
 growth company

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.

 If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.

by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant's executive officers during the relevant recovery period pursuant to § 240.10D-1(b).

by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES NO

 At
June 30, 2023, the last business day of the Registrant's most recently completed second fiscal quarter, the aggregate market value
of the voting and non-voting common equity held by non-affiliates of the Registrant was $ 13,286,909.

 The
number of shares of Registrant's common stock outstanding as of March 12, 2024 was 8,538,883.

 DOCUMENTS
INCORPORATED BY REFERENCE

 Portions
of the Registrant's definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the Registrant intends to file
pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after December 31, 2023, are incorporated
by reference into Part III of this Annual Report on Form 10-K.

 Table
 of Contents

 Page

 Item
 1.

 Business

 Item
 1A.

 Risk Factors

 Item
 1B.

 Unresolved Staff Comments

 Item
 1C.

 Cybersecurity

 Item
 2.

 Properties

 Item
 3.

 Legal Proceedings

 Item
 4.

 Mine Safety Disclosures

 Item
 5.

 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 Item
 6.

 [Reserved]

 Item
 7.

 Management's Discussion and Analysis of Financial Condition and Results of Operations

 Item
 7A.

 Quantitative and Qualitative Disclosures About Market Risk

 Item
 8.

 Financial Statements and Supplementary Data

 Item
 9.

 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 Item
 9A.

 Controls and Procedures

 Item
 9B.

 Other Information

 Item
 9C.

 Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 Item
 10.

 Directors, Executive Officers and Corporate Governance

 Item
 11.

 Executive Compensation

 Item
 12.

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item
 13.

 Certain Relationships and Related Transactions, and Director Independence

 Item
 14.

 Principal Accountant Fees and Services

 Item
 15.

 Exhibits and Financial Statement Schedules

 Item
 16.

 Form 10-K Summary

 ABOUT
THIS ANNUAL REPORT

 All
references to "we," "us," "our," "Indaptus Therapeutics", "Indaptus", "the
Company" and "our company", in this Annual Report on Form 10- K, or our Annual Report, are to Indaptus Therapeutics,
Inc. (formerly Intec Parent, Inc.) and, where appropriate, its consolidated subsidiaries, Intec Pharma Ltd. and Decoy Biosystems, Inc.
All references to "common stock" and "share capital" refer to common stock and share capital of Indaptus. Our
historical results do not necessarily indicate our expected results for any future periods. Any discrepancies in any table between totals
and sums of the amounts listed are due to rounding. Unless otherwise indicated, or the context otherwise requires, references in this
Annual Report to financial and operational data for a particular year refer to the fiscal year of our Company ended December 31 of that
year.

 EXPLANATORY
NOTE

 Market
data and certain industry data and forecasts used throughout this Annual Report were obtained from market research databases, consultant
surveys commissioned by us, publicly available information, reports of governmental agencies and industry publications and surveys. Industry
surveys, publications, consultant surveys commissioned by us and forecasts generally state that the information contained therein has
been obtained from sources believed to be reliable. We have relied on certain data from third-party sources, including internal surveys,
industry forecasts and market research, which we believe to be reliable based on our management's knowledge of the industry. Statements
as to our market position are based on the most currently available data. While we are not aware of any misstatements regarding the industry
data presented in this Annual Report, our estimates involve risks and uncertainties and are subject to change based on various factors,
including those discussed under Part I. Item 1A. "Risk Factors" in this Annual Report.

 CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS

 This
Annual Report contains, and management may make, certain forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking
statements. In some cases, forward-looking statements can be identified by the use of terms such as "believe," "expect,"
"intend," "plan," "may," "should," "anticipate," "could," "might,"
"seek," "target," "will," "project," "forecast," "continue" or
their negatives or variations of these words or other comparable words. These statements include, without limitation, our statements
about: our product candidates' development, including the timing and design of the Phase 1 clinical trial of Decoy20; our expectations
regarding the recommended Phase 2 dose for subsequent multi-dosing and combination studies and related timing; the anticipated effects
of our product candidates; our plans to develop and commercialize our product candidates; the market potential and treatment potential
of our product candidates, including Decoy20; our commercialization, marketing and manufacturing capabilities and strategy; our expectations
about the willingness of healthcare professionals to use our product candidates; our general business strategy and the plans and objectives
of management for future operations; our research and development activities and costs; our future results of operations and condition;
the sufficiency of our cash and cash equivalents to fund our ongoing activities; the impact of current macroeconomic conditions on our
operations, ability to access capital, and liquidity; and any impact of a pandemic, epidemic or other future health crisis, such as the
COVID-19 pandemic on our business.

 The
forward-looking statements in this Annual Report are only predictions and are based largely on our current expectations and projections
about future events and financial trends that we believe may affect our business, financial condition and results of operations. These
forward-looking statements speak only as of the date of this Annual Report and are subject to a number of known and unknown risks, uncertainties
and assumptions, including those described under the sections in this Annual Report entitled "Summary Risk Factors," Part
I. Item 1A. "Risk Factors" and Part II. Item 7. "Management's Discussion and Analysis of Financial Condition
and Results of Operations" and elsewhere in this Annual Report.

 Because
forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some
of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events
and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially
from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties
may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.

 Except
as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as
a result of any new information, future events, changed circumstances or otherwise. We intend the forward-looking statements contained
in this Annual Report to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities
Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.

 Summary
Risk Factors

 The
principal factors and uncertainties that make investing in our common stock risky, include, among others:

 We
 are a clinical-stage company with a limited operating history. We are not currently profitable, do not expect to become profitable
 in the near future and may never become profitable.

 We
 have identified conditions and events that raise substantial doubt regarding our ability to continue as going concern.

 Given
 our lack of current cash flow, we will need to raise additional capital. If we are unable to raise a sufficient amount of capital
 when needed on acceptable terms or at all, we may be forced to delay, limit or eliminate some or all of our research programs, product
 development activities and commercialization efforts.

 Raising
 additional capital would cause dilution to our existing shareholders and may restrict our operations or require us to relinquish
 rights to our technologies or product candidates.

 Clinical
 and preclinical development involves lengthy and expensive processes with uncertain outcomes. Any difficulties or delays in the commencement
 or completion, or the termination or suspension, of our current or planned clinical trials could result in increased costs to us,
 delay or limit our ability to generate revenue or adversely affect our commercial prospects.

 We
 expect to continue to incur significant research and development expenses and other operating expenses, which may make it difficult
 for us to attain profitability.

 We
 may expend our limited resources to pursue a limited number of research programs, product candidates and specific indications and
 fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of
 success.

 Our
 product candidates may cause undesirable side effects that could delay or prevent their regulatory approval or commercialization
 or have other significant adverse implications on our business, financial condition and results of operations.

 The
 commercial success of our product candidates depends upon their market acceptance among physicians, patients, healthcare payors and
 the medical community.

 We
 rely on third parties to conduct our preclinical studies and clinical trials and perform other tasks. If these third parties do not
 successfully carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able
 to obtain regulatory approval for or commercialize our product candidates and our business, financial condition and results of operations
 could be substantially harmed.

 We
 currently rely on third parties for the manufacture of our product candidates during clinical development, and expect to continue
 to rely on third parties for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient
 quantities of our product candidates, or such quantities at an acceptable cost, which could delay, prevent or impair our development
 or potential commercialization efforts.

 The
 successful commercialization of Decoy20 or any future product candidates, if approved, will depend in part on the extent to which
 governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure
 to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease
 our ability to generate revenue.

 enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing
 approval for and commercialize Decoy20 and any future product candidates and may affect the prices we may set.

 If
 our competitors have product candidates that are approved faster, marketed more effectively, are better tolerated, have a more favorable
 safety profile or are demonstrated to be more effective than our product candidates, our commercial opportunity may be adversely
 affected.

 Any
 product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.

 We
 may not be able to adequately protect our proprietary or licensed technology in the marketplace.

 We
 may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.

 We
 are subject to various U.S. federal, state and foreign healthcare laws and regulations, which could increase compliance costs, and
 our failure to comply with these laws and regulations could harm our results of operations and financial condition.

 Actual
 or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements
 could adversely affect our business, results of operations, and financial condition.

 A
 pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business and operations.

 Our
 business and operations may suffer in the event of information technology system failures, cyberattacks or deficiencies in our cybersecurity.

 Maintaining
 and improving our financial controls and the requirements of being a public company may strain our resources, divert management's
 attention and affect our ability to attract and retain qualified board members.

 Unfavorable
 global economic conditions could adversely affect our business, financial condition or results of operations.

 The
 market price of our common stock is volatile and you may sustain a complete loss of your investment.

 PART
I

 Item
1. Business.

 Overview

 We
are a clinical biotechnology company developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy.
We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation
of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package
of immune system activating signals that can be administered safely intravenously. Our patented technology is composed of single strains
of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability
to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral
activity in preclinical models, including durable anti-tumor response synergy observed with each of five different classes of existing
agents, including checkpoint therapy, targeted antibody therapy and low-dose chemotherapy. Tumor eradication by our technology has demonstrated
activation of both innate and adaptive immunological memory and, importantly, did not require provision of or targeting a tumor antigen
in preclinical models. We have carried out successful current Good Manufacturing Practice (cGMP) manufacturing of our lead clinical candidate,
Decoy20, and completed other Investigational New Drug Application (IND)-enabling studies.

 In
May 2022, the U.S. Food and Drug Administration, or the FDA, allowed us to proceed under our IND for a Phase 1 clinical trial in patients
with advanced solid tumors where currently approved therapies have failed, and in December 2022, we initiated this Phase 1 clinical trial
which is an open label, multi-center, dose escalation and expansion, single arm (monotherapy) study conducted in 2 parts. The Phase 1
study has begun with a single dose escalation, which is planned to be followed by an expansion part with continuous weekly administration
of Decoy20. The study is enrolling patients with advanced/metastatic solid tumors, who have exhausted approved treatment options. The
study's objectives are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose and recommended
Phase 2 dose, as well as to assess Decoy20 pharmacokinetics (PK), pharmacodynamics and clinical activity. The primary endpoint of the
study is incidence, relatedness and severity of adverse events and treatment-emergent adverse events and determining the number of subjects
per cohort with dose limiting toxicity-based adverse events. Secondary endpoints include the incidence of anti-drug antibodies and neutralizing
antibodies pre- and post-treatment, change in Decoy20 PK parameters over time, objective response rate in subjects with measurable disease
and duration of response. In August 2023, we completed the first cohort of patients who received a single dose in Part 1 of the Phase
1 clinical trial. Four patients were enrolled and evaluable in the first cohort. Overall, patients experienced symptoms or adverse events
(AEs) that were short-lived and consistent with the mechanism of action of Decoy20. In September 2023, we advanced into the second cohort
of the Phase 1 clinical trial after receiving authorization from the Safety Review Committee. In early March 2024, we completed the second
cohort of patients who received a single dose in Part 1 of the Phase 1 clinical trial and, following authorization from the Safety Review
Committee, advanced into the multi-dosing cohort of the Phase 1 clinical trial. The second cohort dose is a reduction from the dosing
in the first cohort based on the significant pharmacodynamic effect seen with the first cohort and anticipated optimal Decoy20 safety
profile for both multi-dosing and combination approaches.

 Unlike
many competitor products, our technology does not depend on targeting with or to a specific antigen, providing broad potential across
multiple indications. Our products are designed to have a much shorter half-life and produce less systemic exposure than small molecule,
antibody or human cell-based therapies, potentially reducing the risk of non-specific auto-immune reactions. Our technology has produced
single agent activity and/or combination therapy-based durable responses in lymphoma, hepatocellular, colorectal and pancreatic tumors
and has also showed activity against hepatitis B virus (HBV) and HIV infection in standard preclinical models. Our target indications
include, but are not limited to, colorectal, hepatocellular ( HBV), bladder, cervical and pancreatic carcinoma, which according
to GLOBOCAN 2020, account in the aggregate for 23% of yearly cancer cases and over 28% of yearly cancer deaths world-wide.

 Historically,
we have operated virtually with a team of highly experienced consultants and advisors, carrying out research and development at contract
research organizations (CROs). We have developed patented treatment methods (and associated patented compositions) for attenuation and
killing of non-pathogenic, Gram-negative bacteria (34 issued or granted patents). Since our inception, we have funded our operations
primarily through public and private offerings of our equity securities.

 Background

 Approved
immunotherapies, such as Interluekin-2, Interferon-alpha and the more recently approved "checkpoint" and CAR-T therapies
produce durable responses in a few percent to about fifty percent of patients across about a dozen out of over one hundred different
types of cancer. Although checkpoint therapies are able to effectively cure many previously incurable patients, only about 15% of patients
receiving this type of therapy respond. The main limitation of existing immunotherapies is that they each activate only one or a small
number of key steps in either the innate or adaptive immune system, but there is general agreement that highly efficient cancer immunotherapy
will require activation of both innate and adaptive immunity. The human body's innate and adaptive immune systems are each capable
of cell-mediated destruction of tumors if the tumor cells are recognized as foreign or damaged. Activation of innate and adaptive responses
is also dependent on immune cells sensing the presence of "danger." The most potent immune cell activating danger signals
are released by bacteria and viruses in the setting of infection, and include agonists of immune cell receptors, such as Toll-Like (TLR),
NOD and STING. Bacterial danger signals, including TLR agonists are called pathogen-associated molecular patterns (PAMPs) and can activate
both innate and adaptive immune cells, including antigen-presenting cells, promoting innate (NK, macrophage) and adaptive (T cell-mediated)
destruction of tumors.

 The
oldest form of cancer immunotherapy involves the provision of decoy danger signals from bacteria. It was based on the long-standing observation
of tumor regression in the setting of bacterial infection. Treatment of cancer patients with heat-killed bacteria ("Coley's
toxins") was established in 1891 and used for 70 years with significant success. For example, 5-year survival was reported
for 45% of 432 inoperable sarcoma, lymphoma, melanoma, and carcinoma patients. Despite this success, several limitations led to the abandonment
of this approach by the pharmaceutical industry. Although there was an indication that Coley's toxins worked best when administered
intravenously (i.v.), it was too toxic when given by this route, limiting the approach to local administration, which produced highly
variable results. Another limitation was lack of knowledge about the mechanism of action, preventing optimization and standardization
of manufacturing, leading to another source of variability in clinical response. Due to this high variability, Coley's toxins was
not grandfathered-in as an approved drug by the FDA in 1963 and was supplanted by radiation and chemotherapy, despite the fact that these
more modern approaches rarely produce durable responses in advanced cancer patients. Scientists now understand the mechanism of action
of Coley's toxins. Gram-negative bacteria contain multiple immune-stimulating danger signals, including TLR agonists such as lipopolysaccharide
(LPS). Bacteria and purified or mono-specific TLR agonists, including LPS derivatives, have been validated and approved for prevention
and treatment of early stage cancer. However, a safe and effective TLR agonist-based approach for advanced cancer has been elusive, possibly
due to limitations in the ability of intratumorally administered, mono-specific TLR agonists to induce potent, systemic anti-tumor immune
responses. In addition, the intratumoral approach is not feasible with all tumor types or patients. Our hypothesis is that an effective
TLR agonist-based immunotherapy for advanced cancer will require invention of a packaged, multi-TLR agonist or multi-danger signal product
that is modified or attenuated to allow safe i.v. administration.

 Our
Approach

 Our
patented approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor
immune responses can be achieved by using intact bacteria, containing multiple PAMPs, which have been attenuated so that they can be
administered safely intravenously. Because LPS appears to be the most important contributor to both toxicity and efficacy, our patented
product candidates are single strains of killed, non-pathogenic Gram-negative bacteria that have been treated in an effort to kill the
bacteria and significantly reduce, but not completely eliminate, the cell surface LPS-endotoxin activity. Our product candidates are
designed to have enhanced sufficient residual LPS to synergize with other PAMPs in the bacteria to efficiently prime innate and adaptive
immune pathways. This approach has led to broad anti-tumor responses, including synergistic regressions and durable responses with five
different classes of existing anti-tumor agents, in preclinical models, including checkpoint therapy, targeted antibody therapy and low-dose
chemotherapy. Tumor eradication by our technology is designed to produce both innate and adaptive immunological memory and, importantly,
not require provision of an exogenous tumor antigen, potentially due to the ability of LPS and other PAMPS to activate dendritic cells
that have already captured a tumor antigen.

 All
immune cells can participate in killing of tumors and viruses. As illustrated below, current therapies activate only one or a small subset
of both pathways and cure only a small percentage of patients.

 Our
technology, however, is designed to synergize with existing therapies to activate both innate and adaptive immune cells, inducing efficient
anti- tumor immune responses with a wide safety margin. Induction of adaptive anti-tumor immune responses and immunological memory by
our technology does not require an exogenous tumor antigen.

 Innate
and adaptive immune responses require identification of a tumor as foreign or not self. However, most steps required for migration and
activation of immune cells are unrelated to the tumor or are tumor non-specific. All innate and adaptive non-specific steps are induced
or promoted by immune system "danger signal" molecules, such as those found in our bacteria. Bacteria-derived danger signals
are also able to enhance the processing and recognition of tumor antigens, which are frequently present, but not "seen" by
the immune system.

 Results

 Preclinical
Trials

 In
preclinical models, Indaptus treated bacteria induced less systemic toxicity than untreated bacteria but were still able to activate
innate and adaptive immune responses. Despite exhibiting reduced in vivo pyrogenicity and a higher maximally tolerated dose, our bacteria
were able to induce secretion of most cytokines and chemokines from mouse and human immune cells in vitro at levels comparable to those
seen with untreated bacteria. Our bacteria were also able to synergize with human immune cells to kill human tumor cells in vitro.

 We
have observed significant single agent anti-tumor activity and/or combination therapy-mediated regression with durable responses in established
non-Hodgkin's lymphoma, as well as colorectal, hepatocellular and pancreatic carcinoma in preclinical syngeneic and human tumor
xenograft models. Our bacteria synergized with each of five different classes of approved agents in preclinical models, including checkpoint
therapy, targeted antibodies, low-dose chemotherapy, non-steroidal anti-inflammatory drugs (NSAIDs) and cytokines to induce tumor regression,
providing significant flexibility for targeting of diverse types of cancer. Our technology is designed to eradicate tumors via activation
of both innate (NK cell) and adaptive (CD4+ and CD8+ T cell) mechanisms, with the goal of producing both innate and adaptive immunological
memory. In our preclinical studies, tumor eradication occurred at non-toxic doses of our bacteria, with a very wide (10 to 33-fold)
therapeutic index. Notable mechanism of action information has also been obtained, via gene expression analysis with treated tumors and
plasma cytokine analysis, demonstrating that our combination technology has the potential to turn "cold" tumors into "hot"
tumors and induce, activate or recruit innate and adaptive genes, cells and pathways. Immune cell pre-depletion studies have demonstrated
that both innate (NK) and adaptive (CD4 T and CD8 T) immune cells are involved in tumor eradication. We have also demonstrated significant
single agent activity against chronic Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection in standard preclinical
models.

 We
have carried out successful cGMP manufacturing and stability studies with our lead product candidate, Decoy20. In addition, IND-enabling
multi-dose toxicology studies have been completed and did not produce sustained induction of factors that are associated with cytokine
release syndrome.

 The
chart above demonstrates that our bacteria synergize with Anti-PD-1 Checkpoint therapy to regress established mouse hepatocellular carcinoma
(HCC) Tumors. All mice (all groups) received a low-dose, non-steroidal anti-inflammatory drug (NSAID/Indomethacin), which increases the
number of regressions in the combination setting. Most regressions were durable, with 5/6 combination regressions stable through termination
at Day 91 and in a repeat experiment through termination at Day 143 (see next Figure below) (CR = complete response or complete regression).
The repeat experiment also produced 5/6 or 6/6 durable regressions per group over a 33-fold Indaptus concentration range and an absence
of safety concerns, demonstrating a very wide therapeutic index. Similar tumor eradication results have been obtained by combining our
bacteria with low-dose chemotherapy in a mouse non-Hodgkin's lymphoma model. Eradication of established non-Hodgkin's lymphoma
tumors by our technology has also been observed with human tumor xenografts, via activation of the innate immune system. Development
and preclinical efficacy characterization of a systemically administered multiple Toll-like receptor (TLR) agonist for antitumor immunotherapy
[abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into
Survival Sept 30-Oct 3, 2018 New York, NY. Philadelphia (PA): AACR Cancer Immunol Res 2019 7(2 Suppl):Abstract
nr B178.

 The
chart above illustrates that the synergistic tumor eradication by our technology and Anti-PD-1 produces immunological memory. Established
tumors were regressed in 11 mice by combination treatment as in the Figure above and then the mice were re-challenged with fresh HCC
tumor cells, without further treatment. All of the new tumors were rejected. Similar results have been obtained by combining our bacteria
with low-dose chemotherapy in a non-Hodgkin's lymphoma model.

 Clinical
Trial

 In
May 2022, the FDA allowed us to proceed under our IND application for a Phase 1 clinical trial in patients with advanced solid tumors
where currently approved therapies have failed, and in December 2022, we initiated this Phase 1 clinical trial which is an open label,
multi-center, dose escalation and expansion, single arm (monotherapy) study conducted in 2 parts. The Phase 1 study has begun with a
single dose escalation, which is planned to be followed by an expansion part with continuous weekly administration of Decoy20. The study
is enrolling patients with advanced/metastatic solid tumors, who have exhausted approved treatment options. The study's objectives
are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose and recommended Phase 2 dose, as well as
to assess Decoy20 pharmacokinetics PK, pharmacodynamics and clinical activity. The primary endpoint of the study is incidence, relatedness
and severity of adverse events and treatment-emergent adverse events and determining the number of subjects per cohort with dose limiting
toxicity-based adverse events. Secondary endpoints include the incidence of anti-drug antibodies and neutralizing antibodies pre- and
post-treatment, change in Decoy20 PK parameters over time, objective response rate in subjects with measurable disease and duration of
response. In August 2023, we completed the first cohort of patients who received a single dose in Part 1 of the Phase 1 clinical trial.
Four patients were enrolled and evaluable in the first cohort. Overall, patients experienced symptoms or adverse events (AEs) that were
short-lived and consistent with the mechanism of action of Decoy20. In September 2023, we advanced into the second cohort of the Phase
1 clinical trial after receiving authorization from the Safety Review Committee. In early March 2024, we completed the second cohort
of patients who received a single dose in Part 1 of the Phase 1 clinical trial and, following authorization from the Safety Review Committee,
advanced into the multi-dosing cohort of the Phase 1 clinical trial. The second cohort dose was a reduction from the dosing in the first
cohort based on the significant pharmacodynamic effect seen with the first cohort and anticipated optimal Decoy20 safety profile for
both multi-dosing and combination approaches.

 Business
Strategy

 Our
mission is to enhance and expand curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas,
which are responsible for approximately 90% of all cancer deaths.

 Our
business strategy includes:

 adding
 operational, financial and management information systems and personnel, including personnel to support our planned product development
 and commercialization efforts, as well as to support our reporting and other compliance obligations as a public reporting company

 advancing
 to the expansion portion of the Phase 1 clinical trial for Decoy20

 expanding
 our bacterial product platform to target additional types of cancer, as well as additional infectious diseases

 maintaining,
 expanding and protecting our intellectual property portfolio and

 seeking
 regulatory approvals for any product candidates that successfully complete clinical trials.

 Competitive
Advantages

 Our
bacteria contain multiple constituents, capable of priming or activating many of the cellular components of both innate and adaptive
immunity, but have been attenuated by a patented process to reduce the potential for over-stimulation of the immune system and
consequential induction of undesirable autoimmune reactions. Our bacteria are also likely to be cleared very quickly by the liver
and spleen, which may further reduce the risk of non-specific autoimmune side effects, relative to other types of immunotherapy that
are designed for continuous exposure. We believe a short exposure of our products is sufficient to act alone and as a
"primer" to enhance other products. Additionally, our products can be manufactured by a highly cost-efficient process,
potentially providing accelerated patient access in both developed and developing geographical regions.

 Governmental
Regulation

 Among
others, the FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and
burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs such as
those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development,
testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion,
distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.

 U.S.
Regulation of Drugs and Biologics

 In
the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations, and
biologics under the FDCA and the Public Health Service Act (PHSA) and its implementing regulations. FDA approval is required before any
new unapproved drug or dosage form, including a new use of a previously approved drug, can be marketed in the United States. Drugs and
biologics are also subject to other federal, state, and local statutes and regulations. The process required by the FDA before product
candidates may be marketed in the United States generally involves the following:

 completion
 of extensive preclinical laboratory tests, animal studies and formulation studies, performed in accordance with the Good Laboratory
 Practices (GLP) regulations and other applicable regulations;

 submission
 to the FDA an IND, which must become effective before human clinical studies may begin and must be updated annually;

 approval
 by an independent institutional review board (IRB) or ethics committee representing each clinical site before each clinical study
 may be initiated;

 performance
 of adequate and well-controlled human clinical studies in accordance with Good Clinical Practice (GCP), requirements to establish
 the safety and efficacy, or with respect to biologics, the safety, purity and potency of the product candidate for each proposed
 indication;

 preparation
 of and submission to the FDA of a new drug application (NDA) or biologics license application, (BLA), after completion of all pivotal
 clinical studies;

 a
 determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review;

 potential
 review of the product application by an FDA advisory committee, where appropriate and if applicable;

 satisfactory
 completion of an FDA pre-approval inspection of the manufacturing facilities where the proposed product drug is produced to assess
 compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the drug's identity, strength,
 quality and purity, and of potential inspection of selected clinical investigation sites to assess compliance with GCPs; and

 FDA
 review and approval of an NDA or BLA prior to any commercial marketing or sale of the drug in the United States.

 Once
a product candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations
of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical
tests, together with manufacturing information and analytical data, to the FDA as part of an IND. An IND is a request for authorization
from the FDA to administer an investigational drug product to humans. An IND will also include a protocol detailing, among other things,
the objectives of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated,
if the trial includes an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically
becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical
hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical
holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about on-going or proposed clinical
trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor
that the hold has been lifted.

 All
clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCPs, which include
the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical
trials must be conducted under protocols detailing the objectives of the trial, dosing procedures, subject selection and exclusion criteria
and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and a separate
submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent
protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies
performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety
reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies
suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant
risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the
protocol or investigator brochure.

 Furthermore,
an independent IRB at each institution participating in the clinical trial must review and approve each protocol before a clinical trial
commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to
each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. The
FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients
are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution
if the clinical trial is not being conducted in accordance with the IRB's requirements or if the drug has been associated with
unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized
by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial
may move forward at designated check points based on access to certain data from the trial. There are also requirements governing the
reporting of ongoing clinical studies and clinical study results to public registries, including clinicaltrials.gov.

 The
clinical investigation of a drug is generally divided into three phases. Although the phases are usually conducted sequentially, they
may overlap or be combined.

 Phase
 1. The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition. These
 studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product
 in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.

 Phase
 2. The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary
 efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical
 trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.

 Phase
 3. The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant
 evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites.
 These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate
 basis for product approval.

 Post-approval
trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional
experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance
of Phase 4 clinical trials as a condition of approval of an NDA.

 During
the development of a product candidate, sponsors are given opportunities to meet with the FDA at certain points. These points may be
prior to submission of an IND, at the end of Phase 2, and before an NDA or BLA is submitted. Meetings at other times may be requested.
These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide
advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Concurrent with clinical trials, companies
usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics
of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMPs. The manufacturing
process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer
must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must
be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable
deterioration over its shelf life.

 NDA
and BLA Review Process

 Assuming
successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
nonclinical studies and clinical trials are submitted to the FDA as part of an NDA or BLA requesting approval to market the product for
one or more indications. The NDA or BLA must include all relevant data available from pertinent preclinical studies and clinical trials,
including negative or ambiguous results as well as positive findings, together with detailed information relating to the product's
chemistry, manufacturing and controls and proposed labeling, among other things. Data can come from company-sponsored clinical studies
intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and
sponsored by investigators. The submission of an NDA or BLA requires payment of a substantial application user fee to the FDA, unless
a waiver or exemption applies.

 In
addition, under the Pediatric Research Equity Act, or PREA, an NDA or BLA or supplement to an NDA or BLA must contain data to assess
the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations
and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug
Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a drug or biological
product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit
an initial pediatric study plan within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless
otherwise required by regulation, PREA does not apply to any drug or biological product for an indication for which orphan designation
has been granted.

 Within
60 days following submission of the application, the FDA reviews the submitted BLA or NDA to determine if the application is substantially
complete before the agency accepts it for filing. The FDA may refuse to file any NDA or BLA that it deems incomplete or not properly
reviewable at the time of submission and may request additional information. In this event, the NDA or BLA must be resubmitted with the
additional information. Once an NDA or BLA has been accepted for filing, the FDA's goal is to review standard applications within
ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application
for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information
or clarification. The FDA reviews an NDA to determine, among other things, whether a product candidate is safe and effective for its
intended use and whether its manufacturing is sufficient to assure and preserve the product's identity, strength, quality and purity.
The FDA reviews a BLA to determine, among other things, whether a product candidate is safe, pure and potent and the facility in which
it is manufactured, processed, packed or held meets standards designed to assure the product's continued safety, purity and potency.
When reviewing an NDA or BLA, the FDA may convene an advisory committee to provide clinical insight on application review questions.
The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.

 Before
approving an NDA or BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not
approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements
and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or
BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.

 After
the FDA evaluates the NDA or BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug
substance will be produced, the FDA may issue an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes
commercial marketing of the product with specific prescribing information for specific indications. A CRL indicates that the review cycle
of the application is complete, and the application will not be approved in its present form. A CRL usually describes the specific deficiencies
in the NDA or BLA identified by the FDA and may require additional clinical data, including additional clinical trials, or other significant
and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a CRL is issued, the sponsor must
resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data
and information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval.

 If
regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the
indicated uses for which such product may be marketed. For example, the FDA may approve the NDA or BLA with a Risk Evaluation and Mitigation
Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential
serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use,
and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods,
patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed
labeling or the development of adequate controls and specifications. The FDA may also require one or more Phase 4 post-market studies
and surveillance to further assess and monitor the product's safety and effectiveness after commercialization, and may limit further
marketing of the product based on the results of these post-marketing studies.

 Expedited
Development and Review Programs

 The
FDA offers a number of expedited development and review programs for qualifying product candidates. For example, the fast track program
is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, product candidates
are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate
the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product
candidate and the specific indication for which it is being studied. The sponsor of a fast track product candidate has opportunities
for more frequent interactions with the review team during product development and, once an NDA or BLA is submitted, the application
may be eligible for priority review. A fast track product candidate may also be eligible for rolling review, where the FDA may consider
for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule
for the submission of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA or BLA and determines that the schedule
is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA.

 A
product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy
designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical
evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early
in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and
guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate,
including involvement of senior managers.

 Any
marketing application for a drug or biologic submitted to the FDA for approval, including a product candidate with a fast track designation
and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval
process, such as priority review. A product candidate is eligible for priority review if it has the potential to provide a significant
improvement in the treatment, diagnosis or prevention of a serious disease or condition. For new-molecular-entity NDAs and original BLAs,
priority review designation means the FDA's goal is to take action on the marketing application within six months of the 60-day
filing date (as compared to ten months under standard review).

 Additionally,
depending on the design of the applicable clinical trials, product candidates studied for their safety and effectiveness in treating
serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product candidate has
an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured
earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality
or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative
treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled
confirmatory clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical
benefit, and may require that such confirmatory studies be underway before granting any accelerated approval. Products receiving accelerated
approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required confirmatory studies in a timely
manner or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated
approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.

 Fast
track designation, breakthrough therapy designation, priority review, and accelerated approval do not change the standards for approval
but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later
decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will
not be shortened. We may explore some of these opportunities for our product candidates as appropriate.

 Orphan
drug designation

 Under
the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which
is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals
in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United
States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before
submitting an NDA or BLA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use
are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review
and approval process.

 If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to
market the same drug or biologic for the same disease or condition for seven years, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The
designation of such drug or biologic also entitles a party to financial incentives such as opportunities for grant funding towards clinical
trial costs, tax advantages and user-fee waivers. However, competitors, may receive approval of different products for the disease or
condition for which the orphan product has exclusivity or obtain approval for the same product but for a different disease or condition
for which the orphan product has exclusivity. Orphan exclusivity also could block the approval of a competing product for seven years
if a competitor obtains approval of the "same drug," as defined by the FDA, or if the active ingredient of the product candidate
is determined to be contained within the competitor's product for the same disease or condition. In addition, if an orphan designated
product receives marketing approval for a disease or condition broader than what is designated, it may not be entitled to orphan exclusivity.

 Post-Approval
Requirements

 Any
products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including,
among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and
distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new
indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements,
under which the FDA assesses an annual program fee for each product identified in an approved NDA or BLA. Drug and biologic manufacturers
and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic
unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation
requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on
the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and
correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide
to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain
compliance with cGMPs and other aspects of regulatory compliance.

 The
FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product
reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition
of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

 restrictions
 on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;

 fines,
 warning letters or holds on post-approval clinical studies;

 refusal
 of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product
 approvals;

 product
 seizure or detention, or refusal of the FDA to permit the import or export of products;

 consent
 decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;

 mandated
 modification of promotional materials and labeling and the issuance of corrective information;

 the
 issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other
 safety information about the product; or

 injunctions
 or the imposition of civil or criminal penalties.

 The
FDA closely regulates the marketing, labeling, advertising and promotion of drug products and biologics. A company can make only those
claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the
approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure
to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential
civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product's
labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties.
Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate
the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer's communications on the
subject of off-label use of their products.

 Drug
Product Marketing Exclusivity

 Market
exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing applications. For example,
the FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to obtain approval
of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing
the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period,
the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section 505(b)(2),
or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended
for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right
of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification
of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.

 The
FDCA alternatively provides three years of non-patent exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations,
other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval
of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the
modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from
approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and
three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be
required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary
to demonstrate safety and effectiveness.

 Pediatric
exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional
six months of marketing exclusivity attached to another period of existing exclusivity, including patent terms, if a sponsor conducts
clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor
to undertake the described clinical trials.

 Biosimilars
and Reference Product Exclusivity

 The
Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products that
are highly similar, or "biosimilar," to or interchangeable with an FDA-approved reference biological product. The FDA has
issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there
be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency,
is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product
is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results
as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and
the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks
of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with
an FDA-approved reference biological product may rely in part on the FDA's previous determination of safety and effectiveness for
the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product.

 Under
the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference
product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12
years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may
still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant's
own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its
product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it
is unclear whether products deemed "interchangeable" by the FDA will, in fact, be readily substituted by pharmacies, which
are governed by state pharmacy law.

 A
biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months
to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of existing exclusivity protection
or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued "Written
Request" for such a study.

 Other
Healthcare Laws

 Pharmaceutical
companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states
and foreign jurisdictions in which they conduct their business and may constrain the financial arrangements and relationships through
which we research as well as sell, market and distribute any products for which we obtain marketing approval. Such laws include, without
limitation, federal and state anti-kickback, fraud and abuse, false claims, data privacy and security and physician and other healthcare
provider transparency laws and regulations. If our operations are found to be in violation of any of such laws or any other governmental
regulations that apply, they may be subject to penalties, including, without limitation, administrative, civil and criminal penalties,
damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion
from participation in federal and state healthcare programs and imprisonment.

 Coverage
and Reimbursement

 Sales
of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and
foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for
such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on
a plan-by-plan basis. The coverage determination process is often a time-consuming and costly process that will require us to provide
scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement
will be obtained. These third-party payors are increasingly reducing reimbursements for medical products, drugs and services. In addition,
the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price
controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls
and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could
further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to
cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales.

 Healthcare
Reform

 In
March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each as amended,
collectively known as the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private
insurers, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions, including those governing
enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. By way of example, the ACA:

 increased
 the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the average manufacturer
 price;

 required
 collection of rebates for drugs paid by Medicaid managed care organizations;

 required
 manufacturers to participate in a coverage gap discount program, under which they must agree to offer 70 percent point-of-sale discounts
 off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
 manufacturers' outpatient drugs to be covered under Medicare Part D; and

 imposed
 a non-deductible annual fee on pharmaceutical manufacturers or importers who sell "branded prescription drugs" to specified
 federal government programs.

 Other
legislative changes have been proposed and adopted in the United States since the ACA was enacted. On March 11, 2021, the American Rescue
Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate
was previously capped at 100% of a drug's average manufacturer price, or AMP. Most recently, on August 16, 2022, the Inflation
Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in
price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare
Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap
discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human
Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29,
2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the drug price negotiation programs
is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated.

there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products,
which has resulted in several Congressional inquiries, proposed and enacted legislation and executive orders issued by the President
designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer
patient programs, and reform government program reimbursement methodologies for drug products. Individual states in the United States have also become increasingly active in
implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts,
restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage
importation from other countries and bulk purchasing.

 Data
Privacy and Security Laws

 Numerous
state, federal and foreign laws, regulations and standards govern the collection, use, access to, confidentiality and security of health-related
and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United
States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security
laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other
personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data.
Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance
efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions
on data processing.

 Competition

 The
pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis
on proprietary products. While we believe that our technology, knowledge and scientific resources provide us with certain competitive
advantages, we face competition from many sources, including pharmaceutical and biotechnology companies, academic institutions, governmental
agencies and public and private research institutions. Many of these competitors may have access to greater capital and resources than
us. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel. Any product candidates
that we successfully develop and commercialize will compete with new immunotherapies that may become available in the future. Our competitors
include larger and better funded biopharmaceutical, biotechnology and therapeutics companies, specifically companies focused on cancer
immunotherapies, such as Amgen, Inc., AstraZeneca plc, BMS, Genentech, Inc., GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG,
Pfizer Inc., Roche Holding Ltd and Sanofi S.A. On the other hand, many of these companies are developing immunotherapeutics which may
have potential to be used in concert with Decoy20 and in this regard, we view them as potentially complimentary.

 With
respect to our lead candidate, Decoy20, there are a number of companies that are developing possible treatments for cancer, however,
we believe we are the only company using systemic administration of killed, non-pathogenic Gram-negative bacteria with reduced lipopolysaccharide-endotoxin to stimulate innate and adaptive immune system pathways.

 Our
success will be based in part upon our ability to successfully commercialize Decoy20 and to identify, develop and manage a portfolio
of therapeutics that are safer and more effective than competing products in our target indications. Our market opportunity has the potential
to be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects,
are more convenient or are less expensive than any therapeutics we may develop. Our competitive position will also be dependent upon
our ability to attract and retain qualified personnel, to obtain patent protection or otherwise develop proprietary products or processes,
and protect our intellectual property, and to secure sufficient capital resources for the period between technological conception and
commercial sales. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing
and competitiveness of our products. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly
than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able
to enter the market.

 Intellectual
Property

 Our
success depends, at least in part, on our ability to protect our proprietary technology and intellectual property, and to operate without
infringing or violating the proprietary rights of others. We rely on a combination of patent, trademark, trade secret and copyright laws,
know-how, intellectual property licenses and other contractual rights (including confidentiality and invention assignment agreements)
to protect our proprietary technology and intellectual property, including related intellectual property rights.

 Patents

 As
of March 1, 2024, we own 34 granted patents and 18 pending patent applications to use within our field of business. Our patents and patent
applications generally relate to compositions and methods for treating cancer and infectious diseases, and our patents and any patents
that issue from our pending patent applications are expected to expire at various dates between 2033 and 2043.

 We
intend to submit patent applications for each new product and technology that we develop. The patent outlook for companies like ours
is generally uncertain and may involve complex legal and factual questions. Our ability to maintain and consolidate our proprietary position
for our technology will depend on our success in obtaining effective claims and enforcing those claims once granted. We do not know whether
any of our patent applications or any patent applications that we may license will result in the issuance of any patents. Our issued
patents and those that may be issued in the future, or patents that we may exclusively license, may be challenged, narrowed, circumvented
or found to be invalid or unenforceable, which could limit our ability to stop competitors from marketing related products or the length
of term of patent protection that we may have for our products. We cannot be certain that we were the first to invent the inventions
claimed in our owned patents or patent applications. In addition, our competitors may independently develop similar technologies or duplicate
any technology developed by us, and the rights granted under any issued patents may not provide us with any meaningful competitive advantages
against these competitors. Furthermore, because of the extensive time required for development, testing and regulatory review of a potential
product, it is possible that, before any of our products can be commercialized, any related patent may expire or remain in force for
only a short period following commercialization, thereby reducing any advantage of the patent.

 Trade
Secrets and Confidential Information

 In
addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. Trade secrets and know-how
can be difficult to protect. We rely on, among other things, confidentiality and invention assignment agreements to protect our proprietary
know-how and other intellectual property that may not be patentable, or that we believe is best protected by means that do not require
public disclosure. For example, we require our employees to execute confidentiality agreements in connection with their employment relationships
with us, and to disclose and assign to us inventions conceived in connection with their services to us. However, there can be no assurance
that these agreements will be enforceable or that they will provide us with adequate protection. We also seek to preserve the integrity
and confidentiality of our data, trade secrets and know-how by maintaining physical security of our premises and physical and electronic
security of our information technology systems.

 We
may be unable to obtain, maintain and protect the intellectual property rights necessary to conduct our business, and may be subject
to claims that we infringe or otherwise violate the intellectual property rights of others, which could materially harm our business.
For a more comprehensive summary of the risks related to our intellectual property, see Item 1A. "Risk Factors - Risks Related
to Our Intellectual Property."

 Environmental
Matters

 We
are subject to various environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling,
use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites. Our operations involve
the use of potentially hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous
waste products. Although we generally contract with third parties for the operations that involve the disposal of hazardous materials
and wastes, we cannot eliminate the risk of contamination or injury from these materials. Based on information currently available to
us, we do not expect environmental costs and contingencies to have a material adverse effect on us. However, we could incur substantial
costs as a result of violations of or liabilities under environmental requirements in connection with our operations or property, including
fines, penalties and other sanctions, investigation and cleanup costs and third-party claims. In the event of contamination or injury
resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our
resources. See Part I. Item 1A. "Risk Factors – Risks Related to Healthcare Laws and Other Legal Compliance Matters - Violations
of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that
could have a material adverse effect on the success of our business. "

 We
believe that our business, operations and facilities are being operated in compliance in all material respects with applicable environmental
and health and safety laws and regulations.

 Human
Capital Management

 As
of December 31, 2023, we have seven full-time employees. None of our employees are represented by labor unions or covered by collective
bargaining agreements.

 We
believe that our future success will depend, in part, on our continued ability to attract, hire and retain qualified personnel. In particular,
we depend on the skills, experience and performance of our senior management and research personnel. We compete for qualified personnel
with other biotechnology, medical device, pharmaceutical and healthcare companies, as well as universities and non-profit research institutions.

 We
provide competitive compensation and benefits programs to help meet the needs of our employees. In addition to salaries, these programs
include incentive compensation plan, pension, healthcare and insurance benefits, paid time off, and family leave, among others. We also
use targeted equity-based grants with vesting conditions to facilitate retention of personnel, particularly for our key employees.

 The
success of our business is fundamentally connected to the well-being of our people. Accordingly, we are committed to the health and safety
of our employees and we consider our relations with our employees to be good.

 Available
Information

 We
maintain a corporate website at  The information contained on, or that can be accessed through, our website
is neither a part of nor incorporated into this Annual Report.

 Copies
of our reports on Forms 10-K, Forms 10-Q and Forms 8-K, may be obtained, free of charge, electronically through our corporate website
at  as soon as reasonably practicable after we file such material electronically with, or furnish to, the SEC.
Additionally, the SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding
issuers that file electronically with the SEC at www.sec.gov.

 Item
1A. Risk Factors.

 You
should carefully consider the factors described below, together with all of the other information contained in this Annual Report, including
the audited consolidated financial statements and the related notes included in this Annual Report beginning on page F-1, before deciding
whether to invest in our common stock. If any of the risks discussed below actually occur, our business, financial condition, operating
results and cash flows could be materially adversely affected. This could cause the trading price of our common stock to decline, and
you may lose all or part of your investment.

 Risks
Related to Our Financial Position and Capital Requirements

 We
are a clinical-stage company with a limited operating history. We are not currently profitable, do not expect to become profitable in
the near future and may never become profitable.

 We
are a clinical-stage biotechnology company focused primarily on developing a novel and patented systemically-administered anti-cancer
and anti-viral immunotherapy. All of our product candidates are in the preclinical or early clinical development stage, and none of our
product candidates have been approved for marketing or are being marketed or commercialized.

 As
a result, we have no meaningful historical operations upon which to evaluate our business and prospects and have not yet demonstrated
an ability to obtain marketing approval for any of our product candidates or successfully overcome the risks and uncertainties frequently
encountered by companies in the biopharmaceutical industry. As a result, we have not been profitable and have incurred significant operating
losses in every reporting period since our inception. For the year ended December 31, 2023, we reported a net loss of approximately $15.4
million and as of December 31, 2023, we had an accumulated deficit of approximately $45.4 million.

 For
the foreseeable future, we expect to continue to incur losses, which will increase significantly from historical levels as we expand
our development activities, seek regulatory approvals for our product candidates, and begin to commercialize them if they are approved
by the FDA, the European Medicines Agency, or the EMA, or comparable foreign authorities. Further, the net losses we incur may fluctuate
significantly from quarter-to-quarter and year-to-year, such that a period-to-period comparison of our results of operations may not
be a good indication of our future performance. Even if we succeed in developing and commercializing one or more product candidates,
we may never become profitable, or even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent
periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders'
equity and working capital.

 We
have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.

 We
have incurred net losses and utilized cash in operations since inception as described above. In addition, as of December 31, 2023, we
had approximately $13.4 million in cash and cash equivalents, and during the twelve months ended December 31, 2023, we used $13.4 million
of cash in operations and expect to continue to incur significant cash outflows and incur future additional losses to execute our operating
plan. While we intend to finance our cash needs principally through collaborations, strategic alliances, or license agreements with third
parties and/or debt or equity financings, we cannot provide any assurance that new financing will be available to us on commercially
acceptable terms or in the amounts required, if at all. Due to the uncertainty in securing additional funding, and the insufficient amount
of cash and cash equivalents as of December 31, 2023, we have concluded that substantial doubt exists about our ability to continue as
a going concern within one year after the date of the filing of this Annual Report. If we are unsuccessful in securing sufficient financing,
we may need to delay, reduce, or eliminate our research and development programs, which could adversely affect our business prospects,
or cease operations.

 Our
audited consolidated financial statements included in this Annual Report have been prepared on a going concern basis under which an entity
is able to realize its assets and satisfy its liabilities in the ordinary course of business. The audited consolidated financial statements
do not give effect to any adjustments relating to the carrying values and classification of assets and liabilities that would be necessary
should we be unable to continue as a going concern within one year after the date that the financial statements are issued.

 Our
future operations are dependent upon the successful entry into collaborations, strategic alliances, or license agreements with third
parties and/or on the identification and successful completion of equity or debt financing and the achievement of profitable operations
at an indeterminate time in the future. There can be no assurances that we will be successful in completing these collaborations or alliances,
equity or debt financing or in achieving profitability. As such, there can be no assurance that we will be able to continue as a going
concern.

 Substantial
doubt about our ability to continue as a going concern may materially and adversely affect the price per share of our common stock, and
it may be more difficult for us to obtain financing. If potential collaborators decline to do business with us or potential investors
decline to participate in any future financing due to such concerns, our ability to increase our cash position may be limited. The perception
that we may not be able to continue as a going concern may cause others to choose not to deal with us due to concerns about our ability
to meet our contractual obligations. If we are unable to continue as a going concern, you could lose all or part of your investment in
our Company.

 Given
our lack of current cash flow, we will need to raise additional capital. If we are unable to raise a sufficient amount of capital when
needed in required amounts and on acceptable terms or at all, we may be forced to delay, limit or eliminate some or all of our research
programs, product development activities and commercialization efforts.

 Since
we will be unable to generate sufficient, if any, cash flow to fund our operations for the foreseeable future, we will need to seek additional
equity or debt financing to provide the capital required to maintain or expand our operations.

 There
can be no assurance that we will be able to raise sufficient additional capital on acceptable terms or at all. If such additional financing
is not available on satisfactory terms, or is not available in sufficient amounts, we may be required to delay, limit or eliminate some
or all of our research programs, product development activities and commercialization efforts, and our ability to achieve our business
objectives, our competitiveness, and our business, financial condition and results of operations may be materially adversely affected.
In addition, we may be required to grant rights to develop and market product candidates that we would otherwise prefer to develop and
market ourselves. Our inability to fund our business could lead to the loss of your investment.

 Our
future capital requirements will depend on many factors, including, but not limited to:

 the
 scope, rate of progress, results and cost of our clinical trials, preclinical studies and other related activities;

 the
 timing of, and the costs involved in, obtaining regulatory approvals for any of our current or future product candidates;

 the
 number and characteristics of the product candidates we seek to develop or commercialize;

 the
 cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidates;

 the
 cost of commercialization activities, if any, of our current or future product candidates that are approved for sale, including marketing,
 sales and distribution costs;

 the
 expenses needed to attract and retain skilled personnel;

 the
 costs associated with being a public company;

 the
 amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive
 marketing approval; and

 the
 costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible patent claims, including litigation
 costs and the outcome of any such litigation.

 Even
if we believe we have sufficient funds for our current or future operating plans, we may continue to seek additional capital if market
conditions are favorable or in light of specific strategic considerations. Adequate additional financing may not be available to us on
acceptable terms, or at all. If we are unable to obtain sufficient funding on a timely basis, in required amounts or on favorable terms,
we may be required to significantly delay, reduce or eliminate one or more of our research or product development programs and/or commercialization
efforts. We may also be unable to expand our operations or otherwise capitalize on business opportunities as desired. Any of these events
could materially adversely affect our financial condition and business prospects.

 Raising
additional capital would cause dilution to our shareholders and may restrict our operations or require us to relinquish rights to our
technologies or product candidates.

 Until
such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity
and/or debt financings and collaborations, licensing agreements or other strategic arrangements. We may seek additional capital through
a combination of private and public equity offerings, "at-the-market" issuances, equity-linked and structured transactions,
debt (straight, convertible, or otherwise) financings, collaborations and licensing arrangements. To the extent that we raise additional
capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include
liquidation or other preferences that adversely affect your rights as a shareholder. For example, in June 2022, we entered into an at
the market offering agreement, which was amended on September 1, 2022, with a sales agent pursuant to which we may offer and sell from
time to time shares of our common stock for aggregate gross proceeds of up to $3.7 million, and as of the date of this Annual Report,
we have sold 137,836 shares of our common for aggregate gross proceeds of $0.3 million, leaving a balance of $3.4 million remaining
for future sales. Additionally, in December 2022, we entered into a purchase agreement and a registration rights agreement with Lincoln
Park Capital Fund, LLC ("Lincoln Park") pursuant to which Lincoln Park has committed to purchase up to $20.0 million of our
common stock from time to time over a 36-month period (unless extended to a 48-month period pursuant to the terms thereof). We may also
issue in the future equity securities that provide for rights, preferences and privileges senior to those of our common stock. Given
our need for cash and that equity issuances are the most common type of fundraising for similarly situated companies, the risk of dilution
is particularly significant for our stockholders. Depending upon market liquidity at the time, additional sales of shares registered
at any given time could cause the trading price of our common stock to decline. Debt financing, if available, would result in increased
fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions
such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic
alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue
streams or product candidates, or grant licenses on terms that are not favorable to us.

 Risks
Related to the Discovery and Development of Our Product Candidates

 We
are dependent on the success of one or more of our current product candidates, and we cannot be certain that any of them will receive
regulatory approval or be commercialized.

 We
have spent significant time, money and effort on the development of our lead product candidate, Decoy20. As a result, our business is
largely dependent on the commencement of and success of clinical trials evaluating Decoy20 and our ability to complete the development
of, obtain regulatory approval for, and successfully commercialize Decoy20 in a timely manner. The process to develop, obtain regulatory
approval and commercialize Decoy20 is long, complex, costly and uncertain as to the outcome.

 To
date, no clinical trials designed to provide substantial evidence of safety, purity, potency or efficacy have been completed with any
of our product candidates. All of our product candidates will require additional development, including clinical trials as well as further
preclinical studies to evaluate their toxicology and optimize their formulation and regulatory approvals before they can be commercialized.
Positive results obtained during early development do not necessarily mean later development will succeed or that regulatory approvals
will be obtained. Our development efforts may not lead to commercial products, either because our product candidates fail to be safe
and effective, or in the case of our product candidates regulated as biologics, safe, pure and potent, or because we have inadequate
financial or other resources to advance our product candidates through the clinical development and approval processes. If any of our
product candidates fail to demonstrate safety, purity, potency or efficacy at any time or during any phase of development, we would experience
potentially significant delays in, or be required to abandon, development of the product candidate.

 We
do not anticipate that any of our current product candidates will be eligible to receive regulatory approval from the FDA, the EMA or
comparable foreign authorities and begin commercialization for a number of years, if ever. Even if we ultimately receive regulatory approval
for any of these product candidates, we or our potential future partners, if any, may be unable to commercialize them successfully for
a variety of reasons. These include, for example, the availability of alternative treatments, lack of cost-effectiveness, the cost of
manufacturing the product on a commercial scale and competition with other products. The success of our product candidates may also be
limited by the prevalence and severity of any adverse side effects. If we fail to commercialize one or more of our current product candidates,
we may be unable to generate sufficient revenues to attain or maintain profitability, and our financial condition may decline.

 Clinical
and preclinical development involves a lengthy and expensive process with an uncertain outcome. Any difficulties or delays in the commencement
or completion, or the termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay
or limit our ability to generate revenue or adversely affect our commercial prospects.

 Before
obtaining approval from regulatory authorities for the commercialization of any of our product candidates, we must conduct extensive
clinical trials to demonstrate the safety, purity, and potency, or efficacy of the product candidate in humans. Preclinical and clinical
drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any
time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate
can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our
industry is high.

 The
results from preclinical studies or early clinical trials of a product candidate may not predict the results of later clinical trials
of the product candidate, and interim results of a clinical trial are not necessarily indicative of final results. Product candidates
in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through
preclinical studies and initial clinical trials. It is not uncommon to observe results in clinical trials that are unexpected based on
preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results.
Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. A number of companies in the pharmaceutical
and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier
studies.

 Before
we can initiate clinical trials for any product candidates, we must submit the results of preclinical studies to the FDA, the EMA or
comparable foreign regulatory authorities along with other information, including information about product candidate chemistry, manufacturing
and controls and our proposed clinical trial protocol, as part of an IND or similar regulatory submission. The FDA, the EMA or comparable
foreign regulatory authorities may require us to conduct additional preclinical studies for any product candidate before it allows us
to initiate clinical trials under any IND or similar regulatory submission, which may lead to delays and increase the costs of our preclinical
development programs. Moreover, even if we commence clinical trials, issues may arise that could cause regulatory authorities to suspend
or terminate such clinical trials. Any such delays in the commencement or completion of our ongoing and planned clinical trials for our
product candidates could significantly affect our product development timelines and product development costs and harm our financial
position.

 We
do not know whether our planned clinical trials will begin on time or be completed on schedule, if at all. The commencement, data readouts
and completion of clinical trials can be delayed for a number of reasons, including delays related to:

 inability
 to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical
 trials;

 in obtaining allowance or approval from regulatory authorities to commence a trial or reaching a consensus with regulatory authorities
 on trial design;

 the
 FDA, the EMA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;

 any
 failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation
 and may vary significantly among different CROs and trial sites;

 delays
 in identifying, recruiting and training suitable clinical investigators;

 in obtaining approval from one or more institutional review boards (IRBs) or ethics committees at clinical trial sites;

 IRBs
 refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects,
 or withdrawing their approval of the trial;

 changes
 or amendments to the clinical trial protocol;

 clinical
 sites deviating from the trial protocol or dropping out of a trial;

 by our CROs to perform in accordance with Good Clinical Practice (GCP) requirements or applicable regulatory rules and guidelines
 in other countries;

 in manufacturing sufficient quantities of our product candidates, or obtaining sufficient quantities of combination therapies, for
 use in clinical trials;

 subjects
 failing to enroll or remain in our trials at the rate we expect, or failing to return for post-treatment follow-up, including subjects
 failing to remain in our trials;

 patients
 choosing an alternative product for the indications for which we are developing our product candidates, or participating in competing
 clinical trials;

 lack
 of adequate funding to continue a clinical trial, or costs being greater than we anticipate;

 subjects
 experiencing severe or serious unexpected drug-related adverse effects;

 occurrence
 of serious adverse events in trials of the same class of agents conducted by other companies that could be considered similar to
 our product candidates;

 selection
 of clinical endpoints that require prolonged periods of clinical observation or extended analysis of the resulting data;

 transfer
 of manufacturing processes to larger-scale facilities operated by a contract manufacturing organization (CMO), delays or failure
 by our CMOs or us to make any necessary changes to such manufacturing process, or failure of our CMOs to produce clinical trial materials
 in accordance with current Good Manufacturing Practice (cGMP), regulations or other applicable requirements; and

 third
 parties being unwilling or unable to satisfy their contractual obligations to us in a timely manner.

 Clinical
trials must be conducted in accordance with the FDA and other applicable regulatory authorities' legal requirements, regulations
and guidelines, and remain subject to oversight by these governmental agencies and ethics committees or IRBs at the medical institutions
where such clinical trials are conducted. We could also encounter delays if a clinical trial is suspended or terminated by us, by the
IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA, the
EMA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors,
including failure to conduct the clinical trial in accordance with regulatory requirements or applicable clinical trial protocols, adverse
findings from inspections of clinical trial sites by the FDA, the EMA or comparable foreign regulatory authorities, unforeseen safety
issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations
or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements
and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to
resubmit our clinical trial protocols to regulators or to IRBs for reexamination, which may impact the costs, timing or successful completion
of a clinical trial.

principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation
in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA, the
EMA or comparable foreign regulatory authorities. The FDA, the EMA or comparable foreign regulatory authority may conclude that a financial
relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study.
The FDA, the EMA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable
clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection,
of our marketing applications by the FDA, the EMA or comparable foreign regulatory authority, as the case may be, and may ultimately
lead to the denial of marketing approval of one or more of our product candidates.

 In
addition, the FDA's, the EMA's and other regulatory authorities' policies with respect to clinical trials may change
and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently
evolved. The EU Clinical Trials Regulation (CTR) which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became
applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application (CTA) to be submitted
in each member state, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized
process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single
submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state.
The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate
assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member
state's decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development
may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by
the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the Clinical Trials Directive,
or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the Clinical Trials
Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing)
will become subject to the provisions of the CTR. Compliance with the CTR requirements by us and our third-party service providers, such
as CROs, may impact our developments plans. If we are slow or unable to adapt to changes in existing requirements or the adoption of
new requirements or policies governing clinical trials, our development plans may be impacted.

 In
addition, many of the factors that cause, or lead to, the termination or suspension of, or a delay in the commencement or completion
of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any resulting delays to our
clinical trials could shorten any period during which we may have the exclusive right to commercialize our product candidates. In such
cases, our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could
be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects.

 We
expect to continue to incur significant research and development expenses and other operating expenses, which may make it difficult for
us to attain profitability.

 We
expect to expend substantial funds in research and development, including preclinical studies and clinical trials of our product candidates,
and to manufacture and market any product candidates in the event they are approved for commercial sale. We also may need additional
funding to develop or acquire complementary companies, technologies and assets, as well as for working capital requirements and other
operating and general corporate purposes. Moreover, our planned increases in staffing will dramatically increase our costs in the near
and long-term.

 Because
the successful development of our product candidates is uncertain, we are unable to precisely estimate the actual funds we will require
to develop and potentially commercialize them. In addition, we may not be able to generate sufficient revenue, even if we are able to
commercialize any of our product candidates, to become profitable.

 We
may expend our limited resources to pursue a limited number of research programs, product candidates and specific indications and fail
to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

 Due
to our limited financial and managerial resources, we must focus on a limited number of research programs and product candidates and
on specific indications. As such, we are currently focused on the development of Decoy20. As a result, we may forego or delay pursuit
of opportunities with other product candidates or for other indications for anti-cancer and anti-viral immunotherapy that later prove
to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products
or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific
indications may not yield any commercially viable products.

 Our
product candidates may cause undesirable side effects that could delay or prevent their regulatory approval or commercialization, cause
us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved product, or result
in other significant adverse implications on our business, financial condition and results of operations.

 As
is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our product
candidates' use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or
unexpected characteristics. For example, because the mechanism of action of our product candidates depends on stimulation of the immune
system, there is the potential for over-stimulation or undesirable immune reactions. Undesirable side effects caused by our product candidates,
whether used alone or in combination with other therapies, could cause us or regulatory authorities to interrupt, delay or halt clinical
trials or the delay or denial of regulatory approval by the FDA, the EMA or comparable foreign regulatory authorities, or, if such product
candidates are approved, result in a more restrictive label and other post-approval requirements. Any treatment-related side effects
could also affect patient recruitment or the ability of enrolled patients to complete the trial or could result in potential product
liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.

 If
our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical
trial, when used alone or in combination with other approved products or product candidates, we may need to interrupt, delay or abandon
their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics
are less prevalent, less severe or more acceptable from a risk-benefit perspective.

 Patients
in our ongoing and planned clinical trials may, in the future, suffer significant adverse events or other side effects not observed in
our preclinical studies or previous clinical trials. Patients treated with our product candidates may also be undergoing surgical, radiation
or chemotherapy treatments, which can cause side effects or adverse events that are unrelated to our product candidate, but may still
impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other
adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients'
illnesses. If such significant adverse events or other side effects are observed in any of our current or future clinical trials, we
may have difficulty recruiting patients to the clinical trials, or we may be required to abandon the trials or our development efforts
of that product candidate altogether. We, the FDA, other comparable regulatory authorities or an IRB may suspend clinical trials of a
product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable
health risks or adverse side effects. Even if the side effects do not preclude the product candidate from obtaining or maintaining regulatory
approval, undesirable side effects may inhibit market acceptance due to tolerability concerns as compared to other available therapies.
Any of these developments could materially harm our business, financial condition and prospects.

 Additionally,
if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such
product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a Risk
Evaluation and Mitigation Strategy (REMS), to ensure that the benefits of treatment with such product candidate outweigh the risks for
each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education,
extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what
is typical for the industry. We or our collaborators may also be required to adopt a REMS or engage in similar actions, such as patient
education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects
caused by any product that we develop alone or with collaborators. Other potentially significant negative consequences associated with
adverse events include:

 we
 may be required to suspend marketing of a product, or we may decide to remove such product from the marketplace;

 regulatory
 authorities may withdraw or change their approvals of a product;

 regulatory
 authorities may require additional warnings on the label or limit access of a product to selective specialized centers with additional
 safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment;

 we
 may be required to create a medication guide outlining the risks of a product for patients, or to conduct post-marketing studies;

 we
 may be required to change the way a product is administered;

 we
 could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or be sued and held liable for harm caused
 to subjects or patients; and

 a
 product may become less competitive, and our reputation may suffer.

 Any
of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving
or maintaining market acceptance of our product candidates, if approved by the FDA or other regulatory authorities.

 We
may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling patients in our clinical trials,
our clinical development activities could be delayed or otherwise adversely affected.

 Patient
enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials depends, in part, on the speed
at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able
to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible
patients to participate in these trials to such trial's conclusion as required by the FDA or other comparable regulatory authorities.
The conditions for which we currently plan to evaluate our product candidates are diseases with limited patient pools from which to draw
for clinical trials. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial
participants.

 Patient
enrollment for any of our clinical trials may be affected by other factors, including:

 size
 and nature of the targeted patient population;

 severity
 of the disease or condition under investigation;

 availability
 and efficacy of approved therapies for the disease or condition under investigation;

 patient
 eligibility criteria for the trial in question as defined in the protocol;

 perceived
 risks and benefits of the product candidate under study;

 clinicians'
 and patients' perceptions as to the potential advantages of the product candidate being studied in relation to other available
 therapies, including any products that may be approved for, or any product candidates under investigation for, the indications we
 are investigating;

 efforts
 to facilitate timely enrollment in clinical trials;

 patient
 referral practices of physicians;

 the
 ability to monitor patients adequately during and after treatment;

 proximity
 and availability of clinical trial sites for prospective patients;

 continued
 enrollment of prospective patients by clinical trial sites; and

 the
 risk that patients enrolled in clinical trials will drop out of such trials before completion.

 Additionally,
other pharmaceutical companies targeting these same diseases are recruiting clinical trial patients from these patient populations, which
may make it more difficult to fully enroll our clinical trials. We also rely on, and will continue to rely on, CROs and clinical trial
sites to ensure proper and timely conduct of our clinical trials and preclinical studies. Though we have entered into agreements governing
their services, we will have limited influence over their actual performance. Our inability to enroll a sufficient number of patients
for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment
delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain
regulatory approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients
for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials.

 Interim,
"topline" and preliminary data from our clinical trials and preclinical studies that we announce or publish from time to
time may change as more patient data become available and are subject to audit and verification procedures that could result in material
changes in the final data.

 From
time to time, we may publicly disclose interim, topline, or preliminary data from our clinical trials and preclinical studies, which
is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change
following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate
all data. As a result, the interim, topline, or preliminary results that we report may differ from future results of the same studies
or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated.
Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially
different from the topline or preliminary data we previously published. As a result, topline and preliminary data should be viewed with
caution until the final data is available.

 Interim
data from clinical trials that we may complete are further subject to the risk that one or more of the clinical outcomes may materially
change as patient enrollment continues and more patient data becomes available. Adverse differences between interim, topline, or preliminary
data and final data could significantly harm our business prospects. Further, disclosure of such data by us or by our competitors could
result in volatility in the price of our common stock.

 Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability
or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose
to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others
may not agree with what we determine is material or otherwise appropriate information to include in our disclosure, and any information
we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or
otherwise regarding a particular product candidate or our business. If the interim, topline, or preliminary data that we report differ
from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval
for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial
condition.

 Our
efforts to discover product candidates beyond our current product candidates may not succeed, and any product candidates we recommend
for clinical development may not actually begin clinical trials.

 We
intend to expand our existing pipeline of core assets. However, the process of researching and developing new product candidates is expensive,
time-consuming and unpredictable. Data from our current preclinical programs may not support the clinical development of our product
candidates, and we may not identify any additional products suitable for recommendation for clinical development. Moreover, any product
candidate we recommend for clinical development may not demonstrate, through preclinical studies, indications of safety and potential
efficacy that would support advancement into clinical trials. Such findings would potentially impede our ability to maintain or expand
our clinical development pipeline. Our ability to develop new product candidates and advance them into clinical development also depends
upon our ability to fund our research and development operations, and we cannot be certain that additional funding will be available
on acceptable terms, or at all.

 The
regulatory approval processes of the FDA, the EMA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable,
and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.

 The
clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution
of our product candidates are subject to extensive regulation by the FDA in the U.S. and by comparable foreign regulatory authorities
in foreign markets, such as the EMA in Europe. In the U.S., we are not permitted to market our product candidates in the U.S. until we
receive regulatory approval of a Biologics License Application (BLA) or New Drug Application (NDA) from the FDA. The process of obtaining
such regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially
based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population.
Approval policies or regulations may change, and the FDA, EMA and comparable regulatory authorities have substantial discretion in the
approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and
expense invested in clinical development of product candidates, regulatory approval of a product candidate is never guaranteed. Of the
large number of drugs in development, only a small percentage successfully complete the FDA, EMA or comparable regulatory approval processes
and are commercialized.

 Prior
to obtaining approval to commercialize a product candidate in the U.S. or abroad, we must demonstrate with substantial evidence from
adequate and well-controlled clinical trials, and to the satisfaction of the FDA, EMA or comparable foreign regulatory authorities, that
such product candidates are safe and effective for their intended uses, and in the case of biological products, that such product candidates
are safe, pure and potent. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe
available nonclinical or clinical data support the safety purity, potency or efficacy of our product candidates, such data may not be
sufficient to obtain approval from the FDA and comparable foreign regulatory authorities. The FDA, EMA or comparable foreign regulatory
authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for our product candidates
either prior to or post-approval, or may object to elements of our clinical development program.

 The
FDA, EMA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:

 such
 authorities may disagree with the design or execution of our clinical trials;

 negative
 or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA,
 EMA or comparable foreign regulatory agencies for approval;

 serious
 and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs
 similar to our product candidates;

 the
 population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population
 for which we seek approval;

 such
 authorities may not accept clinical data from trials that are conducted at clinical facilities or in countries where the standard
 of care is potentially different from that of their own country;

 we
 may be unable to demonstrate that a product candidate's clinical and other benefits outweigh its safety risks;

 such
 authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

 such
 authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to
 support the submission of a BLA, NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere, and such authorities
 may impose requirements for additional preclinical studies or clinical trials;

 such
 authorities may disagree with us regarding the formulation, labeling and/or the product specifications of our product candidates;

 approval
 may be granted only for indications that are significantly more limited than those sought by us, and/or may include significant restrictions
 on distribution and use;

 such
 authorities may find deficiencies in the manufacturing processes or facilities of the third-party manufacturers with which we contract
 for clinical and commercial supplies; or

 such
 authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.

 With
respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional
product testing, administrative review periods and agreements with pricing authorities. Even if we eventually complete clinical trials
and receive approval of a BLA, NDA or comparable foreign marketing application for our product candidates, the FDA or comparable foreign
regulatory authority may grant approval contingent on the performance of costly additional clinical trials and/or the implementation
of a REMS, which may be required because the FDA believes it is necessary to ensure safe use of the product after approval. Any delay
in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate
and would materially adversely impact our business and prospects.

 Even
if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize such
candidates in any other jurisdiction, which would limit our ability to realize their full market potential.

 In
order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements
on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory
authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our
ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities
in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.

 Approval
processes vary among countries and can involve additional product testing and validation, as well as additional administrative review
periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical
studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country
and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale
in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international
markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or
if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market
potential of any product we develop will be unrealized.

 Disruptions
at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain
or deploy key leadership and other personnel, prevent new or modified products from being developed, reviewed, approved or commercialized
in a timely manner or at all, which could negatively impact our business.

 The
ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including
government budget and funding levels, statutory, regulatory, and policy changes, the FDA's or foreign regulatory authorities'
ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA's
or foreign regulatory authorities' ability to perform routine functions. Average review times at the FDA and foreign regulatory
authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research
and development activities is subject to the political process, which is inherently fluid and unpredictable.

 Disruptions
at the FDA and other agencies, such as the EMA following its relocation to Amsterdam and resulting staff changes, may also slow the time
necessary for new drugs, and biologics or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government
agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several
times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.

 Separately,
in response to the global COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various
points. Even though the FDA has since resumed standard inspection operations, any resurgence of the virus or emergence of new variants
may lead to further inspectional or administrative delays. If a prolonged government shutdown occurs, or if global health concerns continue
to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities,
it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions,
which could have a material adverse effect on our business.

 Even
if we receive regulatory approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory
review, which may result in significant additional expenses.

 Any
regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities
and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions
for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management
requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for
a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution
methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our
product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion,
import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements
include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs
and GCP for any clinical trials that we may conduct. In addition, manufacturers of drug products and their facilities are subject to
continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations
and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated
severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions
on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension
of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject our company
to administrative or judicially imposed sanctions, including:

 restrictions
 on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;

 restrictions
 on product distribution or use, or requirements to conduct post-marketing studies or clinical trials;

 fines,
 restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials;

 refusal
 by the FDA to approve pending applications or supplements to approved applications submitted by us or suspension or revocation of
 approvals;

 product
 seizure or detention, or refusal to permit the import or export of our products; and

 injunctions
 or the imposition of civil or criminal penalties.

 The
occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue
and could require us to expend significant time and resources in response and could generate negative publicity.

 The
FDA's and other regulatory authorities' policies may change and additional government regulations may be promulgated that
could prevent, limit or delay marketing authorization of any product candidates we develop. We also cannot predict the likelihood, nature
or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad.
If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not
able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.

 The
FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.

 The
FDA strictly regulates marketing, labeling, advertising and promotion of prescription drugs. These regulations include standards and
restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving
the internet and off-label promotion. Any regulatory approval that the FDA grants is limited to those specific diseases and indications
for which a product is deemed to be safe and effective by FDA. While physicians in the United States may choose, and are generally permitted,
to prescribe drugs for uses that are not described in the product's labeling and for uses that differ from those tested in clinical
trials and approved by the regulatory authorities, our ability to promote any products will be narrowly limited to those indications
that are specifically approved by the FDA.

 If
we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied
large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from
engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under
which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of any product candidates,
if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.

 Risks
Related to Our Dependence on Third Parties

 The
commercial success of our product candidates depends upon their market acceptance among physicians, patients, healthcare payors and the
medical community.

 Even
if our product candidates obtain regulatory approval, our products, if any, may not gain market acceptance among physicians, patients,
healthcare payors and the medical community. The degree of market acceptance of any of our approved product candidates will depend on
a number of factors, including:

 the
 effectiveness of our approved product candidates as compared to currently available products;

 patient
 willingness to adopt our approved product candidates in place of current therapies;

 our
 ability to provide acceptable evidence of safety and efficacy;

 relative
 convenience and ease of administration;

 the
 prevalence and severity of any adverse side effects;

 restrictions
 on use in combination with other products;

 availability
 of alternative treatments;

 pricing
 and cost-effectiveness assuming either competitive or potential premium pricing requirements, based on the profile of our product
 candidates and target markets;

 effectiveness
 of our or our partners' sales and marketing strategy;

 our
 ability to obtain sufficient third-party coverage or reimbursement; and

 potential
 product liability claims.

 In
addition, the potential market opportunity for our product candidates is difficult to precisely estimate. Our estimates of the potential
market opportunity for our product candidates include several key assumptions based on our industry knowledge, industry publications,
third-party research reports and other surveys. Independent sources have not verified all of our assumptions. If any of these assumptions
prove to be inaccurate, then the actual market for our product candidates could be smaller than our estimates of our potential market
opportunity. If the actual market for our product candidates is smaller than we expect, our product revenues may be limited, it may be
harder than expected to raise funds, and it may be more difficult for us to achieve or maintain profitability. If we fail to achieve
market acceptance of our product candidates in the U.S. and abroad, our revenue will be limited and it will be more difficult to achieve
profitability.

 We
rely on third parties to conduct our preclinical studies and clinical trials and perform other tasks. If these third parties do not successfully
carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory
approval for or commercialize our product candidates and our business, financial condition and results of operations could be substantially
harmed.

 We
rely upon third-party CROs, medical institutions, clinical investigators and contract laboratories to monitor and manage data for our
ongoing preclinical and clinical programs. These CROs, investigators and other third parties play a significant role in the conduct and
timing of these trials and subsequent collection and analysis of data. Though we expect to carefully manage our relationships with such
CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future,
or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. Further,
while we have and will have agreements governing the activities of our third-party contractors, we have limited influence over their
actual performance. Nevertheless, we maintain responsibility for ensuring that each of our clinical trials and preclinical studies is
conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on these third parties
does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with requirements for
cGMP, or similar foreign requirements, GCP, and good laboratory practice (GLP), which are a collection of laws and regulations enforced
by the FDA, the EMA and comparable foreign authorities for all of our product candidates in clinical development. Regulatory authorities
enforce these regulations through periodic inspections of preclinical study and clinical trial sponsors, principal investigators, preclinical
study and clinical trial sites, and other contractors. If we or any of our CROs or vendors fail to comply with applicable regulations,
the data generated in our preclinical studies and clinical trials may be deemed unreliable, and the FDA, the EMA or comparable foreign
authorities may require us to perform additional preclinical studies and clinical trials before approving our marketing applications.
We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical
trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced consistent with cGMP regulations,
or similar foreign requirements. Our failure to comply with these regulations may require it to repeat clinical trials, which would delay
the development and regulatory approval processes.

 We
may not be able to enter into arrangements with CROs on commercially reasonable terms, or at all. In addition, our CROs will not be our
employees, and except for remedies available to us under our agreements with such CROs, we will not be able to control whether or not
they devote sufficient time and resources to our ongoing preclinical and clinical programs. If CROs do not successfully carry out their
contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they
obtain is compromised due to the failure to adhere to our protocols, regulatory requirements, or for other reasons, our clinical trials
may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product
candidates. CROs may also generate higher costs than anticipated. As a result, our business, financial condition and results of operations
and the commercial prospects for our product candidates could be materially and adversely affected, our costs could increase, and our
ability to generate revenue could be delayed.

 In
addition, principal investigators for our clinical trials may be asked to serve as scientific advisors or consultants to us from time
to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation
result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation
of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical
trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any BLA or NDA we submit. Any such delay
or rejection could prevent us from commercializing our product candidates.

 In
addition, our CROs have the right to terminate their agreements with us in the event of an uncured material breach and under other specified
circumstances. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative
third parties on commercially reasonable terms or at all. Switching or adding additional CROs, medical institutions, clinical investigators
or contract laboratories involves additional cost and requires management time and focus. In addition, there is a natural transition
period when a new CRO commences work replacing a previous CRO. As a result, delays occur, which can materially impact our ability to
meet our desired clinical development timelines. There can be no assurance that we will not encounter similar challenges or delays in
the future or that these delays or challenges will not have a material adverse effect on our business, financial condition or results
of operations.

 We
currently rely on third parties for the manufacture of our product candidates during clinical development, and expect to continue to
rely on third parties for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient
quantities of our product candidates, or such quantities at an acceptable cost, which could delay, prevent or impair our development
or potential commercialization efforts.

 We
do not own or operate manufacturing facilities and have no current plans to develop our own clinical or commercial-scale manufacturing
capabilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates, and related raw
materials for clinical development, as well as for commercial manufacture if any of our product candidates receives regulatory approval.
The facilities used by our third-party manufacturers must be approved for the manufacture of our product candidates by the FDA, EMA,
or any comparable foreign regulatory authority, pursuant to inspections that will be conducted after we submit an NDA or BLA to the FDA,
or submit a comparable marketing application to a foreign regulatory authority. We do not control the manufacturing process of, and are
completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of our product candidates. If
these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory
requirements of the FDA or any comparable foreign regulatory authority, they will not be able to secure and/or maintain regulatory approval
for the use of their manufacturing facilities.

 In
addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and
qualified personnel. If the FDA, EMA or any comparable foreign regulatory authority does not approve these facilities for the manufacture
our product candidates, or if such authorities withdraw any such approval in the future, we may be required to find alternative manufacturing
facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates,
if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions
being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures
or recalls, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our financial position.

 Our
or a third party's failure to execute on our manufacturing requirements on commercially reasonable terms and in compliance with
cGMP or other regulatory requirements could adversely affect our business in a number of ways, including:

 an
 inability to initiate or complete clinical trials of our product candidates in a timely manner;

 delay
 in submitting regulatory applications, or receiving regulatory approvals, for our product candidates;

 subjecting
 third-party manufacturing facilities to additional inspections by regulatory authorities;

 requirements
 to cease development or to recall batches of our product candidates; and

 in
 the event of approval to market and commercialize any product candidate, an inability to meet commercial demands.

 In
addition, we do not have any long-term commitments or supply agreements with any third-party manufacturers. We may be unable to establish
any long-term supply agreements with third-party manufacturers or to do so on acceptable terms, which increases the risk of failing to
timely obtain sufficient quantities of our product candidates or such quantities at an acceptable cost. Even if we are able to establish
agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:

 of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;

 breach
 of the manufacturing agreement by the third party;

 to manufacture our product candidates according to our specifications;

 to manufacture our product according to our schedule or at all;

 misappropriation
 of our proprietary information, including our trade secrets and know-how; and

 termination
 or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.

 Any
performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any
related remedial measures may be costly or time consuming to implement. We do not currently have arrangements in place for redundant
supply or a second source for all required raw materials used in the manufacture of our product candidates. If our existing or future
third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace
them on a timely basis or at all, which would have a material adverse impact on our financial position.

 Any
collaboration arrangement that we may enter into in the future may not be successful, which could adversely affect our ability to develop
and commercialize our current and potential future product candidates.

 We
may seek collaboration arrangements with biopharmaceutical companies for the development or commercialization of our current and potential
future product candidates. To the extent that we decide to enter into collaboration agreements, we will face significant competition
in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate, execute and implement.
We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements should we choose
to enter into such arrangements, and the terms of the arrangements may not be favorable to us. If and when we collaborate with a third
party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future
success of that product candidate to the third party. The success of our collaboration arrangements will depend heavily on the efforts
and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that
they will apply to these collaborations.

 Disagreements
between parties to a collaboration arrangement can lead to delays in developing or commercializing the applicable product candidate and
can be difficult to resolve in a mutually beneficial manner. In some cases, collaborations with biopharmaceutical companies and other
third parties are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect our business,
financial condition and results of operations.

 If
we are unable to develop our own commercial organization or enter into agreements with third parties to sell and market our product candidates,
we may be unable to generate significant revenues.

 We
do not have a sales and marketing organization, and we have no experience as a company in the sales, marketing and distribution of pharmaceutical
products. If any of our product candidates are ever approved for commercialization, we may be required to develop our sales, marketing
and distribution capabilities, or make arrangements with a third party to perform sales and marketing services. Developing a sales force
for any product resulting from any of our product candidates is expensive and time consuming and could delay any product launch. We may
be unable to establish and manage an effective sales force in a timely or cost-effective manner, if at all, and any sales force we do
establish may not be capable of generating sufficient demand for our product candidates. To the extent that we enter into arrangements
with collaborators or other third parties to perform sales and marketing services, our product revenues are likely to be lower than if
we marketed and sold our product candidates independently. If we are unable to establish adequate sales and marketing capabilities, independently
or with others, we may not be able to generate significant revenues and may not become profitable.

 Risks
Related to Commercialization

 The
successful commercialization of Decoy20 or any future product candidates, if approved, will depend in part on the extent to which governmental
authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or
maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability
to generate revenue.

 The
availability of coverage and the adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private
health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as Decoy20
and any future product candidates, if approved. Our ability to achieve coverage and acceptable levels of reimbursement for our products
by third-party payors will have an effect on our ability to successfully commercialize those products. Accordingly, we will need to successfully
implement a coverage and reimbursement strategy for any approved product candidate. Even if we obtain coverage for a given product by
a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably
high.

 If
we participate in the Medicaid Drug Rebate Program or other governmental pricing programs, in certain circumstances, our products would
be subject to ceiling prices set by such programs, which could reduce the revenue we may generate from any such products. Participation
in such programs would also expose us to the risk of significant civil monetary penalties, sanctions and fines should we be found to
be in violation of any applicable obligations thereunder.

 For
products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult
because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment
or procedure in which the product is used may not be available, which may impact physician utilization. We cannot be sure that coverage
and reimbursement in the United States, the European Union or elsewhere will be available, or at an acceptable level, for any product
that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.

 Third-party
payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse
to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available.
It is possible that a third-party payor may consider our products as substitutable and only offer to reimburse patients for the less
expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products,
pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement
status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize
an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels,
we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products
that we may develop.

 There
is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States,
third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in
determining the extent to which new drugs will be covered. Some third-party payors may require pre-approval of coverage for new or innovative
devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this
time what third-party payors will decide with respect to the coverage and reimbursement for Decoy20 and any future product candidates.

 Obtaining
and maintaining reimbursement status is time-consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used
as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However,
no uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage
and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often
a time consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each
payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.
Furthermore, rules and regulations regarding reimbursement change frequently and, in some cases, at short notice, and we believe that
changes in these rules and regulations are likely.

 Outside
the United States, international operations are generally subject to extensive governmental price controls and other market regulations,
and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure
on the pricing and usage of our products candidates, if approved in these jurisdictions. In many countries, the prices of medical products
are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own
prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation
could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, if any, the
reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable
revenue and profits.

increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause
such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover
or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products
due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes.
The downward pressure on healthcare costs in general, and prescription drugs, surgical procedures and other treatments in particular,
has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.

enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing
approval for and commercialize Decoy20 and any future product candidates and may affect the prices we may set.

 In
the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and
regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement
for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In
particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare
costs and improve the quality of healthcare.

 By
way of example, in March 2010, the ACA was enacted in the United States. The ACA established an annual, nondeductible fee on any entity
that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers' Medicaid rebate
liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; expanded eligibility criteria
for Medicaid programs; expanded the entities eligible for discounts under the 340B drug pricing program; increased the statutory minimum
rebates a manufacturer must pay under the Medicaid Drug Rebate Program; established a new Patient-Centered Outcomes Research Institute
to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and
establishes a Center for Medicare & Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare
and Medicaid spending.

 Since
its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA, and on June 17, 2021,
the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling
on the constitutionality of the ACA. Prior to the Supreme Court's decision, President Biden had issued an executive order to initiate
a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through
the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies
and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that
include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid
or the ACA. It is unclear how the healthcare reform measures will impact our business.

 In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. On March 11, 2021, the American Rescue
Plan Act of 2021 was signed into law, which eliminate the statutory cap on the Medicaid drug rebate, beginning January 1, 2024 at 100%
of a drug's AMP. Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices
in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed
and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship
between pricing and manufacturer patient assistance programs, and reform government program reimbursement methodologies for products.
Most recently, the Inflation Reduction Act of 2022, or IRA, included a number of significant drug pricing reforms, which include the
establishment of a drug price negotiation program within the U.S. Department of Health and Human Services, or HHS (beginning in 2026)
that requires manufacturers to charge a negotiated "maximum fair price" for certain selected drugs or pay an excise tax for
noncompliance, the establishment of rebate payment requirements on manufacturers under Medicare Parts B and D to penalize price increases
that outpace inflation (first due in 2023), and a redesign of the Part D benefit, as part of which manufacturers are required to provide
discounts on Part D drugs (beginning in 2025). The IRA permits the HHS Secretary to implement many of these provisions through guidance,
as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drug that will be subject
to price negotiations, although the drug price negotiation program is currently subject to legal challenges. For that and other reasons,
it is currently unclear how the IRA will be effectuated. Additional drug pricing proposals could appear in future legislation. Further,
it is possible that additional governmental action is taken in response to the COVID-19 pandemic.

 At
the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and
biological product pricing, including price or reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations,
financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding
procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare
programs. This could reduce the ultimate demand for Decoy20 and any future product candidates, if approved, or put pressure on our product
pricing, which could negatively affect our business, results of operations, financial condition and prospects.

 We
expect that these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions
in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure
on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may
result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms
may prevent us from being able to generate revenue, attain profitability or commercialize Decoy20 and any future product candidates,
if approved.

 Product
liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates
that we may develop.

 We
will face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and
will face an even greater risk if we commercially sell any product candidates that we may develop. If we cannot successfully defend ourselves
against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome,
liability claims may result in:

 decreased
 demand for any product candidates that we may develop;

 injury
 to our reputation and significant negative media attention;

 regulatory
 investigations that could require costly recalls or product modifications;

 withdrawal
 of clinical trial participants;

 significant
 costs to defend the related litigation;

 substantial
 monetary awards to trial participants or patients;

 loss
 of potential revenue;

 the
 diversion of management's attention away from managing our business; and

 the
 inability to commercialize any product candidates that we may develop.

 Although
we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur and is subject to
deductibles and coverage limitations. We anticipate that we will need to increase our insurance coverage when and if we successfully
commercialize any product candidate. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage
at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If we are unable to obtain insurance at acceptable
cost or otherwise protect against potential product liability claims, we will be exposed to significant liabilities, which may materially
and adversely affect our business and financial position. These liabilities could prevent or interfere with our commercialization efforts.

 We
are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit the supply of our product
candidates.

 The
process of manufacturing our product candidates is complex, highly regulated, and subject to several risks. For example, the process
of manufacturing our product candidates is extremely susceptible to product loss due to contamination, equipment failure or improper
installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes for any
of our product candidates could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral,
or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are
made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.
In addition, the manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures,
labor shortages, natural disasters, power failures and numerous other factors.

 In
addition, any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory
shortages, lot failures, withdrawals or recalls, or other interruptions in the supply of our product candidates. We also may need to
take inventory write-offs and incur other charges and expenses for product candidates that fail to meet specifications, undertake costly
remediation efforts, or seek costlier manufacturing alternatives.

 Risks
Related to Competition, Retaining Key Employees and Managing Growth

 If
our competitors have product candidates that are approved faster, marketed more effectively, are better tolerated, have a more favorable
safety profile or are demonstrated to be more effective than our product candidates, our commercial opportunity may be adversely affected.

 The
industry in which we operate is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary
products. While we believe that our technology, knowledge, experience and scientific resources provide it with competitive advantages,
we face potential competition from many different sources, including commercial biotechnology enterprises, academic institutions, government
agencies and private and public research institutions. Any product candidates that we successfully develop and commercialize will compete
with existing immunotherapies and new immunotherapies that may become available in the future.

 Many
of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical
studies, clinical trials, regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also
prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our competitors
may succeed in developing technologies and therapies that are more effective, better tolerated or less costly than any which we are developing,
or that would render our product candidates obsolete and noncompetitive. Even if we obtain regulatory approval for any of our product
candidates, our competitors may succeed in obtaining regulatory approvals for their products earlier than we do. We will also face competition
from these third parties in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites
and patient registration for clinical trials, and in acquiring and in-licensing technologies and products complementary to our programs
or advantageous to our business.

 The
key competitive factors affecting the success of each of our product candidates, if approved, are likely to be its efficacy, safety,
tolerability, frequency and route of administration, convenience and price, the level of branded and generic competition, market acceptance
by physicians and patients, and the availability of coverage and reimbursement from government and other third-party payors.

 Any
product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.

 The
Patient Protection and Affordable Care Act, signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition
and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or
interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be
submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval
of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed.
During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves
a full BLA for the competing product containing the sponsor's own preclinical data and data from adequate and well-controlled clinical
trials to demonstrate the safety, purity and potency of its product.

 We
believe that any of our future product candidates approved as a biological product under a BLA should qualify for the 12-year period
of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the
FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for
generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, could be substituted for any
one of our reference products in a way that is similar to traditional generic substitution for non-biological products will depend on
a number of marketplace and regulatory factors that are still developing.

 Our
future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.

 We
are highly dependent on our current senior management. If we fail to retain current members of our senior management and scientific personnel,
or to attract and keep additional key personnel, we may be unable to successfully develop or commercialize our product candidates. We
are highly dependent on our chief executive officer, Jeffrey A. Meckler, and our chief scientific officer, Michael J. Newman, Ph. D. Our
success depends on our continued ability to attract, retain and motivate highly qualified management and scientific personnel. However,
competition for qualified personnel is intense. We may not be successful in attracting qualified personnel to fulfill our current or
future needs on a full-time employment basis, or at all. In the event we are unable to fill critical open employment positions, we may
need to delay our operational activities and goals, including the development of the company's product candidates, and may have
difficulty in meeting our obligations as a public company. We do not currently maintain "key person" insurance on any of
our employees.

 In
addition, competitors and others are likely in the future to attempt to recruit our employees. The loss of the services of any of our
key personnel, the inability to attract or retain highly qualified personnel in the future or delays in hiring such personnel, particularly
senior management and other technical personnel, could materially and adversely affect our business, financial condition and results
of operations. In addition, the replacement of key personnel likely would involve significant time and costs and may significantly delay
or prevent the achievement of our business objectives. From time to time, our management seeks the advice and guidance of certain scientific
advisors and consultants regarding clinical and regulatory development programs and other customary matters. These scientific advisors
and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may
limit their availability to us. In addition, our scientific advisors may have arrangements with other companies to assist those companies
in developing products or technologies that may compete with us.

 We
will need to increase the size of our organization and may not successfully manage our growth.

 We
are an early clinical-stage biotechnology company with a small number of employees, and our management systems currently in place are
not likely to be adequate to support our future growth plans. Our ability to grow and to manage our growth effectively will require us
to hire, train, retain, manage and motivate additional employees and to implement and improve our operational, financial and management
systems. These demands also may require the hiring of additional senior management personnel or the development of additional expertise
by our senior management personnel. Hiring a significant number of additional employees, particularly those at the management level,
would increase our expenses significantly. Moreover, if we fail to expand and enhance our operational, financial and management systems
in conjunction with our potential future growth, it could have a material adverse effect on our business, financial condition and results
of operations.

 Risks
Related to Our Intellectual Property

 We
may not be able to adequately protect our proprietary or licensed technology in the marketplace.

 We
depend on our ability to protect our proprietary technology and products, or those that we may license. We intend to rely on trade secret,
patent, copyright and trademark laws, confidentiality, license, and other agreements with employees and third parties to protect our
intellectual property. Our success depends in large part on our ability and any licensor's or licensee's ability to obtain
and maintain patent protection in the U.S. and other countries with respect to our proprietary or licensed technology and products. We
cannot be certain that patent enforcement activities by future licensors will be conducted in compliance with applicable laws and regulations
or will result in valid and enforceable patents or other intellectual property rights. We also cannot be certain that future licensors
will allocate sufficient resources or prioritize their or our enforcement of such patents. Even if we are not a party to these legal
actions, an adverse outcome could prevent us from licensing intellectual property that we may need to operate our business, which would
have a material adverse effect on our business, financial condition and results of operations.

 We
believe we will be able to obtain, through prosecution of patent applications covering our owned technology, adequate patent protection
for our proprietary technology. If we are compelled to spend significant time and money protecting or enforcing our patents and future
patents that we may own, designing around patents held by others or licensing or acquiring, potentially for large fees, patents or other
proprietary rights held by others, our business, financial condition and results of operations may be materially and adversely affected.
If we are unable to effectively protect the intellectual property that we own or in-license, other companies may be able to offer the
same or similar products for sale, which could materially adversely affect our business, financial condition and results of operations.
The patents of others from whom we may license technology, and any future patents we may own, may be challenged, narrowed, invalidated
or circumvented, which could limit our ability to stop competitors from marketing the same or similar products or limit the length of
term of patent protection that we may have for our products.

 We
may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.

 We
may be unable to acquire or in-license any compositions, methods of use, processes or other intellectual property rights from third parties
that we identify as necessary for our current or future product candidates. We may face competition with regard to acquiring and in-licensing
third-party intellectual property rights, including from a number of more established companies. These established companies may have
a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.
In addition, companies that perceive us to be a competitor may be unwilling to assign or license intellectual property rights to us.
We also may be unable to acquire or in- license third-party intellectual property rights on terms that would allow us to make an appropriate
return on our investment.

 We
may enter into collaboration agreements with U.S. and foreign academic institutions to accelerate development of our current or future
preclinical product candidates. Typically, these agreements include an option for the company to negotiate a license to the institution's
intellectual property rights resulting from the collaboration. Even with such an option, we may be unable to negotiate a license within
the specified timeframe or under terms that are acceptable to us. If we are unable to license rights from a collaborating institution,
the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our desired program.

 If
we are unable to successfully obtain required third-party intellectual property rights or maintain our existing intellectual property
rights, we may need to abandon development of the related program and our business, financial condition and results of operations could
be materially and adversely affected.

 Obtaining
and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection for licensed patents, pending patent applications and potential future
patent applications and patents could be reduced or eliminated for non-compliance with these requirements.

 Periodic
maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or patent applications will be due to
be paid to the United States Patent and Trademark Office "USPTO" and various governmental patent agencies outside of the
U.S. in several stages over the lifetime of the applicable patent and/or patent application. The USPTO and various non-U.S. governmental
patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent
application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the
applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application,
resulting in partial or complete loss of patent rights in the relevant jurisdiction. If this occurs with respect to our in-licensed patents
or patent applications we may file in the future, our competitors might be able to use our technologies, which would have a material
adverse effect on our business, financial condition and results of operations.

 The
patent positions of products are often complex and uncertain. The breadth of claims allowed in patents in the U.S. and many jurisdictions
outside of the U.S. may not be consistent. Changes in either the patent laws or interpretations of patent laws in the U.S. and other
countries may diminish the value of our licensed or owned intellectual property or create uncertainty. In addition, publication of information
related to our current product candidates and potential products may prevent us from obtaining or enforcing patents relating to these
product candidates and potential products, including without limitation composition-of-matter patents, which are generally believed to
offer the strongest patent protection.

 Patents
that we may own now or may own or license in the future do not necessarily ensure the protection of our licensed or owned intellectual
property for a number of reasons, including, without limitation, the following:

 the
 patents may not be broad or strong enough to prevent competition from other products that are identical or similar to our product
 candidates;

 there
 can be no assurance that the term of a patent can be extended under the provisions of patent term extensions afforded by U.S. law
 or similar provisions in foreign countries, where available;

 the
 issued patents and patents that we may own now or may obtain or license in the future may not prevent generic or biosimilar entry
 into the market for our product candidates;

 we,
 or third parties from whom we in-license or may license patents, may be required to disclaim part of the term of one or more patents;

 there
 may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim;

 there
 may be prior art of which we are aware, which we do not believe affects the validity or enforceability of a patent claim, but which,
 nonetheless, ultimately may be found to affect the validity or enforceability of a patent claim;

 there
 may be other patents issued to others that will affect our freedom to operate;

 if
 the patents are challenged, a court could determine that they are invalid or unenforceable;

 there
 might be a significant change in the law that governs patentability, validity and infringement of our licensed patents or any future
 patents we may own that adversely affects the scope of our patent rights;

 a
 court could determine that a competitor's technology or product does not infringe our patents or any future patents we may
 own; and

 the
 patents could irretrievably lapse due to failure to pay fees or otherwise comply with regulations or could be subject to compulsory
 licensing. If we encounter delays in our development or clinical trials, the period of time during which we could market our potential
 products under patent protection would be reduced.

 Our
competitors may be able to circumvent patents or future patents that we may own by developing similar or alternative technologies or
products in a non-infringing manner. Our competitors may seek to market generic or biosimilar versions of any approved products by submitting
abbreviated new applications or biosimilar biological product applications to the FDA in which our competitors claim that our licensed
patents or any future patents we may own are invalid, unenforceable or not infringed. Alternatively, our competitors may seek approval
to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend or
assert our patents or any future patents we may own, including by filing lawsuits alleging patent infringement. In any of these types
of proceedings, a court or other agency with jurisdiction may find our licensed patents or any future patents we may own invalid or unenforceable.
We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. Even
if we own or in-license valid and enforceable patents, these patents still may not provide protection against competing products or processes
sufficient to achieve our business objectives.

 The
issuance of a patent is not conclusive as to its inventorship, scope, ownership, priority, validity or enforceability. In this regard,
third parties may challenge our patents or any future patents we may own in the courts or patent offices in the U.S. and abroad. Such
challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable,
in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products,
or limit the duration of the patent protection of our technology and potential products. In addition, given the amount of time required
for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire
before or shortly after such product candidates are commercialized.

 Patent
terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

 Patents
have a limited lifespan, and the protection patents afford is limited. In the United States, if all maintenance fees are timely paid,
the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Even if patents covering
our product candidates are obtained, once the patent life has expired for patents covering a product or product candidate, we may be
open to competition from competitive products and services. As a result, our patent portfolio may not provide us with sufficient rights
to exclude others from commercializing products similar or identical to ours. We may infringe the intellectual property rights of others,
which may prevent or delay our product development efforts and prevent us from commercializing, or increase the costs of commercializing,
our products.

 Our
commercial success depends significantly on our ability to operate without infringing the patents and other intellectual property rights
of third parties. For example, there could be issued patents of which we are not aware that our current or potential future product candidates
infringe. There also could be patents that we believe we do not infringe upon, but that we may ultimately be found to infringe upon.

patent applications are in some cases maintained in secrecy until patents are issued. The publication of discoveries in the scientific
or patent literature frequently occurs substantially later than the date on which the underlying discoveries were made and patent applications
were filed. Because patents can take many years to issue, there may be currently pending applications of which we are unaware that may
later result in issued patents that our product candidates or potential products infringe. For example, pending applications may exist
that claim or can be amended to claim subject matter that our product candidates or potential products infringe. Competitors may file
continuing patent applications claiming priority to already issued patents in the form of continuation, divisional, or continuation-in-part
applications, in order to maintain the pendency of a patent family and attempt to cover our product candidates.

 Third
parties may assert that we are employing their proprietary technology without authorization and may sue us for patent or other intellectual
property infringement. These lawsuits are costly and could adversely affect our business, financial condition and results of operations
and divert the attention of managerial and scientific personnel. If we are sued for patent infringement, we would need to demonstrate
that our product candidates, potential products or methods either do not infringe the claims of the relevant patent or that the patent
claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity
requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are
successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel
could be diverted in pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient
resources to bring these actions to a successful conclusion. If a court holds that any third-party patents are valid, enforceable and
cover our products or their use, the holders of any of these patents may be able to block our ability to commercialize our products unless
it acquires or obtains a license under the applicable patents or until the patents expire.

 We
may not be able to enter into licensing arrangements or make other arrangements at a reasonable cost or on reasonable terms. Any inability
to secure licenses or alternative technology could result in delays in the introduction of our products or lead to prohibition of the
manufacture or sale of products by us. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors
access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing
technology or product. In addition, in any such proceeding or litigation, we could be found liable for monetary damages, including treble
damages and attorneys' fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent us from
commercializing our product candidates or force us to cease some of our business operations, which could materially and adversely affect
our business, financial condition and results of operations. Any claims by third parties that we have misappropriated their confidential
information or trade secrets could have a similar material and adverse effect on our business, financial condition and results of operations.
In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect
on our ability to raise the funds necessary to continue our operations.

 Any
claims or lawsuits relating to infringement of intellectual property rights brought by or against us will be costly and time consuming
and may adversely affect our business, financial condition and results of operations.

 We
may be required to initiate litigation to enforce or defend our licensed and owned intellectual property. Lawsuits to protect our intellectual
property rights can be very time consuming and costly. There is a substantial amount of litigation involving patent and other intellectual
property rights in the biopharmaceutical industry generally. Such litigation or proceedings could substantially increase our operating
expenses and reduce the resources available for development activities or any future sales, marketing or distribution activities.

 In
any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information
could be compromised by disclosure during litigation. Moreover, there can be no assurance that we will have sufficient financial or other
resources to file and pursue such infringement claims, which typically last for years before they are resolved. Further, any claims we
assert against a perceived infringer could provoke these parties to assert counterclaims against us alleging that we have infringed their
patents. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because
of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings
could have a material adverse effect on our ability to compete in the marketplace.

 In
addition, our patents and patent applications, and patents and patent applications that we may apply for, own or license in the future,
could face other challenges, such as interference proceedings, opposition proceedings, re-examination proceedings and other forms of
post-grant review. Any of these challenges, if successful, could result in the invalidation of, or in a narrowing of the scope of, any
of our patents and patent applications and patents and patent applications that we may apply for, own or license in the future subject
to challenge. Any of these challenges, regardless of their success, would likely be time consuming and expensive to defend and resolve
and would divert our management and scientific personnel's time and attention.

 Changes
in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.

 As
is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining
and enforcing patents in the biotechnology industry involves both technological and legal complexity and is costly, time-consuming and
inherently uncertain. For example, the U.S. previously enacted and is currently implementing wide-ranging patent reform legislation.
Specifically, on September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law and included a
number of significant changes to U.S. patent law, and many of the provisions became effective in March 2013. However, it may take the
courts years to interpret the provisions of the Leahy-Smith Act, and the implementation of the statute could increase the uncertainties
and costs surrounding the prosecution of our licensed and future patent applications and the enforcement or defense of our licensed and
future patents, all of which could have a material adverse effect on our business, financial condition and results of operations.

 In
addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available
in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard
to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents,
once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents
could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we might obtain in
the future.

 We
may not be able to protect our intellectual property rights throughout the world.

 Filing,
prosecuting and defending patents on product candidates throughout the world could be prohibitively expensive. Competitors may use our
licensed and owned technologies in jurisdictions where we have not licensed or obtained patent protection to develop their own products
and, further, may export otherwise infringing products to territories where we may obtain or license patent protection, but where patent
enforcement is not as strong as that in the U.S. These products may compete with our products in jurisdictions where we do not have any
issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent
them from competing.

 Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual
property protection, which could make it difficult for us to stop the infringement of our licensed patents and future patents we may
own, or marketing of competing products in violation of our proprietary rights generally. Further, the laws of some foreign countries
do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant
problems in protecting and defending our licensed and owned intellectual property both in the U.S. and abroad. Proceedings to enforce
our future patent rights, if any, in foreign jurisdictions could result in substantial cost and divert our efforts and attention from
other aspects of our business.

 We
may be unable to adequately prevent disclosure of trade secrets and other proprietary information.

 In
order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our corporate partners,
employees, consultants, manufacturers, outside scientific collaborators and sponsored researchers and other advisors. These agreements
may not effectively prevent disclosure of our confidential information and may not provide an adequate remedy in the event of unauthorized
disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information.
Failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

 We
may be subject to claims challenging the inventorship of our patents, any future patents we may own, and other intellectual property.

 Although
we are not currently experiencing any claims challenging the inventorship of our patents or our owned intellectual property, we may in
the future be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other
owned intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations
of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and
other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could
have a material adverse effect on our business, financial condition and results of operations. Even if we are successful in defending
against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

 Risks
Related to Healthcare Laws and Other Legal Compliance Matters

 We
are subject to various U.S. federal, state and foreign healthcare laws and regulations, which could increase compliance costs, and our
failure to comply with these laws and regulations could harm our results of operations and financial condition.

 Our
business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors,
patient organizations and customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws
and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations,
including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include:

 the
 federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting,
 offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly
 or covertly, in cash or in kind, in return for, either the referral of an individual or the purchase, lease, or order, or arranging
 for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole
 or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge
 of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation;

 the
 federal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit, among other things,
 individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval
 that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false
 or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation
 to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting
 from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims
 Act;

 the
 federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability for, among
 other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or
 knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection
 with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti- Kickback Statute, a person
 or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

 the
 federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for
 which payment is available under Medicare, Medicaid or the Children's Health Insurance Program (with certain exceptions) to
 report annually to the Centers for Medicare & Medicaid Services (CMS), information related to payments and other "transfers
 of value" made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician
 practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology
 assistants and certified nurse-midwives), and teaching hospitals and other healthcare providers, as well as ownership and investment
 interests held by such healthcare professionals and their immediate family members; and

 analogous
 state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing
 arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private
 insurers; some state laws require biotechnology companies to comply with the biotechnology industry's voluntary compliance
 guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report
 information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures;
 some state laws that require biotechnology companies to report information on the pricing of certain drug products; and some state
 and local laws that require the registration or pharmaceutical sales representatives.

 Efforts
to ensure that our current and future business arrangements with third parties will comply with applicable healthcare and privacy laws
and regulations will involve ongoing substantial costs. It is possible that governmental authorities will conclude that our business
practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that
may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines,
disgorgement, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, integrity
oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment
or restructuring of our operations. Defending against any such actions can be costly and time-consuming and may require significant financial
and personnel resources.

 Therefore,
even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further,
if any of the physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance
with applicable laws or regulations, they may be subject to significant criminal, civil or administrative sanctions, including exclusions
from government-funded healthcare programs.

 Actual
or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements
could adversely affect our business, results of operations, and financial condition.

 The
global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements
and regulations governing the collection, use, disclosure, retention, and security of personal information. Implementation standards
and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws,
regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business,
affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate
the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. Each of these laws
is subject to varying interpretations by courts and government agencies, creating complex compliance issues. If we fail to comply with
applicable laws and regulations, we may face government investigations and/or enforcement actions, fines, civil or criminal penalties,
private litigation or adverse publicity that could adversely affect our business, financial condition and results of operation. For example,
we may be subject to criminal penalties if we knowingly obtain or disclose individually identifiable health information from a covered
entity in a manner that is not authorized or permitted by the Health Insurance Portability and Accountability Act, as amended by the
Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder or applicable state
laws.

 Violations
of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that
could have a material adverse effect on the success of our business.

 We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling,
use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites. Our operations involve
the use of potentially hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous
waste products. We could incur substantial costs as a result of violations of or liabilities under environmental requirements in connection
with our operations or property, including fines, penalties and other sanctions, investigation and cleanup costs and third-party claims.
Although we generally contract with third parties for the disposal of hazardous materials and wastes from our operations, we cannot eliminate
the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous
materials, we could be held liable for any resulting damages, and any liability could exceed our resources.

 Furthermore,
environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact
of changes to applicable laws and regulations and cannot be certain of our future compliance. In addition, we may incur substantial costs
in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations
may impair our research, development or production efforts.

 Although
we maintain workers' compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal
of biological, hazardous or radioactive materials.

 Other
Risks Related to Our Business

 A
pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business and operations.

 Pandemics,
epidemics or other infectious disease outbreaks have in the past and could in the future negatively affect our business. The COVID-19
pandemic has affected the United States and global economies and has affected our operations and those of third parties on which we rely,
including by causing disruptions in the supply of our product candidates and the conduct of current and future clinical trials. For example,
the pandemic has caused our GMP process to take longer than expected. In addition, the COVID-19 pandemic has affected, and may continue
to affect, the operations of the FDA and other health authorities, which could result in delays of reviews and approvals, including with
respect to our product candidates. Additionally, the COVID-19 pandemic has contributed to the current economic downturn and volatility
in the global financial markets making our ability to access capital more challenging and thereby negatively impacting our short-term
and long-term liquidity. The ultimate impact of the COVID-19 pandemic (including any variants thereof) or any future pandemic, epidemic
or outbreak of an infectious disease is highly uncertain and cannot be predicted.

 Our
business and operations may suffer in the event of information technology system failures, cyberattacks or deficiencies in our cybersecurity.

 We
collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information
technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit
large amounts of confidential information, including intellectual property, proprietary business information and personal information
of customers and our employees and contractors. It is critical that we do so in a secure manner to maintain the confidentiality and integrity
of such confidential information.

 Our
information technology systems and those of our third-party service providers, strategic partners and other contractors or consultants
are vulnerable to attack and damage or interruption from computer viruses and malware (e.g. ransomware), malicious code, natural disasters,
terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes,
employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported
actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. We
have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could
have access to our confidential information.

 Further,
attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and
are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of
the changes brought about by the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology
and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.
Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not
recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures.
We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately
investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent
controls, to avoid detection, and to remove or obfuscate forensic evidence.

 We
and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that
we have experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions
in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a
loss, corruption or unauthorized disclosure of our trade secrets, personal information or other proprietary or sensitive information
or other similar disruptions. If a security breach or other incident were to result in the unauthorized access to or unauthorized use,
disclosure, release or other processing of personal information, it may be necessary to notify individuals, governmental authorities,
supervisory bodies, the media and other parties pursuant to privacy and security laws. We could also incur liability, including litigation
exposure, penalties and fines, and we could become the subject of regulatory action or investigation. Our competitive position could
be harmed and the further development and commercialization of our products and services could be delayed. We maintain cyber liability
insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result
from an interruption or breach of our systems. While we have implemented a cybersecurity risk management program, there can be no assurance
that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully implemented,
complied with or effective in protecting our systems and information.

 We
may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our
management.

 From
time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing
of products, product candidates or technologies. Additional potential transactions that we may consider include a variety of different
business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations
and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures
and may pose significant integration challenges or disrupt our management or business, which could adversely affect our business, financial
condition and results of operations. For example, these transactions may entail numerous operational and financial risks, including:

 exposure
 to unknown liabilities;

 disruption
 of our business and diversion of our management's time and attention in order to develop acquired products, product candidates
 or technologies;

 incurrence
 of substantial debt or dilutive issuances of equity securities to pay for any of these transactions;

 higher-than-expected
 transaction and integration costs;

 write-downs
 of assets or goodwill or impairment charges;

 increased
 amortization expenses;

 difficulty
 and cost in combining the operations and personnel of any acquired businesses or product lines with our operations and personnel;

 impairment
 of relationships with key suppliers or customers of any acquired businesses or product lines due to changes in management and ownership;
 and

 inability
 to retain key employees of any acquired businesses.

 Accordingly,
although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any
transactions that we do complete may be subject to the foregoing or other risks and could have a material adverse effect on our business,
financial condition and results of operations.

 Risks
Related to Our Common Stock

 The
market price of our common stock is volatile and you may sustain a complete loss of your investment.

 Our
common stock currently trades on the Nasdaq Capital Market. The market price of our common stock has been, and is likely to continue
to be, volatile. The market price of our common stock may fluctuate significantly in response to numerous factors, some of which are
beyond our control, such as:

 inability
 to obtain the approvals necessary to commence clinical trials;

 results
 of clinical and preclinical studies;

 announcements
 of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes
 or delays in the regulatory review process;

 announcements
 of technological innovations, new products or product enhancements by us or others;

 adverse
 actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities;

 changes
 or developments in laws, regulations or decisions applicable to our product candidates or patents;

 any
 adverse changes to our relationship with manufacturers, suppliers or partners;

 announcements
 concerning our competitors or the pharmaceutical or biotechnology industries in general;

 achievement
 of expected product sales and profitability or our failure to meet expectations;

 our
 commencement of or results of, or involvement in, litigation, including, but not limited to, any product liability actions or intellectual
 property infringement actions;

 any
 major changes in our board of directors, management or other key personnel;

 legislation
 in the United States, Europe and other foreign countries relating to the sale or pricing of pharmaceuticals;

 announcements
 by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments;

 expiration
 or terminations of licenses, research contracts or other collaboration agreements;

 public
 concern as to the safety of therapeutics we, any licensees or others develop;

 success
 of research and development projects;

 developments
 concerning intellectual property rights or regulatory approvals;

 variations
 in us and our competitors' results of operations;

 changes
 in earnings estimates or recommendations by securities analysts, if our common stock is covered by analysts;

 future
 issuances of common stock or other securities;

 general
 market conditions, including the volatility of market prices for shares of biotechnology companies generally, and other factors,
 including factors unrelated to our operating performance;

 political
 and economic instability, war or acts of terrorism (such as Russia's invasion of Ukraine and the conflict in the Middle East)
 or natural disasters, emergence of a pandemic, or other widespread health emergencies (or concerns over the possibility of such an
 emergency, similar to the unprecedented COVID-19 pandemic); and

 the
 other factors described in this "Risk Factors" section.

 These
factors and any corresponding price fluctuations may materially and adversely affect the market price of our common stock, which would
result in substantial losses by our investors.

 Further,
the stock market in general, the Nasdaq Capital Market and the market for biotechnology companies in particular, have experienced extreme
price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies like theirs.
See also "General Risk Factors - " Unfavorable global economic conditions could adversely affect our business, financial
condition or results of operations." Broad market and industry factors may negatively affect the market price of our common
stock regardless of our actual operating performance. In addition, a systemic decline in the financial markets and related factors beyond
our control may cause our share price to decline rapidly and unexpectedly. Price volatility of our common stock might be worse if the
trading volume of our common stock is low. In the past, following periods of market volatility, stockholders have often instituted securities
class action litigation. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock
price volatility in recent years. If we face such securities litigation, it could result in substantial costs and a diversion of management's
resources and attention, which could harm our business. Future sales of our common stock could also reduce the market price of our stock.

the liquidity of our common stock will be limited, not only in terms of the number of shares of common stock that can be bought and sold
at a given price, but by potential delays in the timing of executing transactions in our common stock and a reduction in security analyst
and media's coverage of us, if any. These factors may result in lower prices for our common stock than might otherwise be obtained
and could also result in a larger spread between the bid and ask prices for our common stock. In addition, without a large float, our
common stock will be less liquid than the stock of companies with broader public ownership and, as a result, the trading prices of our
common stock may be more volatile. In the absence of an active public trading market, an investor may be unable to liquidate their investment
in our common stock. Trading of a relatively small volume of our common stock may have a greater impact on the trading price of our common
stock than would be the case if our public float were larger. We cannot predict the prices at which our common stock will trade in the
future.

 An
active trading market for our common stock may not be sustained.

 An
active public trading market for our common stock may not be sustained. The lack of an active market may impair your ability to sell
your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce
the fair value of your shares. An inactive market may also impair our ability to raise capital to continue to fund operations by selling
shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.

 If
securities or industry analysts do not publish or cease publishing research or reports, or publish unfavorable reports about us, our
business or our market, our share price and trading volume could be negatively impacted.

 The
trading market for our common stock could be influenced by the research and reports that industry or securities analysts may publish
about us, our business, our market or our competitors. We do not have any control over these analysts and cannot provide any assurance
that analysts will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation
regarding our common stock, or provide more favorable relative recommendations about our competitors, our share price would likely decline.
If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in
the financial markets, which in turn could negatively impact our share price or trading volume.

 Sales
of a substantial number of our shares in the public market by our existing shareholders could cause our share price to decline.

 Sales
of a substantial number of our shares in the public market or the perception that these sales might occur, could depress the market price
of our securities and could impair our ability to raise capital through the sale of additional equity securities. We are not able to
predict the effect that sales may have on the prevailing market price of our securities.

 We
are a "smaller reporting company" and the reduced disclosure requirements applicable to smaller reporting companies may make
our common stock less attractive to investors.

 We
are considered a "smaller reporting company." We are therefore entitled to rely on certain reduced disclosure requirements,
such as an exemption from providing selected financial data and executive compensation information. These exemptions and reduced disclosures
in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations
and financial prospects. We cannot predict whether investors will find our common stock less attractive because we may rely on these
exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common
stock and our stock prices may be more volatile.

 Maintaining
and improving our financial controls and the requirements of being a public company may strain our resources, divert management's
attention and affect our ability to attract and retain qualified board members.

 As
a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act, the Sarbanes-Oxley
Act and The Nasdaq Stock Market LLC ("Nasdaq") rules. The requirements of these rules and regulations increase our legal
and financial compliance costs, make some activities more difficult, time-consuming or costly and place strain on our personnel, systems
and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our
business and financial condition.

 The
Sarbanes-Oxley Act requires, among other things, that we disclose whether we maintain effective disclosure controls and procedures and
internal control over financial reporting. Ensuring that we have adequate internal financial and accounting controls and procedures in
place is a costly and time-consuming effort that needs to be re-evaluated frequently.

 We
may need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge.
Implementing any appropriate changes to our internal controls may require specific compliance training for our directors, officers and
employees, entail substantial costs, and take a significant period of time to complete. Such changes may not, however, be effective in
maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate
financial statements on a timely basis, could increase our operating costs and could materially impair our ability to operate our business.
Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent fraud.

 In
accordance with Nasdaq rules, we will be required to maintain a majority independent board of directors. The various rules and regulations
applicable to public companies make it more difficult and more expensive for us to maintain directors' and officers' liability
insurance, and we may be required to accept reduced coverage or incur substantially higher costs to maintain coverage. If we are unable
to maintain adequate directors' and officers' insurance, our ability to recruit and retain qualified officers and directors
will be significantly curtailed.

 It
is expected that the rules and regulations applicable to public companies will result in us incurring substantial legal and financial
compliance costs. These costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas
of our business.

 Failure
to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could
have a material adverse effect on our share price.

 As
a public company in the U.S., we incur significant accounting, legal and other expenses in order to comply with requirements of the SEC,
and the Nasdaq Capital Market, including requirements under Section 404 and other provisions of the Sarbanes-Oxley Act. Pursuant to Section
404, we are required to furnish a report by our management on our internal control over financial reporting. However, so long as we remain
a smaller reporting company, we will not be required to include an attestation report on internal control over financial reporting issued
by our independent registered public accounting firm. The process to document and evaluate our internal control over financial reporting
to achieve compliance with Section 404 within the prescribed period is both costly and challenging. If we fail to maintain the adequacy
of our internal control over financial reporting as such standards are modified, supplemented or amended from time to time, we may not
be able to ensure that we can conclude on an ongoing basis that we have effective internal control over financial reporting in accordance
with Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC. If we cannot in the future favorably
assess the effectiveness of our internal control over financial reporting, investor confidence in the reliability of our financial reports
may be adversely affected, which could have a material adverse effect on our share price.

 If
the Domestication Merger (defined below), taken together with the Merger (defined below), fails to qualify as a Section 351(a) Exchange,
former U.S. holders of Intec Pharma ("Intec Israel") ordinary shares may recognize taxable gain as a result of the Domestication
Merger.

 On
July 27, 2021, Intec Israel, Indaptus Therapeutics, Inc. and Domestication Merger Sub Ltd., an Israeli company and a wholly owned subsidiary
of Indaptus, completed a domestication merger (the "Domestication Merger"), pursuant to the terms and conditions of an Agreement
and Plan of Merger and Reorganization, dated April 27, 2021, whereby Domestication Merger Sub Ltd. merged with and into Intec Israel,
with Intec Israel being the surviving entity and a wholly-owned subsidiary of Indaptus Therapeutics, Inc. On August 3, 2021, Indaptus
Therapeutics, Inc. completed its merger with Decoy, pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger
Agreement"), dated March 15, 2021, following which Decoy became the surviving entity and a wholly-owned subsidiary of Indaptus
Therapeutics, Inc. and the business conducted by Decoy became the business conducted by the combined company. Intec Israel intended for
the Merger to qualify as a Section 351(a) Exchange. The position of Intec Israel is not binding on the IRS or the courts, and Intec Israel
does not intend to request a ruling from the IRS with respect to the Merger. Accordingly, there can be no assurance that the IRS will
not challenge the qualification of the Domestication Merger and the Merger as a Section 351(a) Exchange or that a court will not sustain
such a challenge. If the IRS were to be successful in any such contention, or if for any other reason the Domestication Merger was not
treated as part of a Section 351(a) Exchange, the Domestication Merger could be a taxable event to the former U.S. holders of ordinary
shares of Intec Israel. Former holders of Intec Israel's ordinary shares are urged to consult with their own tax advisors with
respect to the tax consequences of the Domestication Merger.

 Notwithstanding
that the Domestication Merger and the Merger together are intended to qualify as a Section 351(a) Exchange, the Domestication Merger
could be a taxable event for certain former U.S. Holders of Intec Israel ordinary shares.

 Subject
to the limitations and qualifications described in " The Merger - Material U.S. Federal Income Tax Consequences of the Domestication
Merger and the Merger," described in the registration statement on Form S-4, as amended (File No. 333-255389), filed by us
with the SEC, or the Form S-4, including the application of the passive foreign investment company, or PFIC rules, the Domestication
Merger is intended to qualify, taken together with the Merger, as a Section 351(a) Exchange. Nonetheless, certain former U.S. Holders
of Intec Israel's ordinary shares are likely to be taxed under the PFIC rules of the Code because of the likelihood that Intec
Israel is classified as a PFIC.

Risk Factors

 Unfavorable
global economic or geopolitical conditions could adversely affect our business, financial condition or results of operations.

 Our
results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For
example, the U.S. and global markets have been experiencing and are continuing to experience extreme volatility and disruptions in the
capital and credit markets and commodity prices due to rising inflation and interest rates, geopolitical tensions such as the conflict
between Russia and Ukraine and the armed conflict in Israel and Gaza, and other macroeconomic factors. A severe or prolonged economic
downturn, such as the current macroeconomic environment, could result in a variety of risks to our business, including, our ability to
raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers of raw
materials used to manufacture our product candidates for our clinical trials, possibly resulting in supply disruption. Furthermore, our
stock price may decline due in part to the volatility of the stock market and any general economic downturn.

 Changes
in tax law and regulations could adversely affect our business, financial condition and results of operations.

 New
income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the
tax treatment of any of our future earnings. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted,
changed, modified or applied adversely to us. Generally, future changes in applicable tax laws and regulations, or their interpretation
and application, potentially with retroactive effect, could have an adverse effect on our business, financial condition and results of
operations. We are unable to predict whether such changes will occur and, if so, the ultimate impact on our business. We urge investors
to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common
stock.

 Item
1B. Unresolved Staff Comments.

 We
do not have any unresolved comments issued by the SEC staff.

 Item
1C. Cybersecurity

 Cybersecurity
Risk Management and Strategy

 We, through our third party service provider that manages our information
technology systems and networks,
have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability
of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan.

 We
design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does
not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide
to help us identify, assess, and manage cybersecurity risks relevant to our business.

 Our
cybersecurity risk management program includes:

 risk
 assessments designed to help identify material cybersecurity risks to our critical systems,
 information, products, services, and our broader enterprise IT environment;

 designated
 team members are responsible for managing (1) our cybersecurity risk assessment processes,
 (2) our security controls, and (3) our response to cybersecurity incidents;

 the
 use of external service providers, where appropriate, to assess, test or otherwise assist
 with aspects of our security controls; and

 a
 cybersecurity incident response plan that includes procedures for responding to cybersecurity
 incidents.

 We
have not identified risks from known cybersecurity threats, that have materially affected or are reasonably likely to materially affect
us, including our operations, business strategy, results of operations, or financial condition. See Item 1A. "Risk Factors –
Our Risks Related to Our Business - Our business and operations may suffer in the event of information technology system failures,
cyberattacks or deficiencies in our cybersecurity. "

 Cybersecurity
Governance

 Our Board considers cybersecurity
risk as part of its risk oversight function and oversees our cybersecurity and other information technology risks and management's
implementation of our cybersecurity risk management program.

 Our Board receives periodic reports
from management on our cybersecurity risks. In addition, management updates the Board and the Audit Committee, as necessary, regarding
any material cybersecurity incidents, as well as any incidents with lesser impact potential.

 Our management team,
including our Chief Operating Officer, is responsible for assessing and managing our material risks from cybersecurity threats. Our Chief
Operating Officer has primary responsibility for our overall cybersecurity risk management program and supervises our retained provider
of IT services and external cybersecurity consultants. Our Chief Operating Officer has experience supervising and managing company security
and privacy departments.

 Our
management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means,
which may include briefings from external security personnel; threat intelligence and other information obtained from governmental, public
or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the IT
environment.

 Item
2. Properties

 Our
principal executive offices are located at 3 Columbus Circle, 15th Floor, New York, NY. In addition, we lease approximately 2,000 square
feet of office space in San Diego, California under a lease agreement that was amended on April 19, 2023 and will expire on October 31,
2025. We believe that our facilities are sufficient to meet our current needs and that suitable
additional space will be available as and when needed.

 Item
3. Legal Proceedings

 From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation
is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

 As
of March 12, 2024, there are no pending material legal proceedings, and we are currently not aware of any legal proceedings or claims
against us or our property that we believe will have any significant effect on our business, financial position or operating results.
None of our officers or directors is a party against us in any legal proceeding.

 Item
4. Mine Safety Disclosures.

 Not
applicable.

 PART
II

 Item
5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 Market
Information

 Our
common stock is listed on the Nasdaq Capital Market under the name "Indaptus Therapeutics, Inc." and ticker symbol "INDP".

 Holders

 As
of March 12, 2024, we had 8 record holders of our common stock. This number does not include the number of persons whose shares
are in nominee or in "street name" accounts through brokers.

 Dividend
Policy

 We
have never declared or paid cash dividends to our shareholders, and we do not intend to pay cash dividends in the foreseeable future.
We intend to reinvest any earnings in developing and expanding our business. Any future determination relating to our dividend policy
will be at the discretion of our board of directors and will depend on a number of factors, including our financial condition, operating
results, contractual restrictions, capital requirements, business prospects, our strategic goals and plans to expand our business, applicable
law and other factors that our board of directors may deem relevant.

 Securities
Authorized for Issuance under Equity Compensation Plans

 Information
about our equity compensation plan under which the Company's equity securities are authorized for issuance is set forth in "Part
III - Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" of this Annual Report.

 Recent
Sales of Unregistered Securities

 We
did not have any sales of unregistered securities during the year ended December 31, 2023.

 Purchases
of Equity Securities by the Issuer and Affiliated Purchasers

 We
did not repurchase any of our equity securities during the quarter ended December 31, 2023.

 Item
6. [Reserved]

 Item
7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

 You
should read the following discussion and analysis of our financial condition and results of operations along with our consolidated financial
statements and the related notes and other financial information included elsewhere in this Annual Report. The following discussion contains
forward-looking statements that are subject to risks, uncertainties and assumptions. You should review the sections titled "Summary
Risk Factors" and Part I, Item 1A. "Risk Factors" in this Annual Report for a discussion of important factors that
could cause actual results to differ materially from the results described below.

 Overview

 We
are a clinical biotechnology company developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy.
We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation
of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package
of immune system activating signals that can be administered safely intravenously. Our patented technology is composed of single strains
of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability
to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral
activity in preclinical models, including durable anti-tumor response synergy observed with each of five different classes of existing
agents, including checkpoint therapy, targeted antibody therapy and low-dose chemotherapy. Tumor eradication by our technology has demonstrated
activation of both innate and adaptive immunological memory and, importantly, did not require provision of or targeting a tumor antigen
in preclinical models. In 2023, we initiated a Phase 1 clinical trial with our lead clinical candidate,
Decoy20, in patients with advanced solid tumors where currently approved therapies have failed. For further information regarding
our business and operations, see "Part I. Item 1. Business."

 Impact
of Macroeconomic Conditions on our Operations

 Economic
developments such as supply chain constraints and rising inflation and interest rates have negatively affected the global financial markets
and may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. The ultimate impact
of the current economic conditions is highly uncertain and subject to change. While it is unknown how long these conditions will last and
what the complete financial effect will be to us, capital raise efforts and additional development of our technologies may be negatively
affected. In addition, our business operations expose us to risks associated with public health crises and epidemics/pandemics, such
as COVID-19. A resurgence of the COVID-19 pandemic or any new public health crisis could again affect our operations and those of third
parties on which we rely, including by causing disruptions in the supply of our product candidates and the conduct of current and future
clinical trials.

 Components
of Operating Results

and Development Expenses

and development expenses account for a significant portion of our operating expenses. Research and development expenses consist primarily
of fees paid to contract research organizations, or CROs, and contract manufacturing organizations, or CMOs, as well as compensation
expenses for certain employees involved in the planning, managing, and analyzing the work of the CROs and CMOs and materials used for
research and development activities. We expense research and development costs as incurred.

 We
accrue expenses for manufacturing, preclinical studies and clinical trial activities performed by third parties based on estimates of
services received and efforts expended pursuant to agreements with CROs, CMOs, and other outside service providers. We determine these
estimates based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel
and external service providers as to the progress or stage of completion of the services. In the event advance payments are made to a
CRO, CMO, or outside service provider, we record the payments as a prepaid asset, which will be amortized or expensed as the contracted
services are performed. However, actual costs and timing of these activities are highly uncertain, subject to risks and may change depending
upon a number of factors, including our clinical development plan.

 We
expect our research and development expenses to increase substantially for the foreseeable future as we continue to ramp up our clinical
development activities and incur expenses associated with hiring additional personnel to support our research and development efforts.
Our expenditures on future nonclinical and clinical development programs are subject to numerous uncertainties in timing and cost to
completion. The duration, costs and timing of preclinical studies and clinical trials and development of product candidates will depend
on a variety of factors, including:

 the
 timing and receipt of regulatory approvals

 the
 scope, rate of progress and expenses of preclinical studies and clinical trials and other research and development activities

 potential
 safety monitoring and other studies requested by regulatory agencies and

 significant
 and changing government regulation.

 The
process of conducting the necessary clinical research to obtain FDA and other regulatory approval is costly and time consuming and the
successful development of product candidates is highly uncertain. These risks and uncertainties associated with our research and development
projects are discussed more fully in Part I. Item 1A. "Risk Factors - We expect to continue to incur significant research and
development expenses and other operating expenses, which may make it difficult for us to attain profitability." As a result
of these risks and uncertainties, we are unable to determine with any degree of certainty the duration and completion costs of our research
and development projects, or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our
product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates.

and Administrative Expenses

and administrative expenses include compensation, employee benefits, and stock-based compensation for executive management, finance administration
and human resources, facility costs (including rent), professional service fees, and other general overhead costs, including depreciation,
to support our operations.

 We
expect our general and administrative expenses to increase substantially for the foreseeable future as we continue to increase our headcount
to support our research and development activities and operations generally, the growth of our business and, if any of our product candidates
receive marketing approval, commercialization activities. We also expect to continue to incur additional expenses as a result of operating
as a public company, including expenses related to compliance with the rules and regulations of the SEC, additional director and officer
insurance expenses, investor relations activities, and other administrative and professional services.

 Other
Income, Net

 Other
income, net includes interest earned on deposits and investments and other items of income, expense, gain and loss that are incidental
to the core operations of the Company.

 Results
of Operations

 Year
Ended December 31, 2023 compared to Year Ended December 31, 2022

 The
following tables set forth our results of operations for the years ended December 31, 2023 and 2022 and the relative dollar and percentage
change between the two years.

 Year
 ended
 December
 31,

 Change
 (2023
 to 2022)

 2023

 2022

 ($)

 %

 Operating expenses:

 Research and development

 $
 7,621,707

 $
 6,324,657

 $
 1,297,050

 %

 General and administrative

 8,756,767

 8,586,249

 170,518

 %

 Total operating expenses

 16,378,474

 14,910,906

 1,467,568

 %

 Loss from operations

 (16,378,474
)

 (14,910,906
)

 (1,467,568
)

 %

 Other income, net

 955,003

 588,108

 366,895

 %

 $
 (15,423,471
)

 $
 (14,322,798
)

 $
 (1,100,673
)

 %

 Net loss attributable to common stockholders per share, basic and diluted

 $
 (1.83
)

 $
 (1.73
)

 $
 (0.10
)

 %

 Weighted average number of shares used in calculating net loss per share, basic
 and diluted

 8,262,119

and Development Expenses

 Our
research and development expenses for the year ended December 31, 2023 amounted to approximately $7.6 million, an increase of approximately
$1.3 million, or approximately 21%, compared with approximately $6.3 million for the year ended December 31, 2022. This increase was
attributable primarily to (i) an increase of approximately $0.4 million for payroll and related expenses including approximately $0.1
million of stock-based compensation, and (ii) an increase of approximately $0.9 million for the Phase 1 clinical trial and activities
related to the expansion of our pipeline.

and Administrative Expenses

 Our
general and administrative expenses for the year ended December 31, 2023 amounted to approximately $8.8 million, an increase of approximately
$0.2 million, or approximately 2%, compared with approximately $8.6 million for the year ended December 31, 2022. This increase was attributable
primarily to an increase of approximately $0.6 million for legal fees, recruitment costs, investor relations expenses and other professional
fees, and was partially offset by a decrease of approximately $0.4 million for payroll and related expenses and for directors'
and officers' insurance expenses.

 Other
Income

 Our
other income, net, for the year ended December 31, 2023 amounted to approximately $1.0 million, an increase of approximately $0.4 million,
or approximately 62%, compared to approximately $0.6 million for the year ended December 31, 2022. This increase was attributable primarily
to an increase of approximately $0.7 million in interest earned on deposits and interest earned on marketable securities, which was partially
offset by a decrease of approximately $0.3 million from a gain that resulted from our settlement relating to a contractual
dispute with Lohmann Therapie Systeme AG in February 2023.

 Liquidity
and Resources

 We
do not currently have any approved products and have never generated any revenue from product sales. Since our inception, we have funded
our operations primarily through public and private offerings of our equity securities.

 In
June 2022, we entered into an At The Market Offering Agreement (the "ATM Agreement") which was amended on September 1, 2022
with H.C. Wainwright & Co., LLC, as sales agent ("Wainwright"), pursuant to which we may offer and sell, from time to
time through Wainwright, shares of our common stock, par value $0.01 per share, for aggregate gross proceeds of up to $3.7 million. The
issuance and sale of common stock by us under the ATM Agreement is being made pursuant to our effective "shelf" registration
statement on Form S-3 filed with the SEC on September 1, 2022 and declared effective on September 9, 2022. In March 2024, we sold 137,836 shares of our common stock for an aggregate gross proceeds of $0.3 million.

 In
December 2022, we entered into a purchase agreement and a registration rights agreement with Lincoln Park pursuant to which we have the
right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $20.0 million of our common stock
(subject to certain limitations) from time to time over the term of the purchase agreement. We also filed a registration statement on
Form S-1 to cover the resale of shares of our common stock issuable under the purchase agreement.

 Upon
execution of the purchase agreement, we issued to Lincoln Park 142,450 initial commitment shares and are obligated to issue additional
shares of common stock to Lincoln Park with a value of $125,000, calculated in accordance with the purchase agreement, on the date we
have sold over $10.0 million in shares of common stock under the purchase agreement, up to a maximum of 76,220 shares of common stock
(to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other
similar transaction), in each case as consideration for Lincoln Park's irrevocable commitment to purchase shares of our common
stock at our direction under the purchase agreement. Additionally, we have reserved up to 3,781,330 shares of our common stock for issuance
and sale to Lincoln Park under the purchase agreement from time to time, if and when we determine to sell additional shares to Lincoln
Park. No shares of common stock have been sold under the program.

 As
of December 31, 2023, we had cash and cash equivalents of approximately $13.4 million, which we believe will enable us to fund our operating
expenses and capital expenditure requirements through the third quarter of 2024. While we intend to finance our cash needs principally
through collaborations, strategic alliances, or license agreements with third parties and/or debt or equity financings, we cannot provide
any assurance that new financing will be available to us on commercially acceptable terms or in the amounts required, if at all. These
conditions raise substantial doubt regarding our ability to continue as a going concern within one year after the date of the filing
of this Annual Report. For additional information, see Note 1 to our consolidated financial statements included elsewhere in this Annual
Report. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we
currently expect.

 We
have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over
the next five years.

 Cash
Flows

 Operating
Activities

 Net
cash used in operating activities was approximately $13.4 million for the year ended December 31, 2023, compared with net cash used in
operating activities of approximately $13.1 million for the year ended December 31, 2022. The approximately $0.3 million increase in
net cash used was primarily attributable to an increase in our spending related to research and development activities in connection
with the Phase 1 clinical trial.

 Investing
Activities

 Net
cash provided by investing activities was approximately $17.1 million for the year ended December 31, 2023 which was related to the maturity
of $24.0 million in marketable securities, offset by investment of approximately $6.9 million in marketable securities. Net cash
used in investing activities was approximately $16.4 million for the year ended December 31, 2022, which was primarily related to approximately
$29.6 million investment in marketable securities, offset by approximately $0.2 million from the proceeds received for assets held
for sale and by $13.0 million from the maturity of marketable securities.

 Financing
Activities

 There
was no net cash provided by or used in financing activities for the years ended December 31, 2023 and 2022.

 Funding
Requirements

 Our
operating expenses increased in 2023 and are expected to continue to increase in the future in connection with our ongoing activities,
particularly as we expect to continue to ramp up our clinical development activities and incur expenses associated with hiring additional
personnel to support our research and development efforts. In addition, if we obtain marketing approval for any of our product candidates,
we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore,
we expect to continue to incur significant costs associated with operating as a public company.

 We
believe that our existing cash and cash equivalents and marketable securities as of December 31, 2023 are adequate to fund our ongoing
activities through the third quarter of 2024.

 Our
future capital requirements will depend on many factors, including, but not limited to:

 the
 scope, progress, results and costs of preclinical studies and clinical trials

 the
 scope, prioritization and number of our clinical trials and other research and development programs

 the
 amount of revenues we receive under future licensing, collaboration, development and commercialization arrangements with respect
 to our product candidates

 the
 impact of any pandemic, such as the COVID-19 pandemic, epidemic or other future health crisis on our business and operations

 the
 costs of the development and expansion of our operational infrastructure

 the
 costs, timing and outcome of regulatory review of our product candidates

 the
 ability of us, or our collaborators, to achieve development milestones, marketing approval and other events or developments under
 our potential future licensing agreements

 the
 costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights

 the
 costs and timing of securing manufacturing arrangements for clinical or commercial production

 the
 costs of contracting with third parties to provide sales and marketing capabilities for us or establishing such capabilities ourselves

 the
 costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or technology

 the
 magnitude of our general and administrative expenses and

 any
 cost that we may incur under future in- and out-licensing arrangements relating to one or more of our product candidates.

 Identifying
potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process
that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and
achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues,
if any, will be derived from sales of product candidates that we do not expect to be commercially available for the next couple of years,
if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional
financing may not be available to us on acceptable terms, or at all. For example, the trading prices for our and other biopharmaceutical
companies' stock have been highly volatile as a result of current macroeconomic conditions and market volatility. As a result,
we may face difficulties raising capital through sales of our common stock on acceptable terms, if at all. If we are unsuccessful in
securing sufficient financing, we may need to delay, reduce, or eliminate our research and development programs, which could adversely
affect our business prospects, or cease operations. For additional information, see Note 1 to our consolidated financial statements included
elsewhere in this Annual Report and "Risk Factors" in Item 1A. of this Annual Report.

 Contractual
Obligations

 Operating
lease liabilities represent our commitment for future rent made under a non-cancelable lease for our offices in San Diego, CA. The total
future payments for our operating lease obligation on December 31, 2023 were approximately $0.2 million, of which approximately $0.1
million is due in the next twelve months and the remaining payments are due over the following year. For additional details regarding
our lease, see Note 8 to our consolidated financial statements included in this Annual Report.

 We
did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under the SEC
rules.

 Critical
Accounting Policies

 This
discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which
have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates
that affect the reported amounts of our assets, liabilities and expenses. Significant accounting policies employed by us, including the
use of estimates, are presented in the notes to our annual financial statements included in this Annual Report. We periodically evaluate
our estimates, which are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances.
Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations
and require our subjective or complex judgments, resulting in the need to make estimates about the effect of matters that are inherently
uncertain. If actual performance should differ from historical experience or if the underlying assumptions were to change, our financial
condition and results of operations may be materially impacted.

 We
believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our
consolidated financial statements:

 Accounting
for Research and Development Costs

 We
record the costs associated with services provided by CROs and CMOs as they are incurred. Though the scope and timing of work are generally
based on signed agreements, some judgement is involved in determining periodic expenses because payment flows do not always match the
periods over which services and materials are provided to us. As a result, our management is required to make estimates of services received
and efforts expended pursuant to agreements established with these third-parties at each period-end date. During the year ended December
31, 2023, we incurred approximately $7.6 million of research and development expenses, of which approximately $3.9 million were for services
provided by our CROs and CMOs. As of December 31, 2023, we recorded an accrued liability of approximately $0.4 million for expenses incurred,
but not yet invoiced, and prepaid expenses and non-current other assets of approximately $0.8 million for payments made that relate to
future periods. Overestimating or underestimating the services received or efforts expended could cause us to overstate or understate
research and development expenses incurred within a reporting period, and related accrued and prepaid expenses.

 Stock-Based
Compensation

 Compensation
expense related to stock options granted is measured at the grant date based on the estimated fair value of the award and is recognized
over the requisite service period of the individual grant, generally equal to the vesting period, on a straight-line basis. We determine
the estimated fair value of each stock option on the date of grant using the Black-Scholes valuation model which uses assumptions regarding
a number of complex and subjective variables. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent
with the expected term of the option in effect at the time of the grant. Expected volatility is based on an analysis of the historical
volatility of a peer group of companies. The expected term represents the period that we expect our stock options to be outstanding.
The expected term assumption is estimated using the simplified method set forth in the U.S. Securities and Exchange Commission's
Staff Accounting Bulletin Topic 14, which is the mid-point between the option vesting date and the expiration date. We have never declared
or paid dividends on our common stock and have no plans to do so in the foreseeable future. Changes in these assumptions may lead to
variability with respect to the amount of stock compensation expense we recognize related to stock options.

Issued Accounting Pronouncements

 Certain
recently issued accounting pronouncements are discussed in Note 2, Significant Accounting Policies, to the consolidated financial
statements included in Item 8. "Financial Statements and Supplementary Data" of this Annual Report.

 Item
7A. Quantitative and Qualitative Disclosures About Market Risk.

 We
are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise
required under this Item 7A.

 Item
8. Financial Statements and Supplementary Data.

 CONSOLIDATED
FINANCIAL STATEMENTS

 TABLE
OF CONTENTS

 Page

 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB name: HASKELL & WHITE LLP and PCAOB ID: 200)

 CONSOLIDATED
 FINANCIAL STATEMENTS:

 Consolidated Balance Sheets as of December 31, 2023 and 2022

 Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022

 Consolidated Statements of Stockholders' Equity for the years ended December 31, 2023 and 2022

 Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022

 Notes to the Consolidated Financial Statements

 F- 1

 REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 To
the Stockholders and Board of Directors

 Indaptus
Therapeutics, Inc.

 Opinion
on the Consolidated Financial Statements

 We
have audited the accompanying consolidated balance sheets of Indaptus Therapeutics, Inc. (the "Company") as of December 31,
2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows for
each of the years then ended, and the related notes (collectively, the "consolidated financial statements"). In our opinion,
the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as
of December 31, 2023 and 2022, and the consolidated results of its operations and its cash flows for each of the years then ended, in
conformity with U.S. generally accepted accounting principles.

 Going
Concern

 The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 1 to the consolidated financial statements, the Company has experienced recurring losses, negative cash flows from operations,
and has limited capital resources. These matters raise substantial doubt about the Company's ability to continue as a going concern.
Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty.

 Basis
for Opinion

 These
consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion
on the consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with
the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.

 Critical
Audit Matters

 Critical
audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required
to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the consolidated financial
statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit
matters.

 / s/
 Haskell & White LLP

 HASKELL
 & WHITE LLP

 We
 have served as the Company's auditor since 2021.

 Irvine,
 California

 March

 F- 2

Balance Sheets

 December 31,

 2023

 2022

 Assets

 Current assets:

 Cash and cash equivalents

 $
 13,362,053

 $
 9,626,800

 Marketable securities

 -

 Prepaid expenses and other current assets

 633,156

 811,433

 Total current assets

 13,995,209

 27,244,242

 Non-current assets:

 Property and equipment, net

 2,019

 Right-of-use asset

 173,206

 79,294

 Other assets

 754,728

 738,251

 Total non-current assets

 928,669

 819,564

 Total assets

 $
 14,923,878

 $
 28,063,806

 Liabilities and stockholders' equity

 Current liabilities:

 Accounts payable and other current liabilities

 $
 2,672,327

 $
 3,352,847

 Operating lease liability, current portion

 101,705

 80,494

 Total current liabilities

 2,774,032

 3,433,341

 Non-current liabilities:

 Operating lease liability, net of current portion

 73,348

 -

 Total non-current liabilities

 73,348

 -

 Total liabilities

 2,847,380

 3,433,341

 Commitments and contingencies (Note 8)

 -

 -

 Stockholders' equity:

 Common stock: $ 0.01 par value, 200,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 8,401,047 shares issued and outstanding as of December 31, 2023 and December 31, 2022

 Additional paid in capital

 57,409,643

 54,443,705

 Accumulated deficit

 ( 45,417,156
)

 ( 29,993,685
)

 Accumulated other comprehensive income

 -

 96,434

 Total stockholders' equity

 12,076,498

 24,630,465

 Total liabilities and stockholders' equity

 $
 14,923,878

 $
 28,063,806

 See
accompanying notes to the consolidated financial statements and report of independent registered public accounting firm

 F- 3

Statements of Operations and Comprehensive Loss

 2023

 2022

 Operating expenses:

 Research and development

 $
 7,621,707

 $
 6,324,657

 General and administrative

 8,756,767

 8,586,249

 Total operating expenses

 16,378,474

 14,910,906

 Loss from operations

 ( 16,378,474
)

 ( 14,910,906
)

 Other income, net

 955,003

 588,108

 $
)

 $
)

 Net loss available to common stockholders per share of common stock, basic and diluted

 $
 ( 1.83
)

 $
 ( 1.73
)

 Weighted average number of shares used in calculating net loss per share, basic and diluted

 8,262,119

 $
)

 $
)

 Other comprehensive income:

 Reclassification adjustment for interest earned on marketable securities included in net loss

 ( 430,993
)

 ( 110,002
)

 Change in unrealized gain on marketable securities

 334,559

 206,436

 Comprehensive loss

 $
 ( 15,519,905
)

 $
 ( 14,226,364
)

 See
accompanying notes to the consolidated financial statements and report of independent registered public accounting firm

 F- 4

Statements of Stockholders' Equity

 Common stock

 Additional paid in

 Accumulated

 Accumulated
Other Comprehensive

 Shares

 Amount

 Capital

 deficit

 Income (Loss)

 Total

 Balance, January 1, 2022

 8,258,597

 $
 82,586

 $
 51,487,881

 $
 ( 15,670,887
)

 $
 -

 $
 35,899,580

 -

 -

 2,957,249

 -

 -

 2,957,249

 Issuance of initial commitment shares

 142,450

 1,425

 ( 1,425
)

 -

 -

 -

 Reclassification adjustment for interest earned on marketable securities included in net loss

 -

 -

 -

 -

 ( 110,002
)

 ( 110,002
)

 Change in unrealized gain on marketable securities

 -

 -

 -

 -

 206,436

 206,436

 -

 -

 -

)

 -

)

 Balance, December 31, 2022

 $

 $
 54,443,705

 $
 ( 29,993,685
)

 $
 96,434

 $
 24,630,465

 Balance

 $

 $
 54,443,705

 $
 ( 29,993,685
)

 $
 96,434

 $
 24,630,465

 -

 -

 2,965,938

 -

 -

 2,965,938

 Reclassification adjustment for interest earned on marketable securities included in net loss

 -

 -

 -

 -

 ( 430,993
)

 ( 430,993
)

 Change in unrealized gain on marketable securities

 -

 -

 -

 -

 334,559

 334,559

 -

 -

 -

)

 -

)

 Balance, December 31, 2023

 $

 $
 57,409,643

 $
 ( 45,417,156
)

 $
 -

 $
 12,076,498

 Balance

 $

 $
 57,409,643

 $
 ( 45,417,156
)

 $
 -

 $
 12,076,498

 See
accompanying notes to the consolidated financial statements and report of independent registered public accounting firm

 F- 5

Statements of Cash Flows

 2023

 2022

 2023

 2022

 Cash flows from operating activities:

 $
)

 $
)

 Adjustments to reconcile net loss to net cash used in operating activities:

 Depreciation

 1,284

 1,781

 2,965,938

 2,957,249

 Realized gain on assets held for sale

 -

 ( 24,155
)

 Interest earned on marketable securities

 ( 430,993
)

 ( 110,002
)

 Changes in operating assets and liabilities:

 Prepaid expenses and other current assets

 161,800

 295,220

 Accounts payable and other current liabilities

 ( 680,520
)

 ( 1,154,829
)

 Other assets

 -

 ( 721,774
)

 Operating lease right-of-use asset and liability, net

 Net cash used in operating activities

 ( 13,405,315
)

 ( 13,078,347
)

 Cash flows from investing activities:

 Proceeds received for assets held for sale

 -

 172,555

 Purchase of marketable securities

 ( 6,859,432
)

 ( 29,599,573
)

 Maturity of marketable securities

 24,000,000

 13,000,000

 Net cash provided by (used in) investing activities

 17,140,568

 ( 16,427,018
)

 Net increase (decrease) in cash and cash equivalents

 3,735,253

 ( 29,505,365
)

 Cash and cash equivalents at beginning of year

 9,626,800

 39,132,165

 Cash and cash equivalents at end of year

 $
 13,362,053

 $
 9,626,800

 Noncash investing and financing activities

 ASC 842 lease renewal option exercise

 $
 236,506

 $
 -

 Issuance of initial commitment shares

 $
 -

 $
 1,425

 Change in accumulated other comprehensive (loss) income

 $
 ( 96,434
)

 $
 96,434

 Supplemental cash flow disclosures

 Cash paid for income taxes

 $
 1,600

 $
 2,400

 See
accompanying notes to the consolidated financial statements and report of independent registered public accounting firm

 F- 6

 Notes
to Consolidated Financial Statements

 NOTE
1: GENERAL

 Indaptus
Therapeutics, Inc. and its wholly-owned subsidiaries, Decoy Biosystems, Inc. and Intec Pharma Ltd., collectively (the "Company"),
is a biotechnology company dedicated to enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic
solid tumors and lymphomas, which are responsible for more than 90% of all cancer deaths. The Company is developing a novel, multi-targeted
product that activates both innate and adaptive anti-tumor and anti-viral immune responses.

 Risks
and uncertainties

 The
Company is subject to a number of risks similar to those of other companies of similar size in its industry, including, but not limited
to, the need for successful development of products, the need for additional capital (or financing) to fund operations (see below), competition
from substitute products and services from larger companies, protection of proprietary technology, patent litigation, and dependence
on key individuals.

 Going
concern and management's plans

 The
Company has incurred net losses and utilized cash in operations since inception. For the year ended December 31, 2023, the Company incurred
a net loss of approximately $ 15.4 million, and as of December 31, 2023, the Company had an accumulated deficit of approximately $ 45.4
million. In addition, during the year ended December 31, 2023, the Company used approximately $ 13.4 million of cash in operations and
expects to continue to incur significant cash outflows and incur future additional losses as clinical trials and commercialization of
the Company's product candidates will require significant additional financing. The Company believes that, as of the date of the
issuance of these consolidated financial statements, it will not have adequate cash to fund its ongoing activities beyond the third quarter
of 2024 based on its current operating plan. The Company plans to execute its operating plan by obtaining additional capital, principally
through entering into collaborations, strategic alliances, or license agreements with third parties and/or additional public or private
debt and equity financing. However, there is no assurance that additional capital and/or financing will be available to the Company,
and even if available, whether it will be on terms acceptable to the Company or in the amounts required. If the Company is unsuccessful
in securing sufficient financing, it may need to delay, reduce, or eliminate its research and development programs, which could adversely
affect its business prospects, or cease operations.

 As
a result of these uncertainties, there is substantial doubt about the Company's ability to continue as a going concern. The consolidated
financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would
result if the Company was unable to continue as a going concern.

 NOTE
2: SIGNIFICANT ACCOUNTING POLICIES

 Basis
of presentation

 The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America ("US GAAP").

 Principles
of consolidation

 The
consolidated financial statements include the accounts of Indaptus and its subsidiaries. Intercompany balances and transactions have
been eliminated upon consolidation.

 F- 7

 Use
of estimates

 The
preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the
reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value
of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates
its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment,
and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the
consolidated financial statements; therefore, actual results could differ from those estimates.

 Loss
per share

 Loss
per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of common
stock outstanding during the period. Diluted loss per share is based upon the weighted average number of common stock and of common stock
equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under
the treasury stock method when dilutive.

 The
following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would
have been anti-dilutive for the periods presented (share data):

OF ANTI-DILUTIVE SECURITIES

 2023

 2022

 Outstanding stock options

 1,979,196

 1,600,830

 Warrants

 3,090,787

 3,090,787

 Cash
and cash equivalents

 The
Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
As of December 31, 2023, and 2022, cash and cash equivalents consist primarily of checking and money market deposits. The Company's
cash balances exceed those that are federally insured; however, the Company believes it is not exposed to significant credit risk due
to the financial strength of the depository institutions in which the cash and cash equivalents are held. To date, the Company has not
recognized any losses caused by uninsured balances.

 Marketable
securities

 The
Company's investments in marketable securities included U.S. treasury bonds that were classified as available-for-sale securities
pursuant to Accounting Standards Codification ("ASC") 320 "Investments — Debt Securities ". These
investments were recorded at fair value with unrealized gains and losses recorded in Accumulated Other Comprehensive Income (Loss), or
AOCI, as a separate component of stockholders' equity.

 Property
and equipment

 Property
and equipment assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets. The Company uses an estimated useful life of three years for employee-related computers and
other office equipment and five years for furniture. Leasehold improvements are amortized over the shorter of the lease-term or the estimated
useful life of the related asset.

 Patents

 The
Company expenses patent costs, including related legal costs, as incurred and records such costs within general and administrative expense
in the accompanying consolidated statements of operations.

and development expenses

and development expenses include costs directly attributable to the conduct of research and development programs, including the cost
of salaries, stock-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research
and development activities, including clinical trials and professional services. All costs associated with research and development are
expensed as incurred.

 F- 8

 The
Company accrues for expenses resulting from obligations under agreements with contract research organizations ("CROs"), contract
manufacturing organizations ("CMOs"), and other outside service providers for which payment flows do not match the periods
over which services or materials are provided to the Company. Accruals are recorded based on estimates of services received and efforts
expended pursuant to agreements with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO, or other outside service
provider, the payments will be recorded as a prepaid expense or other asset, which will be amortized or expensed as the contracted services
are performed.

and administrative expenses

and administrative expenses include compensation, employee benefits, and stock-based compensation for executive management, finance administration
and human resources, facility costs (including rent), professional service fees, and other general overhead costs, including depreciation,
to support the Company's operations.

 Income
taxes

 Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation
allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will
not be realized in the foreseeable future. As of December 31, 2023, and 2022, the Company has recorded a full valuation allowance against
its deferred tax assets.

 The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or
measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized
tax benefits in interest expense and penalties in general and administrative expenses.

 Stock-based
compensation

 The
Company measures and records the expense related to stock-based payment awards based on the fair value of those awards as determined
using the Black-Scholes-Merton ("Black-Scholes") model as of the date of grant. The Company recognizes stock-based compensation
expense over the requisite service period of the individual grant, generally equal to the vesting period, on a straight-line basis.

 The
Black-Scholes model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based payment
awards, including the option's expected term and the price volatility of the underlying stock. The Company estimates the fair value
of options granted by using the Black-Scholes model with the following assumptions:

 Expected
Volatility —The Company estimated volatility for option grants by evaluating the historical volatility of a peer group of companies
for the period immediately preceding the option grant for a term that is approximately equal to the options' expected term.

 Expected
Term —The expected term of the Company's options represents the period that the stock-based payment awards are expected
to be outstanding. The expected term was estimated using the simplified method for employee stock options since the Company does not
have adequate historical exercise data to estimate the expected term.

 F- 9

 Risk-Free
Interest Rate —The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues
with a term that is equal to the options' expected term at the grant date.

 Dividend
Yield —The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend
yield has been estimated to be zero.

 The
Company has elected to recognize forfeitures as they occur.

 Fair
value measurements

 Fair
value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability
in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the
measurement date. The Company follows the established framework for measuring fair value and providing disclosures about fair value measurements.

 The
accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

 Level
 1:

 Quoted
 prices in active markets for identical assets or liabilities.

 Level
 2:

 Inputs
 other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

 Level
 3:

 Unobservable
 inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies,
 or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

 ASC
820, Fair Value Measurement, requires all entities to disclose the fair value of financial instruments, both assets and liabilities,
for which it is practicable to estimate fair value, and defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties. As of December 31, 2023, and 2022, the recorded values of cash and
cash equivalents, prepaid expenses, and accounts payable and other current liabilities approximate their fair values
due to the short-term nature of these items.

 The
following financial assets are measured and recorded at fair value on the Company's consolidated balance sheet as of December 31,
2022. As of December 31, 2023, there were no such assets on the Company's consolidated balance sheet.

OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE MEASUREMENT

 December 31, 2022

 Total

 Level 1

 Level 2

 Level 3

 Marketable securities

 $

 $
 -

 $

 $
 -

 Total

 $

 $
 -

 $

 $
 -

 Segment
information

 Operating
segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the
Chief Operating Decision Maker ("CODM"). The Company's Chief Executive Officer is the CODM. The CODM reviews financial
information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial
performance. The Company currently operates in one business segment, which is biotechnology. The Company is not organized by market and
is managed and operated as one business.

 F- 10

adopted accounting pronouncements

 On
January 1, 2023, the Company adopted ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. This standard amended
guidance on the recognition of impairment losses of certain financial instruments. The ASU established the current expected credit loss
model, which is based on expected losses rather than incurred losses. Adoption of this standard had no impact on the Company's
consolidated financial statements.

issued accounting pronouncements

 In
December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09
requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income
taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted.
The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

 NOTE
3: MARKETABLE SECURITIES

 The
Company's investments in marketable securities included U.S. treasury bonds with maturities of less than one year. These investments
were classified as available-for-sale and were recorded at fair value with unrealized gains and losses recorded in Accumulated Other
Comprehensive Income (Loss). These investments were categorized as Level 2.

 As
of December 31, 2023, the Company had no marketable securities. As of December 31, 2022, the fair value of the marketable securities
was $ 16,806,009.

 NOTE
4: PREPAID EXPENSES AND OTHER CURRENT ASSETS

 Prepaid
expenses and other current assets are comprised of the following:

OF PREPAID EXPENSE AND OTHER CURRENT ASSETS

 2023

 2022

 Prepaid insurance

 $
 554,097

 $
 610,208

 Prepaid research and development

 17,309

 80,910

 Other prepaid expenses

 61,750

 120,315

 Total prepaid expenses and other current assets

 $
 633,156

 $
 811,433

 Prepaid expenses and other current assets

 $
 633,156

 $
 811,433

 NOTE
5: ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

 Accounts
payable and other current liabilities are comprised of the following:

OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

 2023

 2022

 Accounts payable

 $
 806,004

 $
 1,378,316

 Accrued employee costs

 1,213,054

 1,216,242

 Accrued professional fees

 39,165

 172,356

 Accrued research and development

 439,024

 311,036

 Accrued board fees

 117,750

 116,000

 Delaware franchise taxes payable

 40,000

 128,929

 Other accrued expenses

 17,330

 29,968

 Total accounts payable and other current liabilities

 $
 2,672,327

 $
 3,352,847

 NOTE
6: STOCK-BASED COMPENSATION

 The
Company has an equity incentive plan for grants to employees, officers, consultants, directors, and other service providers that was
approved in 2021 (the "2021 Plan"). The maximum aggregate number of shares that may be issued pursuant to this 2021 Plan
is 1,864,963 shares
(the "Pool"); provided, however that the
Pool will increase on January 1 of each calendar year beginning on January 1, 2022 and ending on and including January 1, 2024
(each, an "Evergreen Date"), in an amount equal to the lesser of (i) 3% of the total number of shares of common stock
outstanding on the December 31st immediately preceding the applicable Evergreen Date and (ii) such lesser number of shares of common
stock as determined to be appropriate by the Committee (as defined in the 2021 Plan) in its sole discretion. On January 1, 2022,
January 1, 2023 and January 1, 2024 the Pool was increased by 247,758
shares, 252,031
shares and 252,031
shares, respectively. In no event shall more than 1,864,963
shares be available for issuance for Incentive Stock Options (as defined in the 2021 Plan) under the 2021 Plan.

 F- 11

 The
2021 Plan provides for the grant of non-qualified stock options, incentive stock options, restricted stock awards, restricted stock units,
unrestricted stock awards, stock appreciation rights and other forms of stock-based compensation. The 2021 Plan permits the Company's
board to change the type, terms and conditions of awards as circumstances may change. This flexibility to adjust the type of compensation
to be granted is particularly important given current economic and world events.

 A
summary of the stock option activity during the year ended December 31, 2023, is presented in the table below:

 SCHEDULE OF SHARE BASED COMPENSATION

 Weighted average

 Number of
 options

 Exercise
 price

 Remaining
 contractual
 life
 (in years)

 Intrinsic value

 Outstanding as of January 1, 2023

 1,672,873

 $
 13.01

 8.5

 $
 -

 Granted

 425,750

 $
 1.70

 -

 $
 -

 Forfeited and cancelled

 ( 48,426
)

 $
 4.34

 -

 $
 -

 Outstanding as of December 31, 2023

 $
 10.90

 7.9

 $
 36,363

 Exercisable as of December 31, 2023

 1,184,749

 $
 15.59

 7.4

 $
 -

 Vested and expected to vest as of December 31, 2023

 $
 10.90

 7.9

 $
 36,363

 The
following table summarizes the total stock-based compensation expense included in the consolidated statements of operations for the periods
presented:

 SCHEDULE OF STOCK BASED COMPENSATION EXPENSES

 2023

 2022

 2023

 2022

 Research and development

 $
 792,273

 $
 709,527

 General and administrative

 2,173,665

 2,247,722

 Total stock-based compensation expense

 $
 2,965,938

 $
 2,957,249

 As
of December 31, 2023, total compensation cost not yet recognized related to unvested stock options was approximately $ 2.2 million, which
is expected to be recognized over a weighted-average period of approximately 0.7 years.

 The
Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes
option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. The weighted
average inputs used to measure the value of the options granted during the years ended December 31, 2023 and 2022 are presented in the
table below. The weighted average fair value of stock options issued during the years ended December 31, 2023 and 2022 was $ 1.43 and
$ 3.27 per share, respectively.

 SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED

 2023

 2022

 Exercise price

 $
 1.70

 $
 4.04

 Expected term (in years)

 5.8

 5.8

 Volatility

 110.9
 %

 106.6
 %

 Risk free rate

 3.7
 %

 2.2
 %

 Dividend yield

 0.0
 %

 0.0
 %

 F- 12

 The
following table presents the exercise price of outstanding stock options as of December 31, 2023:

 SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS

 Exercise price

 Options
 outstanding

 $0.01 - $8.00

 1,023,249

 $ 0.01 - $ 8.00

 1,023,249

 $ 8.01 - $ 16.00

 992,250

 $ 16.01 or higher

 34,698

 Total

 NOTE
7: CAPITALIZATION

 a.
 As
of December 31, 2023 and December 31, 2022, the Company had 200,000,000 shares of common stock authorized and 8,401,047 shares of common
stock issued and outstanding. As of December 31, 2023 and December 31, 2022, there were warrants outstanding to purchase an aggregate
of 3,090,787 shares of common stock of the Company. As of December 31, 2023, these warrants are exercisable at a weighted average price
of $ 12.50 and their weighted average remaining contractual term is approximately 3.0 years.

 b.
 On
 June 1, 2022, the Company entered into an At The Market Offering Agreement (the "ATM
 Agreement") which was amended on September 1, 2022 with H.C. Wainwright & Co.,
 LLC, as sales agent ("Wainwright"), pursuant to which the Company may offer and
 sell, from time to time through Wainwright, shares of the Company's common stock, par
 value $ 0.01 per share, for aggregate gross proceeds of up to $ 3.7 million. The
 issuance and sale of common stock by the Company under the ATM
 Agreement is being made pursuant to the Company's effective "shelf"
 registration statement on Form S-3 filed with the SEC on September 1, 2022 and declared effective
 on September 9, 2022. In March 2024, The Company sold
 137,836 shares of the Company's common stock for an aggregate gross proceeds
 of $ 0.3 million. The Company's effective "shelf" registration
 statement on Form S-3 is under General Instruction I.B.6 to Form S-3, or the Baby Shelf Rule.

 c.
 On December, 22, 2022, the
 Company entered into a purchase agreement (the "Purchase Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln
 Park"), which provides that, upon the terms and subject to the conditions and limitations in the Purchase Agreement, Lincoln
 Park is committed to purchase up to an aggregate of $ 20.0 million of the Company's shares of common stock over a 36-month
 period (unless extended to a 48-month period pursuant to the Purchase Agreement). The Company will control the timing and amount of
 sales of the Company's shares to Lincoln Park. As consideration for Lincoln Park's irrevocable commitment to purchase
 shares of the Company's common stock upon the terms of and subject to satisfaction of the conditions set forth in the Purchase
 Agreement, upon execution of the Purchase Agreement, the Company (i) issued to Lincoln Park 142,450 shares of common stock, as the
 initial commitment shares, and (ii) will issue additional commitment shares, of common stock equal to $ 125,000 divided by the
 arithmetic average of the ten (10) Nasdaq Official Closing Prices (as defined in the Purchase Agreement) for the common stock
 immediately preceding the date that the Company has sold over $ 10,000,000 of shares to Lincoln Park, (to be appropriately adjusted
 for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction) provided
 that the additional commitment shares number shall be no greater than 76,220. On December 23, 2022, the Company filed a Form S-1
 covering the resale of up to 4,000,000 shares of common stock comprised of (i) 142,450 initial commitment shares, (ii) up to a
 maximum of 76,220 additional commitment shares, and (iii) up to 3,781,330 shares of common stock reserved for issuance and sale to
 Lincoln Park under the Purchase Agreement. The Form S-1 was declared effective on December 30, 2022.

 NOTE
8: COMMITMENTS AND CONTINGENCIES

 Litigation

 On
July 13, 2022, LTS Lohmann Therapie Systeme AG ("LTS") filed a Request for Arbitration with the International Chamber of
Commerce ("Request"), naming as respondent the Company's subsidiary, Intec Pharma. The Request alleges that LTS is
entitled to payment of Euro 2 million under a process development agreement ("PDA") following discontinuation of the former
Accordion Pill business. Intec Israel had previously accrued this amount along with other related costs. In 2022, Intec Israel paid approximately
Euro 1 million (approximately $ 1 million USD) towards the alleged obligation.

 On
February 7, 2023, Intec Israel settled the dispute with LTS by paying Euro 800,000 (approximately $ 860,000). As the settlement amount
was less than the amount accrued, the Company also recognized other income of approximately Euro 345,000 (approximately $ 365,000) during
the year ended December 31, 2022.

 From
time to time, the Company could become involved in additional disputes and various litigation matters that arise in the normal
course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee
relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential
financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount of such potential loss
can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the
outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time.
As additional information becomes available, the Company reassesses the potential liability related to pending claims and
litigation.

 Leases

 On
October 1, 2021, the Company entered into a noncancelable two-year operating lease agreement for approximately 2,000 square feet of office
space in San Diego, California. The base rent was $ 7,999 per month with an increase of 3 % after the first anniversary of the lease term
commencement, which was November 1, 2022.

 On
April 19, 2023, the Company executed an amendment to the lease agreement to extend the lease through October 31, 2025. Accordingly, the
Company remeasured its operating lease liability under the agreement and recognized an incremental lease liability and right-of-use asset
of $ 236,506. The remeasurement was based on a 9 % incremental borrowing rate.

 F- 13

 Future
minimum annual lease payments and a reconciliation to the Company's operating lease liability under the Company's noncancelable
operating lease as of December 31, 2023 are as follows:

 SUMMARY OF MINIMUM LEASE PAYMENTS

 2024

 $
 101,705

 2025

 86,862

 Total minimum lease payments

 188,567

 Less: amount representing interest

 ( 13,514
)

 Present value of operating lease liability

 175,053

 Less: current portion

 ( 101,705
)

 Operating lease liability, net of current portion

 $
 73,348

 The
Company recognized rent expense of $ 100,742 and $ 97,425 during the years ended December 31, 2023 and 2022, respectively. Total cash payments
for the operating lease totaled $ 99,254 and $ 96,465 during the years ended December 31, 2023 and 2022, respectively.

 NOTE
9: INCOME TAXES

 As
of December 31, 2023, the Company had net operating loss carry forwards that may be available to reduce future years' taxable income.

 The
Company's provision for income taxes consisted of the following:

OF PROVISION FOR INCOME TAXES

 2023

 2022

 Computed "expected" tax benefit

 $
 ( 3,238,593
)

 $
 ( 3,007,284
)

 State taxes, net of federal benefit

 1,304

 ( 8,797
)

 Non-deductible items

 61,842

 86,955

 Change in deferred tax asset valuation allowance

 2,509,496

 ( 1,351,029
)

 613,167

 544,640

 Return-to-provision adjustments

 41,316

 3,662,174

 Other

 13,918

 73,371

 Income tax expense

 $
 2,450

 $

 Deferred
income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.

 The
Company's net deferred tax assets were comprised of the following as of December 31, 2023 and 2022:

OF NET DEFERRED TAX ASSETS

 2023

 2022

 Deferred tax assets:

 Net operating losses

 $
 51,846,000

 $
 50,244,447

 Capitalized research and development

 2,162,872

 1,054,824

 261,052

 234,350

 Accruals

 220,923

 447,973

 Operating lease liabilities

 36,761

 16,960

 Other

 Total gross deferred tax assets

 54,528,167

 51,999,005

 Deferred tax liabilities:

 Right-of-use asset

 ( 36,373
)

 ( 16,707
)

 Gross deferred tax liabilities

 ( 36,373
)

 ( 16,707
)

 Less: Deferred tax asset valuation allowance

 ( 54,491,794
)

 ( 51,982,298
)

 Total net deferred tax assets

 $
 -

 $
 -

 F- 14

 Deferred
income tax assets and liabilities are recorded for differences between the financial statement and tax basis of the assets and liabilities
that will result in taxable or deductible amounts in the future based on enacted laws and rates applicable to the periods in which the
differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets
to the amount expected to be realized.

 ASC
740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to
the extent that management assesses that realization is "more likely than not." Realization of the future tax benefits is
dependent on the Company's ability to generate sufficient taxable income within the carryforward periods. Because of the Company's
recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned
future tax benefits is currently not likely to be realized and, accordingly, has provided a full valuation allowance for the years ended
December 31, 2023 and 2022. The net change in total valuation allowance for the years ended December 31, 2023 and 2022 was an increase
of $ 2.5 million and decrease of $ 1.5 million respectively.

 At
December 31, 2023, the Company has United States federal and state net operating loss (NOL) carryforwards of $ 26.9 million and $ 7.4 million,
respectively. The federal NOL carryforwards generated in pre-2018 tax years of $ 0.8 million will begin to expire in 2036 while federal
NOLs generated after 2017 of $ 26.1 million will carry forward indefinitely. The state NOL carryforwards of $ 7.4 million will begin to
expire in 2035 unless previously utilized. At December 31, 2023, the Company also had Israel NOL carryforwards of $ 198.6 million. The
Israel NOLs carry forward indefinitely.

 The
Company's ability to utilize its net operating losses may be limited under Section 382 and 383 of the Internal Revenue Code. The
limitations apply if an ownership change, as defined by Section 382, occurs. Generally, an ownership change occurs when certain shareholders
increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period (typically
three years). Although the Company has not undergone a Section 382 analysis, it is possible that the utilization of the net operating
losses could be substantially limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be utilized against
future taxes. As a result, the Company may not be able to take full advantage of these carryforwards for federal and state tax purposes.
Future changes in stock ownership may also trigger an ownership change and, consequently, a Section 382 limitation.

 The
Company recognizes the benefit of tax positions taken or expected to be taken in its tax returns in the consolidated financial statements
when it is more likely than not that the position will be sustained upon examination by authorities. Recognized tax positions are measured
at the largest amount of benefit that is greater than 50% likely of being realized upon settlement. As of December 31, 2023 and 2022,
the Company has not recorded any unrecognized tax benefits.

 The
Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses.
As of December 31, 2023 and 2022, the Company recorded no accrued interest and penalties related to unrecognized tax benefits. The Company
does not expect any significant changes in its tax positions that would warrant recognition of a liability for unrecognized income tax
benefits during the next 12 months.

 The
Company files U.S. federal and various state income tax returns and is subject to the examination for tax years back to 2020 and 2019
for federal and state purposes, respectively, and its NOL's dating back to inception are subject to adjustment by the taxing authorities
if claimed on future tax filings for which the statute remain open to examination. The Company also files Israeli tax returns and is
subject to examination for tax years back to 2019. The Company is not currently under audit by the Internal Revenue Service or other
similar national, state and local authorities.

 NOTE
10: SUBSEQUENT EVENTS

 The
Company evaluated subsequent events from December 31, 2023, the date of these consolidated financial statements, through March 13, 2024,
which represents the date the consolidated financial statements were issued, for events requiring recognition or disclosure in the consolidated
financial statements for the year ended December 31, 2023. The Company concluded that no events have occurred that would require recognition or disclosure in the consolidated
financial statements, except for the sale of 137,836
shares of the Company's common stock for an aggregate gross proceeds of $ 0.3 million as
described in Note 7(b).

 F- 15

 Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 None.

 Item
9A. Controls and Procedures. Disclosure Controls and Procedures.

 Limitations
on Effectiveness of Controls and Procedures

 In
designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how
well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design
of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply
judgment in evaluating the benefits of possible controls and procedures relative to their costs.

 Evaluation
of Disclosure Controls and Procedures

 Our
management, with the participation of our principal executive officer and principal financial officer, evaluated, as of December 31,
2023, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act).
Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and
procedures were effective at the reasonable assurance level as of December 31, 2023.

 Management's
Annual Report on Internal Control over Financial Reporting

 Our
management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined
in Rule 13a-15(f) under the Exchange Act.

 Our
management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth
in "Internal Control- Integrated Framework (2013)" issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on our assessment, our management concluded that as of December 31, 2023, our internal control over financial reporting was effective.

 Attestation
Report of the Independent Registered Public Accounting Firm

 This
Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial
reporting due to an exemption provided to issuers that are not "large accelerated filers" nor "accelerated filers"
under applicable SEC rules.

 Changes
in Internal Control over Financial Reporting

 There
were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)
during the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.

 Item
9B. Other Information.

 None.

 Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

 Not
applicable.

 PART
III

 Item
10. Directors and Executive Officers.

 The
following table sets forth information relating to our executive officers and directors as of March 12, 2024.

 Name

 Age

 Position

 Executive
 Officers

 Jeffrey
 A. Meckler

 Chief
 Executive Officer and Director

 Michael
 J. Newman, Ph. D.

 Chief
 Scientific Officer and Director

 Nir
 Sassi

 Chief
 Financial Officer

 Walt
 A. Linscott, Esq.

 Chief
 Operating Officer

 Roger
 J. Waltzman

 Chief
 Medical Officer

 Non-Executive
 Directors

 Dr.
 Roger J. Pomerantz

 Chairman
 of the Board of Directors

 Hila
 Karah

 Anthony
 J. Maddaluna

 William
 B. Hayes

 Mark
 J. Gilbert, M.D.

 Robert
 E. Martell, M.D., Ph. D.

 Biographical
information with respect to our executive officers and directors is provided below.

 Information
about Our Executive Officers

 Jeffrey
A. Meckler has served as our Chief Executive Officer since July 2021 and member of our board of directors since inception in
February 2021. Previously, Mr. Meckler served as our sole officer from inception to July 2021, Intec Israel's Vice Chairman of
the board of directors from April 2017, as Intec Israel's Chief Executive Officer from July 2017 and as President and Secretary
and director of Intec Parent, Inc. from March 2021 until the Merger. Mr. Meckler has served on numerous public and private corporate
boards and since October 2014 has served as a director of Travere Therapeutics (Nasdaq: TVTX). Mr. Meckler served as Chief Executive
Officer and a director of CoCrystal Pharma, Inc., a pharmaceutical company, from April 2015 to July 2016. He has also served as a director
of QLT, Inc. (Nasdaq: QLTI), a biotechnology company, from June 2012 to November 2016, as well as the Managing Director of The Andra
Group, a life sciences consulting firm since 2009. Mr. Meckler also served as Chief Executive Officer of Trieber Therapeutics from January
2017 to July 2017. Earlier in his career, Mr. Meckler held a series of positions at Pfizer Inc. in manufacturing systems, market research,
business development, strategic planning and corporate finance, which included playing a significant role in acquisitions and divestitures.
Mr. Meckler is the past President and continues to serve on the board of directors of Children of Bellevue, a non-profit organization
focused on advocating and developing pediatric programs at Bellevue Hospital Center. Mr. Meckler holds a B.S. in Industrial Management
and M.S. in Industrial Administration from Carnegie Mellon University. In addition, Mr. Meckler received his J.D. from Fordham University
School of Law. We believe that Mr. Meckler is qualified to serve on our board of directors because of his extensive executive leadership
experience in the biopharmaceutical industry, including his service at Pfizer, and his experience serving on public company boards.

 Michael
J. Newman, Ph. D. has served as our Chief Scientific Officer and a member of our board of directors since August 2021. Dr. Newman
is a pharmaceutical/biotechnology executive with over 40 years of experience carrying out and managing oncology research and development,
in addition to undergraduate and graduate research and training in microbiology. He was the Founder, President, Chief Executive Officer
and a member of the board of directors of Decoy (from August 2013 to August 2021). His previous positions also include faculty appointments
in Biochemistry at Brandeis University (from 1984 to 1987) and the Roche Institute of Molecular Biology (from 1987 to 1992), Senior Associate
Director of Oncology at Sandoz Pharmaceuticals (world-wide head of Cancer Biology), and Executive Director of Oncology at Novartis Pharmaceuticals
(Head of Cancer Biology in the U.S.) (from 1992 to 1997), and senior management at several Biotechnology companies (from 1998 to 2012).
Dr. Newman received a bachelor's degree in Biology from the University of California at San Diego, a Ph. D. in Cell and Developmental
Biology from Harvard Medical School (National Science Foundation Pre-Doctoral Fellow), and carried out post-doctoral research at Cornell
University. We believe that Dr. Newman is qualified to serve on our board of directors because of his extensive scientific and research
background, as well as his experience as founder and CEO of Decoy.

 Nir
Sassi has served as our Chief Financial Officer since July 2021 and served as Intec Israel's Chief Financial Officer from
March 2010 until the Merger (other than from January 2015 to August 2016, during which period Mr. Sassi served as Intec Israel's
VP Finance), and its President from March 2021 until the Merger. Prior to his service with Intec Israel, Mr. Sassi served as a Senior
Manager at PricewaterhouseCoopers Israel, an accounting firm, from 2002 until 2010, including two years relocation to the PricewaterhouseCoopers
New York office. Mr. Sassi is a certified public accountant in Israel and has a bachelor's degree in economics and accounting from
Ben Gurion University in Be'er Sheva, Israel.

 Walt
A. Linscott, Esq. has served as our Chief Operating Officer since March 2023. Prior to that, he served as our Chief Business
Officer from July 2021 until March 2023. Mr. Linscott joined Intec Israel in October 2017 and served as its Chief Business Officer from
July 2018 until the Merger. Previously, from October 2017 to July 2018, Mr. Linscott served as Intec Israel's Chief Administrative
Officer. Prior to his service with Intec Israel, Mr. Linscott co-founded a global consulting enterprise in October 2014 providing strategic
advice to developing companies and most recently served as the President and Chief Operating Officer of Treiber Therapeutics, Inc. from
March 2017 to October 2017. Mr. Linscott also has held senior level executive positions at public and private medical device and pharmaceutical
companies including Cocrystal Pharma, Inc., from July 2015 to March 2017, Carestream Health, Inc., from January 2011 to January 2015
and Solvay Pharmaceuticals, Inc., from 2001 to 2005. In addition to this experience, he was an associate and partner at Thompson Hine
LLP from 1990 to 2001, and again as a partner from 2005 to 2010 where he founded the firm's Atlanta, Georgia office, served as
Partner in Charge and Chair of the firm's Life Science Practice Group. Mr. Linscott holds a Master of Science in Experimental and
Translational Therapeutics from the University of Oxford, a Postgraduate Diploma in Global Business from the University of Oxford and
a Postgraduate Diploma in Entrepreneurship from Cambridge University. He earned a bachelor's degree from Syracuse University and
a Juris Doctor from the University of Dayton School of Law. Mr. Linscott served on active duty as an Officer in the United States Marine
Corps prior to attending law school.

 Roger
Waltzman M.D., M.B.A. has served as our Chief Medical Officer since August 2023. Prior to that, he served as Chief Business Officer
of Molecular Templates from 2019 to 2023 and in multiple senior drug development roles at Novartis Oncology from 2007 to 2013, where
he played a leading role in the development of imatinib, nilotinib, and ruxolitinib. From 2013 to 2016, Dr. Waltzman was the Full Development
Head of Malaria Drug Development at Novartis. More recently, Dr. Waltzman was CMO at Rgenix (now Inspirna), where he supervised the development
of immuno-oncology and metabolic inhibitor assets through Phase 1 a/b. Previously, he served as CSO at Jaguar Health and Napo Pharmaceuticals,
where he led scientific aspects of development and commercialization of Mytesi (crofelemer). Before joining the industry, Dr. Waltzman
held assistant professorships in medical oncology and palliative care at Saint Vincent's Hospital and Mount Sinai School of Medicine
in New York. He completed his fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. Dr. Waltzman earned a Master
of Business Administration at Columbia Business School and a Doctor of Medicine and Bachelor of Arts from Brown University.

 Non-Employee
Directors

 Dr.
Roger J. Pomerantz has served as our Chairman since July 2021 and previously served on Intec Israel's board of directors
from March 2018 until the Merger. Dr. Pomerantz served as Chairman and Chief Executive Officer of Contrafect Corporation (Nasdaq: CFRX)
from April 2019 to November 2023. Prior to that, he served as Vice Chairman of Contrafect from May 2014 to April 2019. Previously, Dr.
Pomerantz was a Venture Partner at Flagship Pioneering from 2014 through 2019. In addition, from November 2013 to December 2019, Dr.
Pomerantz served as Chairman of the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB), a biotechnology company, and as its
President and Chief Executive Officer from June 2014 to January 2019. Prior to joining Seres, Dr. Pomerantz was Worldwide Head of Licensing
& Acquisitions, Senior Vice President at Merck & Co., Inc., where he oversaw all licensing and acquisitions at Merck Research
Laboratories, including external research, out-licensing regional deals, and academic alliances. Previously, he served as Senior Vice
President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global Head of Infectious
Diseases for J&J. Dr. Pomerantz has served as a member of the board of directors of Viracta (Nasdaq: VIRX) since June 2020 and was
appointed Chair in September 2020. Since February 2020, he served as Chairman of Collplant Biotechnologies (Nasdaq: CLPT) and was previously
a member of the board of directors of Rubius Therapeutics (Nasdaq: RUBY). Dr. Pomerantz earned his B.A. in biochemistry at the Johns
Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He completed his internal medicine internship and residency
training, and his subspecialty clinical and research training in infectious diseases and virology at the Massachusetts General Hospital
of Harvard Medical School. His post-doctoral research training in molecular retrovirology was obtained at both Harvard Medical School
and the Whitehead Institute of the Massachusetts Institute of Technology (MIT). Dr. Pomerantz also served as the Chief Resident at the
Massachusetts General Hospital. Following his medical-scientist training, he was an Endowed, Tenured Professor of Medicine and Molecular
Pharmacology and Chairman of the Infectious Diseases Department of Thomas Jefferson University in Philadelphia. Dr. Pomerantz is an internationally
recognized expert in HIV molecular pathogenesis and latency. He has developed ten approved infectious disease drugs in important diseases
including HIV, HCV, tuberculosis, and Clostridium difficile infection. We believe Dr. Pomerantz is qualified to serve on our board of
directors because of his significant scientific, executive and board leadership experience in drug development and in the pharmaceutical
industry.

 Hila
Karah has served on our board since July 2021 and previously served as a member of Intec Israel's board of directors since
December 2009 until the Merger. Ms. Karah is a managing Partner of Pitango HealthTech VC and an experienced board director. Prior to
Pitango she served as an independent business consultant to private and public companies on strategy, operations, financing, regulatory
and corporate governance. From 2006 until 2013, Ms. Karah was the chief investment officer of Eurotrust Ltd., a family office, where
she focused primarily on investments in life science, internet and high-tech companies. Prior to joining Eurotrust, Ms. Karah served
as a senior analyst at Perceptive Life Sciences Ltd., a New York-based life healthcare focused hedge fund. Prior to her position at Perceptive,
Ms. Karah was a research analyst at Oracle Partners Ltd., a healthcare-focused hedge fund based in Connecticut. Ms. Karah has served
on the board of Cyren Ltd., a cyber security company (Nasdaq, TASE: CYRN), since 2008 and the board of Dario Health Corp. (Nasdaq: DRIO)
since 2014. She also serves on the board of several private companies. Ms. Karah has a BA in molecular and cell biology from the University
of California, Berkeley, and has studied at the UCSB – UCSF Joint Medical Program. We believe Ms. Karah is qualified to serve on
our board of directors because of her longstanding service with Intec Israel, her investment career in life science companies, her scientific
background and experience serving on public company boards.

 Anthony
J. Maddaluna has served on our board since July 2021 and previously served on Intec Israel's board of directors since December
2017 until the Merger. Mr. Maddaluna has more than 40 years of experience in the pharmaceutical manufacturing industry, including leadership
positions in plants, regions and globally. From January 2011 to December 2016, Mr. Maddaluna held a series of positions at Pfizer Inc.,
most recently serving as the Executive Vice President and President of Pfizer Global Supply. Prior to that Mr. Maddaluna served as Senior
Vice President of Pfizer Global Manufacturing Strategy and Supply Network Transformation from 2008 until 2011, and as Vice President
of Pfizer Global Manufacturing Europe Area from 1998 until 2008. Mr. Maddaluna served as a director of Albany Molecular Research Inc.
from February 2016 until its acquisition by The Carlyle Group and GTCR in August 2017 and currently serves on the board of managers for
the private company. Mr. Maddaluna holds a B.S. in Chemical Engineering from Northeastern University and an M.B.A. from Southern Illinois
University. We believe Mr. Maddaluna is qualified to serve on our board of directors because of his extensive experience in the pharmaceutical
manufacturing industry, including his service at Pfizer, and his experience serving on company boards.

 William
B. Hayes has served on our board since July 2021 and previously served on Intec Israel's board of directors since June
2018 until the Merger. Most recently, Mr. Hayes was Executive Vice President, Chief Financial Officer and Treasurer of Laboratory Corporation
of America Holdings (LabCorp) (NYSE: LH), a diagnostics laboratory company. Mr. Hayes joined LabCorp in 1996, where he was responsible
for day-to-day operations of the revenue cycle function. He rose through a series of promotions and in 2005 was named Executive Vice
President, Chief Financial Officer and Treasurer of LabCorp, a role he held until his retirement in 2014. Prior to LabCorp, Mr. Hayes
was at KPMG for nine years in their audit department. Since October 2019, Mr. Hayes has served on the board of Builders FirstSource,
a supplier and manufacturer of building materials (Nasdaq: BLDR), and currently chairs its audit committee. Previously, Mr. Hayes served
as a director from March 2016 for Patheon N.V. (NYSE: PTHN), a pharmaceutical manufacturing company, until its acquisition by Thermo
Fisher in late 2017. Mr. Hayes holds a Bachelor of Science in accounting from the University of North Carolina at Greensboro. We believe
Mr. Hayes is qualified to serve on our board of directors because of his accounting background and experience serving on public company
boards.

 Mark
J. Gilbert has served on our board of directors since November 2021. Dr. Gilbert brings more than 30 years of experience in
global medical and clinical research and development, and management of medical affairs. From March 2019 to March 2022, Dr. Gilbert
served as Executive Vice President of Research and Development at Acepodia, Inc., a clinical-stage biotechnology company addressing
gaps in cancer care and since June 2021, Dr. Gilbert has served as a Clinical Development Advisor to Decoy Biosystems, Inc., the
Company's wholly owned-subsidiary. In addition, from October 2020 to January 2024, Dr. Gilbert served as the Chairman of the
Scientific Advisory Board at Inceptor Bio, LLC, a biotechnology company developing multiple next- generation cell and gene therapy
platforms for underserved and difficult-to-treat cancers, after January 2024 he remains an SAB member, and from October 2020, he
serves as a Strategic Advisor at Kineticos Ventures, a firm providing advisory services and capital to emerging life sciences firms.
Prior to these positions, between November 2013 and January 2020, Dr. Gilbert was the Chief Medical Officer of Juno Therapeutics
Inc., a biopharmaceutical company, where he led the clinical development of some of the first CAR-T cell therapies. Before that, Dr.
Gilbert held leadership positions at Bayer Schering Pharma AG, where he served as Vice President and Head of Global Clinical
Development, Therapeutic Area Oncology Berlex Pharmaceuticals, Inc., where he served as Vice President of Medical Affairs,
Oncology, and Vice President and Head of Global Medical Development Group, Oncology and Immunex Corporation, where he served
as Senior Medical Director, Clinical Research and Development. Between May 2019 and May 2021, Dr. Gilbert served as an Independent
Director of Silicon Therapeutics, Inc., a fully integrated drug design and development company. Dr. Gilbert earned a Bachelor of
Science degree in Biochemistry from the University of Iowa and a Medical Doctor degree from the University of Iowa College of
Medicine. He trained in internal medicine, infectious disease and medical oncology at the University of California, San Francisco,
and the University of Washington, respectively. We believe Dr. Gilbert is qualified to serve on our board of directors because of
his significant scientific and executive in drug development and in the pharmaceutical industry.

 Robert
E. Martell, M.D., Ph. D. has served on our board of directors since February 2023. Dr. Martell brings more than 20 years of experience
in the pharmaceutical industry. Dr. Martell is Chief Scientific Officer at Curis, having previously served as Head of Research &
Development. From September 2011 to May 2018, Dr. Martell served on Curis' Board of Directors. He is also co-founder of Epi-Cure
Pharmaceuticals, a privately held early-stage biotechnology company, and served as its president and member of board of directors from
2016 to 2018. Dr. Martell served as Chief Medical Officer of Tesaro, Inc., a biopharmaceutical company developing Zejula and Varubi from
2012 to 2015; as Chief Medical Officer at MethylGene, a publicly traded biopharmaceutical focused on cancer therapeutics from 2005 to
2009; as Director of Oncology Global Clinical Research at Bristol-Myers Squibb, a biopharmaceutical company developing Sprycel, Erbitux
and Ixempra from 2002 to 2005; and as Associate/Deputy Director at Bayer Corporation Pharmaceutical Division developing Nexavar from
2000 to 2002. In addition, Dr. Martell is a part-time treating physician at Champlain Valley Hematology Oncology and he has held a number
of academic positions, including at Tufts Medical Center since 2009, where he has served in various roles including Associate Chief in
the Division of Hematology/Oncology, Director of the Neely Center for Clinical Cancer Research, Leader of the Cancer Center's Program
in Experimental Therapeutics and Attending Physician; at Yale University School of Medicine as Assistant Clinical Professor of Oncology
from 2001 to 2005; and as Assistant Professor at Duke Medical Center from 1998 to 2000. Dr. Martell received a B.A. in chemistry from
Kalamazoo College, a Ph. D. in Pharmacology from University of Michigan and an M.D. from Wayne State University. He completed his Internal
Medicine internship and residency at Duke University Medical Center, and his Fellowship in Medical Oncology also at Duke.

 Code
of Business Conduct and Ethics

 We
have a Code of Business Conduct and Ethics that applies to our directors, officers and employees, including our principal executive officer,
principal financial officer, principal accounting officer or controller, or persons performing similar functions. The Code of Business
Conduct and Ethics is publicly available on our website at  We intend to satisfy the disclosure requirement
under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics, as well as
Nasdaq's requirement to disclose waivers with respect to directors and executive officers, by posting such information on our website
at the address and location specified above. The information contained on our website is not incorporated by reference into this Annual
Report.

 Other

 The
remainder of the information required to be disclosed by this Item 10 will be included in our definitive Proxy Statement for the 2024
Annual Meeting of Stockholders and is incorporated herein by reference.

 Item
11. Executive Compensation.

 The
information required by this Item 11 will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders and
is incorporated herein by reference.

 Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 Securities
Authorized for Issuance under Equity Compensation Plans

 The
following table gives information as of December 31, 2023 about shares of our common stock that may be issued upon the exercise of options
under the Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan, or the 2021 Plan:

 Plan Category

 Number of securities to be issued
 upon exercise of outstanding options, warrants and rights(1)

 Weighted-average exercise price of
 outstanding options, warrants and rights

 Number of securities remaining available
 for future issuance under equity compensation plans (excluding securities reflected in first column)

 Equity
 compensation plan approved by security holders (2)

 $
 10.90

 189,201

 Equity compensation plans not approved by security holders

 —

 —

 —

 Total

 $
 10.90

 189,201

 (1)

 The
 weighted average remaining term for the expiration of stock options under the 2021 Plan is 7.9 years.

 (2)

 Our
 2021 Plan has an evergreen provision that allows for an annual increase beginning on January 1, 2022 and ending on and including
 January 1, 2024, equal to the lesser of (A) 3% of the aggregate number of shares of our shares of common stock outstanding on the
 final day of the immediately preceding calendar year or (B) such smaller number of shares as is determined by our board of directors.

 Other

 The
remaining information required by this Item 12 will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders
and is incorporated herein by reference.

 Item
13. Certain Relationships and Related Transactions, and Director Independence.

 The
information required by this Item 13 will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders and
is incorporated herein by reference.

 Item
14. Principal Accountant Fees and Services.

 The
information required by this Item 14 will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders and
is incorporated herein by reference.

 PART
IV

 Item
15. Exhibits and Financial Statement Schedules.

 (a)(1)
Financial Statements.

 The
financial statements required by this item are listed in Item 8. "Financial Statements and Supplementary Data" in this Annual
Report.

 (a)(2)
Financial Statement Schedules.

 The
financial statement schedules are omitted because they are either not applicable or the information required is presented in the financial
statements and notes thereto under Item 8. "Financial Statements and Supplementary Data" in this Annual Report.

 (a)(3)
Exhibits.

 The
following is a list of exhibits filed as part of this Annual Report.

 Exhibit

 Exhibit
 No.

 Exhibit
 Description

 2.1++

 Agreement and Plan of Merger and Reorganization, dated as of March 15, 2021, by and among Intec Pharma Ltd., Intec Parent, Inc., Dillon Merger Sub Inc., Domestication Merger Sub Ltd., and Decoy Biosystems, Inc. (incorporated herein by reference to Exhibit 2.1 to Intec Israel's Report on Form 8-K filed with the SEC on March 15, 2021)

 2.2

 Agreement and Plan of Merger, dated as of April 27, 2021, by and among Intec Pharma Ltd., Intec Parent, Inc. and Domestication Merger Sub Ltd. (incorporated herein by reference to Exhibit 2.1 to Intec Israel's Report on Form 8-K filed with the SEC on April 30, 2021)

 3.1

 Amended and Restated Certificate of Incorporation of Indaptus Therapeutics, Inc., dated as of July 23, 2021 (incorporated herein by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed with the SEC on July 23, 2021)

 3.2

 Amended and Restated Bylaws of Indaptus Therapeutics, Inc., dated as of January 22, 2024 (incorporated herein by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed with the SEC on January 23, 2024)

 3.3

 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Indaptus Therapeutics, Inc. dated August 3, 2021 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the SEC on August 6, 2021)

 4.1

 Description of Securities Registered under Section 12 (incorporated herein by reference to Exhibit 4.1 of the Company's Annual Report on Form 10-K filed with the SEC on March 21, 2021)

 4.2

 Form of Ordinary Share Purchase Warrant of Intec Parent, Inc. (incorporated herein by reference to Exhibit 10.2 to Intec Israel's Current Report on Form 8-K filed with the SEC on May 6, 2020)

 4.3

 Form of Series A Common Stock Purchase Warrant of Intec Parent, Inc.(incorporated herein by reference to Exhibit 10.3 to Indaptus' Current Report on Form 8-K filed with the SEC on July 29, 2021)

 10.1*+

 Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan

 10.1+

 First Amendment to the Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.7 to the Company's Current Report on Form 8-K filed with the SEC on August 6, 2021)

 10.2*+

 Form of Option Award Agreement

 10.3+

 Form of Indemnification Agreement (incorporated herein by reference to Exhibit 10.5 of the Company's Current Report on Form 8-K filed with the SEC on August 6, 2021)

 10.4+

 Employment Agreement between Jeffrey Meckler and Indaptus Therapeutics, Inc., effective as of August 4, 2021 (incorporated herein by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the SEC on August 6, 2021)

 10.5+

 Employment Agreement between Michael J. Newman, Ph. D. and Indaptus Therapeutics, Inc., effective as of August 4, 2021 (incorporated herein by reference to Exhibit 10.2 of the Company's Current Report on Form 8-K filed with the SEC on August 6, 2021)

 10.6+

 Employment Agreement between Walt Linscott and Indaptus Therapeutics, Inc., effective as of August 4, 2021 (incorporated herein by reference to Exhibit 10.3 of the Company's Current Report on Form 8-K filed with the SEC on August 6, 2021)

 10.7+

 Employment Agreement between Nir Sassi and Indaptus Therapeutics, Inc., effective as of January 1, 2022 (incorporated herein by reference to Exhibit 10.6 of the Company's Annual Report on Form 10-K filed with the SEC on March 21, 2022)

 10.8+*

 Employment Agreement between Roger J. Waltzman and Indaptus Therapeutics, Inc., effective as of August 7, 2023

 10.9+

 Indaptus Therapeutics, Inc. Non-Employee Director Compensation Program (Effective April 2, 2023) (incorporated herein by reference to Exhibit 10.1 of the Company's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023)

 10.10

 Form of Securities Purchase Agreement, dated July 23, 2021, between Intec Parent, Inc. and each purchaser identified on the signature pages hereto (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on July 29, 2021)

 10.11

 Form of Registration Rights Agreement, dated July 23, 2021, between Intec Parent, Inc. and each purchaser identified on the signature pages hereto (incorporated herein by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed with the SEC on July 29, 2021)

 10.12

 At the Market Offering Agreement, dated June 1, 2022, by and between Indaptus Therapeutics, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 1.2 of the Company's Registration Statement on Form S-3 filed on September 1, 2022)

 10.13

 Purchase Agreement, dated December 22, 2022, by and between Indaptus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on December 23, 2022)

 10.14

 Registration Rights Agreement, dated December 22, 2022, by and between Indaptus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on December 23, 2022)

 21.1

 List of Subsidiaries (incorporated herein by reference to Exhibit 21.1 to the Company's Annual Report on Form 10-K filed with the SEC on March 21, 2021)

 23.1*

 Consent of Haskell & White LLP, independent registered public accounting firm

 31.1*

 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 31.2*

 Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 32.1#

 Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002

 32.2#

 Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002

 97.1*

 Indaptus Therapeutics, Inc. Policy for Recovery of Erroneously Awarded Compensation

 101.INS*

 101.SCH*

 101.CAL*

 101.DEF*

 101.LAB*

 101.PRE*

 Cover

 *

 Filed
 herewith

 #

 Furnished
 herewith

 +

 Indicates
 management contract or compensatory plan.

 ++

 The
 schedules to the agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule will be
 furnished to the SEC upon request.

 Item
16. Form 10-K Summary

 None.

 SIGNATURES

 Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report
to be signed on its behalf by the undersigned, thereunto duly authorized.

 Indaptus
 Therapeutics, Inc.

 Date:
 March 13, 2024

 By:

 /s/
 Jeffrey A. Meckler

 Jeffrey
 A. Meckler

 Chief
 Executive Officer

 POWER
OF ATTORNEY

 KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Jeffrey Meckler and Nir
Sassi, and each of them acting individually, as his attorney-in-fact, each with full power of substitution, for him in any and all capacities,
to sign any and all amendments to this Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection
therewith, with the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said
attorney to any and all amendments to said Report.

 Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on
behalf of the Registrant in the capacities and on the dates indicated.

 Name

 Title

 Date

 /s/
 Jeffrey A. Meckler

 Chief
 Executive Officer and Director

 March

 Jeffrey
 A. Meckler

 (Principal
 Executive Officer)

 /s/
 Nir Sassi

 Chief
 Financial Officer

 March

 Nir
 Sassi

 (Principal
 Financial and Accounting Officer)

 /s/
 Michal J. Newman, Ph. D.

 Chief
 Scientific Officer and Director

 March

 Michael
 J. Newman, Ph. D.

 /s/
 Roger J. Pomerantz, M.D.

 Chairman
 of the Board of Directors

 March

 Dr.
 Roger J. Pomerantz, M.D.

 /s/
 Hila Karah

 March

 Hila
 Karah

 /s/
 Anthony J. Maddaluna

 March

 Anthony
 J. Maddaluna

 /s/
 Mark J. Gilbert

 March

 Mark
 J. Gilbert

 /s/
 William B. Hayes

 March

 William
 B. Hayes

 /s/
 Robert E. Martell, M.D., Ph. D.

 March

 Robert
 E. Martell, M.D., Ph. D.